

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
**WO 02/00655 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 471/04**,  
487/04, A61K 31/415 // (C07D 471/04, 231:00, 221:00)  
(C07D 487/04, 239:00, 231:00)

(74) Agent: **ROPER, David, J.**; Dupont Pharmaceuticals  
Company, Legal Patent Records Center, 1007 Market  
Street, Wilmington, DE 19898 (US).

(21) International Application Number: **PCT/US01/20113**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 22 June 2001 (22.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/214,032 23 June 2000 (23.06.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **DUPONT PHARMACEUTICALS COM-  
PANY** [US/US]; Chestnut Run Plaza, 974 Centre Road,  
Wilmington, DE 19805 (US).

(72) Inventors: **PINTO, Donald, J., P.**; 425 Brentford Road,  
Kennett Square, PA 19348 (US). **QUAN, Mimi, L.**; 113  
Venus Drive, Newark, DE 19711 (US). **WOERNER,**  
**Francis, J.**; 241 Cornwell Drive, Bear, DE 19701 (US).  
**LI, Renhua**; 1209 Crestover Road, Wilmington, DE  
19803 (US).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



**WO 02/00655 A1**

(54) Title: 1 - (HETEROARYL-PHENYL) - CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS

(57) Abstract: The present application describes heteroaryl-phenyl heterobicycles and derivatives thereof, or pharmaceutically ac-  
ceptable salt forms thereof, which are useful as inhibitors of factor Xa.

BEST AVAILABLE COPY

## TITLE

1- (HETEROARYL-PHENYL)-CONDENSED PYRAZOL DERIVATIVES AS FACTOR Xa INHIBITORS


5

## FIELD OF THE INVENTION

This invention relates generally to heteroaryl-phenyl heterobicyclic compounds, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.

## BACKGROUND OF THE INVENTION

WO00/20416 and WO00/40583 describe imidazole[4,3-c]-pyridin-4-one compounds of the following formula.



These compounds are stated to be factor Xa inhibitors.

Compounds of this type, however, are not considered to be part of the presently claimed invention.

20

Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca<sup>2+</sup> and phospholipid). Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K.: Optimization of conditions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood

coagulation. *Thromb. Res.* **1979**, *15*, 617-629), inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system.

Therefore, efficacious and specific inhibitors of factor Xa are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders. It is thus desirable to discover new factor Xa inhibitors.

#### SUMMARY OF THE INVENTION

Accordingly, one object of the present invention is to provide novel heteroaryl-phenyl heterobicyclic compounds that are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof.

It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

It is another object of the present invention to provide novel heteroaryl-phenyl heterobicyclic compounds for use in therapy.


It is another object of the present invention to provide the use of novel heteroaryl-phenyl heterobicyclic compounds for the manufacture of a medicament for the treatment of a thromboembolic disorder.

These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that the presently

claimed heteroaryl-phenyl heterobicyclic compounds, or pharmaceutically acceptable salt or prodrug forms thereof, are effective factor Xa inhibitors.

# 5 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[1] Thus, in a first embodiment, the present invention provides a novel compound of formula Ia, Ib, or Ic:



or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

15 ring D<sub>1</sub> is selected from pyridine, pyrazine, pyridazine, and pyrimidine and is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

ring D<sub>2</sub> is a 5-membered heteroaromatic ring system comprising E, carbon atoms, and 0-3 N atoms, wherein E is selected from O, S, and N-R<sup>c</sup> and ring D<sub>2</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

20

ring D<sub>3</sub> is a 5-membered heteroaromatic ring system comprising carbon atoms and from 0-3 additional N atoms and ring D<sub>3</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

25

R is selected from H, C<sub>1-4</sub> alkyl, F, Cl, Br, I, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH(CH<sub>3</sub>)<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CN, C(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>, NHC(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>, NR<sup>8</sup>CH(=NR<sup>7</sup>), NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, C(=NH)NH<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>NR<sup>7</sup>R<sup>8</sup>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>C(O)NR<sup>7</sup>R<sup>8</sup>, and OCF<sub>3</sub>;

30



$R^a$  is selected from H,  $C_{1-4}$  alkyl, F, Cl, Br, I, OH,  $OCH_3$ ,  
 $OCH_2CH_3$ ,  $OCH(CH_3)_2$ ,  $OCH_2CH_2CH_3$ , CN,  $C(=NR^8)NR^7R^9$ ,  
 $NHC(=NR^8)NR^7R^9$ ,  $NR^8CH(=NR^7)$ ,  $NH_2$ ,  $NH(C_{1-3} \text{ alkyl})$ ,  $N(C_{1-3}$   
5  $alkyl)_2$ ,  $C(=NH)NH_2$ ,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3} \text{ alkyl})$ ,  $CH_2N(C_{1-3}$   
 $alkyl)_2$ ,  $CH_2CH_2NH_2$ ,  $CH_2CH_2NH(C_{1-3} \text{ alkyl})$ ,  $CH_2CH_2N(C_{1-3}$   
 $alkyl)_2$ ,  $(CR^8R^9)_tNR^7R^8$ ,  $(CR^8R^9)_tC(O)NR^7R^8$ , and  $OCF_3$ ;

$R^b$  is selected from H,  $C_{1-4}$  alkyl, F, Cl, Br, I, OH,  $OCH_3$ ,  
10  $OCH_2CH_3$ ,  $OCH(CH_3)_2$ ,  $OCH_2CH_2CH_3$ , CN,  $C(=NR^8)NR^7R^9$ ,  
 $NHC(=NR^8)NR^7R^9$ ,  $NR^8CH(=NR^7)$ ,  $NH_2$ ,  $NH(C_{1-3} \text{ alkyl})$ ,  $N(C_{1-3}$   
 $alkyl)_2$ ,  $C(=NH)NH_2$ ,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3} \text{ alkyl})$ ,  $CH_2N(C_{1-3}$   
 $alkyl)_2$ ,  $CH_2CH_2NH_2$ ,  $CH_2CH_2NH(C_{1-3} \text{ alkyl})$ ,  $CH_2CH_2N(C_{1-3}$   
 $alkyl)_2$ ,  $(CR^8R^9)_tNR^7R^8$ ,  $(CR^8R^9)_tC(O)NR^7R^8$ , and  $OCF_3$ ;

15  $R^c$  is selected from H,  $C_{1-4}$  alkyl,  $OCH_3$ ,  $OCH_2CH_3$ ,  $OCH(CH_3)_2$ ,  
 $OCH_2CH_2CH_3$ ,  $NH_2$ ,  $NH(C_{1-3} \text{ alkyl})$ ,  $N(C_{1-3} \text{ alkyl})_2$ ,  
 $C(=NH)NH_2$ ,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3} \text{ alkyl})$ ,  $CH_2N(C_{1-3} \text{ alkyl})_2$ ,  
 $CH_2CH_2NH_2$ ,  $CH_2CH_2NH(C_{1-3} \text{ alkyl})$ ,  $CH_2CH_2N(C_{1-3} \text{ alkyl})_2$ ,  
20  $(CR^8R^9)_tNR^7R^8$ ,  $(CR^8R^9)_tC(O)NR^7R^8$ , and  $OCF_3$ ;


G is absent or is selected from  $CH_2$ ,  $C(O)$ , O,  $NR^3$ ,  $S(O)_p$ ,  
 $CH_2CH_2$ ,  $C(O)CH_2$ ,  $CH_2C(O)$ ,  $OCH_2$ ,  $CH_2O$ ,  $NR^3CH_2$ ,  $CH_2NR^3$ ,  
 $S(O)_pCH_2$ ,  $CH_2S(O)_p$ ,  $CH_2CH_2CH_2$ ,  $C(O)CH_2CH_2$ ,  $CH_2C(O)CH_2$ ,  
25  $CH_2CH_2C(O)$ ,  $OCH_2CH_2$ ,  $CH_2OCH_2$ ,  $CH_2CH_2O$ ,  $NR^3CH_2CH_2$ ,  $CH_2NR^3CH_2$ ,  
 $CH_2CH_2NR^3$ ,  $S(O)_pCH_2CH_2$ ,  $CH_2S(O)_pCH_2$ , and  $CH_2CH_2S(O)_p$ ;

$G_1$  is absent or is selected from  $(CR^3R^{3a})_{1-5}$ ,  
 $(CR^3R^{3a})_{0-2}CR^3=CR^3(CR^3R^{3a})_{0-2}$ ,  $(CR^3R^{3a})_{0-2}C\equiv C(CR^3R^{3a})_{0-2}$ ,  
30  $(CR^3R^{3a})_uC(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_uC(O)O(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_uOC(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_uO(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_uNR^3(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_uC(O)NR^3(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_uNR^3C(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_uOC(O)NR^3(CR^3R^{3a})_w$ ,

- $(\text{CR}^3\text{R}^{3a})_u\text{NR}^3\text{C}(\text{O})\text{O}(\text{CR}^3\text{R}^{3a})_w$ ,  $(\text{CR}^3\text{R}^{3a})_u\text{NR}^3\text{C}(\text{O})\text{NR}^3(\text{CR}^3\text{R}^{3a})_w$ ,  
 $(\text{CR}^3\text{R}^{3a})_u\text{NR}^3\text{C}(\text{S})\text{NR}^3(\text{CR}^3\text{R}^{3a})_w$ ,  $(\text{CR}^3\text{R}^{3a})_u\text{S}(\text{CR}^3\text{R}^{3a})_w$ ,  
 $(\text{CR}^3\text{R}^{3a})_u\text{S}(\text{O})(\text{CR}^3\text{R}^{3a})_w$ ,  $(\text{CR}^3\text{R}^{3a})_u\text{S}(\text{O})_2(\text{CR}^3\text{R}^{3a})_w$ ,  
 $(\text{CR}^3\text{R}^{3a})_u\text{S}(\text{O})\text{NR}^3(\text{CR}^3\text{R}^{3a})_w$ ,  $(\text{CR}^3\text{R}^{3a})_u\text{NR}^3\text{S}(\text{O})_2(\text{CR}^3\text{R}^{3a})_w$ ,  
 $(\text{CR}^3\text{R}^{3a})_u\text{S}(\text{O})_2\text{NR}^3(\text{CR}^3\text{R}^{3a})_w$ , and  $(\text{CR}^3\text{R}^{3a})_u\text{NR}^3\text{S}(\text{O})_2\text{NR}^3(\text{CR}^3\text{R}^{3a})_w$ ,  
 5 wherein  $u + w$  total 0, 1, 2, 3, or 4, provided that  $G_1$   
 does not form a N-N, N-O, N-S,  $\text{NCH}_2\text{N}$ ,  $\text{NCH}_2\text{O}$ , or  $\text{NCH}_2\text{S}$   
 bond with either group to which it is attached;

- 10  $G^2$  is phenyl, naphthyl, or a 5-10 membered heteroaryl  
 consisting of carbon atoms and from 1-3 heteroatoms  
 selected from N, O, and S;


Q is a group of formula II:



15

II

- one of  $P_4$  and  $M_3$  is  $-\text{Z}-\text{A}-\text{B}$  and the other is attached to  $G_1$ ;  
 20 ring M, including  $M_1$  and  $M_2$ , is a 6 or 7 membered carbocycle  
 or 6 or 7 membered heterocycle, consisting of: carbon  
 atoms and 1-3 heteroatoms selected from O,  $\text{S}(\text{O})_p$ , N, and  
 $\text{NZ}^2$ ;  
 25 ring M is substituted with 0-2  $\text{R}^{1a}$  and 0-2 carbonyl groups,  
 and, comprises: 0-2 additional double bonds;  
 ring P, including  $P_1$ ,  $P_2$ ,  $P_3$ , and  $P_4$  is selected from group:



"a" is absent or is a bond

5 provided that when Q is a dihydroimidazolo[4,5-c]-pyridin-4-one then:

- (i) G<sub>1</sub> is present and is other than alkylene;
- (ii) Z is present and is other than alkylene;
- (iii) Ring D<sub>1</sub>-G is present, D<sub>1</sub>-G is other than benzyloxy;
- (iv) Ring D<sub>3</sub> is present; or
- (v) Ring D<sub>2</sub> is present and is other than 5-methyl-1,2,4-oxadiazole or 5-oxo-1,2,4-oxadiazole;

15 Z is selected from a bond,  $-(CR^2R^{2a})_{1-4}-$ ,  $(CR^2R^{2a})_qO(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qC(O)(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qC(O)O(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qOC(O)(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qC(O)NR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3C(O)(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qOC(O)O(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qOC(O)NR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3C(O)O(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3C(O)NR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qS(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qS(O)(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qS(O)_2(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qSO_2NR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3SO_2(CR^2R^{2a})_{q^1}$ , and  $(CR^2R^{2a})_qNR^3SO_2NR^3(CR^2R^{2a})_{q^1}$ ,  
 20 wherein  $q + q^1$  total 0, 1, or 2, provided that Z does

not form a N-N, N-O, N-S, NCH<sub>2</sub>N, NCH<sub>2</sub>O, or NCH<sub>2</sub>S bond with either group to which it is attached;

5           Z<sup>2</sup> is selected from H, C<sub>1-4</sub> alkyl, phenyl, benzyl, C(O)R<sup>3</sup>,  
and S(O)<sub>p</sub>R<sup>3c</sup>;

10           R<sup>1a</sup> is selected from H, -(CH<sub>2</sub>)<sub>r</sub>-R<sup>1b</sup>, -CH=CH-R<sup>1b</sup>, NCH<sub>2</sub>R<sup>1c</sup>,  
OCH<sub>2</sub>R<sup>1c</sup>, SCH<sub>2</sub>R<sup>1c</sup>, NH(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>, O(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>,  
S(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>, S(O)<sub>p</sub>(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, O(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, NR<sup>3</sup>(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>,  
OC(O)NR<sup>3</sup>(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, NR<sup>3</sup>C(O)NR<sup>3</sup>(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, NR<sup>3</sup>C(O)O(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>,  
and NR<sup>3</sup>C(O)(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, provided that R<sup>1a</sup> forms other than  
an N-halo, N-N, N-S, N-O, or N-CN bond;

15           alternatively, when two R<sup>1a'</sup>s are attached to adjacent atoms,  
together with the atoms to which they are attached they  
form a 5-7 membered ring consisting of: carbon atoms  
and 0-2 heteroatoms selected from the group consisting  
of N, O, and S(O)<sub>p</sub>, this ring being substituted with 0-2  
R<sup>4b</sup> and comprising: 0-3 double bonds;

20           R<sup>1b</sup> is selected from H, C<sub>1-3</sub> alkyl, F, Cl, Br, I, -CN, -CHO,  
(CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, NR<sup>2</sup>R<sup>2a</sup>, C(O)R<sup>2c</sup>, OC(O)R<sup>2</sup>,  
(CF<sub>2</sub>)<sub>r</sub>CO<sub>2</sub>R<sup>2a</sup>, S(O)<sub>p</sub>R<sup>2b</sup>, NR<sup>2</sup>(CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, C(=NR<sup>2c</sup>)NR<sup>2</sup>R<sup>2a</sup>,  
NR<sup>2</sup>C(O)R<sup>2b</sup>, NR<sup>2</sup>C(O)NHR<sup>2b</sup>, NR<sup>2</sup>C(O)<sub>2</sub>R<sup>2a</sup>, OC(O)NR<sup>2a</sup>R<sup>2b</sup>,  
25           C(O)NR<sup>2</sup>R<sup>2a</sup>, C(O)NR<sup>2</sup>(CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>R<sup>2b</sup>, C<sub>3-6</sub>  
carbocycle substituted with 0-2 R<sup>4a</sup>, and 5-10 membered  
heterocycle consisting of carbon atoms and from 1-4  
heteroatoms selected from the group consisting of N, O,  
and S(O)<sub>p</sub> substituted with 0-2 R<sup>4a</sup>, provided that R<sup>1b</sup>  
30           forms other than an N-halo, N-N, N-S, N-O, or N-CN  
bond;

R<sup>1c</sup> is selected from H, CH(CH<sub>2</sub>OR<sup>2</sup>)<sub>2</sub>, C(O)R<sup>2c</sup>, C(O)NR<sup>2</sup>R<sup>2a</sup>,  
S(O)R<sup>2b</sup>, S(O)<sub>2</sub>R<sup>2b</sup>, and SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>;

5 R<sup>1d</sup> is selected from C<sub>3-13</sub> carbocycle substituted with 0-2  
R<sup>4a</sup>, and 5-13 membered heterocycle consisting of carbon  
atoms and from 1-4 heteroatoms selected from the group  
consisting of N, O, and S(O)<sub>p</sub> substituted with 0-2 R<sup>4a</sup>,  
provided that R<sup>1d</sup> forms other than an N-N, N-S, or N-O  
bond;  
10  
R<sup>2</sup>, at each occurrence, is selected from H, CF<sub>3</sub>, C<sub>1-6</sub> alkyl,  
benzyl, C<sub>3-6</sub> carbocyclic residue substituted with 0-2  
R<sup>4b</sup>, and 5-6 membered heterocyclic system comprising  
carbon atoms and from 1-4 heteroatoms selected from the  
15 group consisting of N, O, and S substituted with 0-2  
R<sup>4b</sup>;

R<sup>2a</sup>, at each occurrence, is selected from H, CF<sub>3</sub>, C<sub>1-6</sub> alkyl,  
benzyl, phenethyl, C<sub>3-6</sub> carbocyclic residue substituted  
20 with 0-2 R<sup>4b</sup>, and 5-6 membered heterocyclic system  
comprising carbon atoms and from 1-4 heteroatoms  
selected from the group consisting of N, O, and S  
substituted with 0-2 R<sup>4b</sup>;

25 R<sup>2b</sup>, at each occurrence, is selected from CF<sub>3</sub>, C<sub>1-4</sub> alkoxy,  
C<sub>1-6</sub> alkyl, benzyl, C<sub>3-6</sub> carbocyclic residue substituted  
with 0-2 R<sup>4b</sup>, and 5-6 membered heterocyclic system  
comprising carbon atoms and from 1-4 heteroatoms  
selected from the group consisting of N, O, and S  
30 substituted with 0-2 R<sup>4b</sup>;

R<sup>2c</sup>, at each occurrence, is selected from CF<sub>3</sub>, OH, C<sub>1-4</sub>  
alkoxy, C<sub>1-6</sub> alkyl, benzyl, C<sub>3-6</sub> carbocyclic residue

substituted with 0-2 R<sup>4b</sup>, and 5-6 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R<sup>4b</sup>;

5

alternatively, R<sup>2</sup> and R<sup>2a</sup>, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R<sup>4b</sup> and comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

10

R<sup>3</sup>, at each occurrence, is selected from H, C<sub>1-4</sub> alkyl, and phenyl;

15

R<sup>3a</sup>, at each occurrence, is selected from H, C<sub>1-4</sub> alkyl, and phenyl;

R<sup>3b</sup>, at each occurrence, is selected from H, C<sub>1-4</sub> alkyl, and phenyl;

20

R<sup>3c</sup>, at each occurrence, is selected from C<sub>1-4</sub> alkyl, and phenyl;

R<sup>3d</sup>, at each occurrence, is selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl-phenyl, and C(=O)R<sup>3c</sup>;

25

A is selected from:

C<sub>3-10</sub> carbocyclic residue substituted with 0-2 R<sup>4</sup>, and 5-12 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R<sup>4</sup>;

30

B is selected from: H, Y, and X-Y, provided that Z and B are attached to different atoms on A;

X is selected from  $-(CR^2R^{2a})_{1-4}-$ ,  $-CR^2(CR^2R^{2b})(CH_2)_t-$ ,  $-C(O)-$ ,  
 5  $-C(=NR^{1c})-$ ,  $-CR^2(NR^{1c}R^2)-$ ,  $-CR^2(OR^2)-$ ,  $-CR^2(SR^2)-$ ,  
 $-C(O)CR^2R^{2a}-$ ,  $-CR^2R^{2a}C(O)-$ ,  $-S-$ ,  $-S(O)-$ ,  $-S(O)_2-$ ,  
 $-SCR^2R^{2a}-$ ,  $-S(O)CR^2R^{2a}-$ ,  $-S(O)_2CR^2R^{2a}-$ ,  $-CR^2R^{2a}S-$ ,  
 $-CR^2R^{2a}S(O)-$ ,  $-CR^2R^{2a}S(O)_2-$ ,  $-S(O)_2NR^2-$ ,  $-NR^2S(O)_2-$ ,  
 $-NR^2S(O)_2CR^2R^{2a}-$ ,  $-CR^2R^{2a}S(O)_2NR^2-$ ,  $-NR^2S(O)_2NR^2-$ ,  
 10  $-C(O)NR^2-$ ,  $-NR^2C(O)-$ ,  $-C(O)NR^2CR^2R^{2a}-$ ,  $-NR^2C(O)CR^2R^{2a}-$ ,  
 $-CR^2R^{2a}C(O)NR^2-$ ,  $-CR^2R^{2a}NR^2C(O)-$ ,  $-NR^2C(O)O-$ ,  $-OC(O)NR^2-$ ,  
 $-NR^2C(O)NR^2-$ ,  $-NR^2-$ ,  $-NR^2CR^2R^{2a}-$ ,  $-CR^2R^{2a}NR^2-$ , O,  
 $-CR^2R^{2a}O-$ , and  $-OCR^2R^{2a}-$ ;

15 Y is selected from:

C<sub>3-10</sub> carbocyclic residue substituted with 0-2 R<sup>4a</sup>, and  
 5-12 membered heterocyclic system comprising carbon  
 atoms and from 1-4 heteroatoms selected from the group  
 consisting of N, O, and S substituted with 0-2 R<sup>4a</sup>;

20

R<sup>4</sup>, at each occurrence, is selected from H, =O,  $(CH_2)_rOR^2$ ,  
 $(CH_2)_rF$ ,  $(CH_2)_rCl$ ,  $(CH_2)_rBr$ ,  $(CH_2)_rI$ , C<sub>1-4</sub> alkyl,  
 $(CH_2)_rCN$ ,  $(CH_2)_rNO_2$ ,  $(CH_2)_rNR^2R^{2a}$ ,  $(CH_2)_rN(\rightarrow O)R^2R^{2a}$ ,  
 $(CH_2)_rC(O)R^{2c}$ ,  $(CH_2)_rNR^2C(O)R^{2b}$ ,  $(CH_2)_rC(O)NR^2R^{2a}$ ,  
 25  $(CH_2)_rNR^2C(O)NR^2R^{2a}$ ,  $(CH_2)_rC(=NR^2)NR^2R^{2a}$ ,  
 $(CH_2)_rC(=NS(O)_2R^5)NR^2R^{2a}$ ,  $(CH_2)_rNHC(=NR^2)NR^2R^{2a}$ ,  
 $(CH_2)_rC(O)NHC(=NR^2)NR^2R^{2a}$ ,  $(CH_2)_rSO_2NR^2R^{2a}$ ,  
 $(CH_2)_rNR^2SO_2NR^2R^{2a}$ ,  $(CH_2)_rNR^2SO_2-C_{1-4}$  alkyl,  
 $(CH_2)_rNR^2SO_2R^5$ ,  $(CH_2)_r-NR^2SO_2R^{5a}$ ,  $(CH_2)_rS(O)_pR^5$ ,  $(CH_2)_r-$   
 30  $S(O)_pR^{5a}$ ,  $(CF_2)_rCF_3$ ,  $(CH_2)_r-CF_3$ ,  $(CR^{4c}R^{4d})(CR^{3e}R^{3e})_r-NR^{4e}R^{4f}$ ,  
 $(CR^{4c}R^{4d})(CR^{3e}R^{3e})_r-OR^{4e}$ ,  $(CR^{4c}R^{4d})(CR^{3e}R^{3e})_r-SR^{4e}$ ,  
 $(CR^{4c}R^{4d})(CR^{3e}R^{3e})_r-N(\rightarrow O)R^{4e}R^{4f}$ ,  $(CH_2)_rNCH_2R^{1c}$ ,

$(\text{CH}_2)_r\text{OCH}_2\text{R}^{1c}$ ,  $(\text{CH}_2)_r\text{SCH}_2\text{R}^{1c}$ ,  $(\text{CH}_2)_r\text{N}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  
 $(\text{CH}_2)_r\text{O}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  $(\text{CH}_2)_r\text{S}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  $(\text{CH}_2)_r$  5-6  
 membered carbocycle substituted with 0-1  $\text{R}^5$ , and  
 $(\text{CH}_2)_r$  5-6 membered heterocycle consisting of: carbon  
 5 atoms and 1-4 heteroatoms selected from the group  
 consisting of N, O, and  $\text{S}(\text{O})_p$  substituted with 0-1  $\text{R}^5$ ;

$\text{R}^4$ , at each occurrence, is selected from H, =O,  $(\text{CH}_2)_r\text{OR}^2$ ,  
 $(\text{CH}_2)_r\text{F}$ ,  $(\text{CH}_2)_r\text{Cl}$ ,  $(\text{CH}_2)_r\text{Br}$ ,  $(\text{CH}_2)_r\text{I}$ ,  $\text{C}_{1-4}$  alkyl,  
 10  $(\text{CH}_2)_r\text{CN}$ ,  $(\text{CH}_2)_r\text{NO}_2$ ,  $(\text{CH}_2)_r\text{NR}^2\text{R}^{2a}$ ,  $\text{C}(\text{O})\text{R}^{2c}$ ,  $\text{NR}^2\text{C}(\text{O})\text{R}^{2b}$ ,  
 $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$ ,  $\text{C}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  
 $\text{C}(=\text{NS}(\text{O})_2\text{R}^5)\text{NR}^2\text{R}^{2a}$ ,  $\text{NHC}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  $\text{C}(\text{O})\text{NHC}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  
 $\text{SO}_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{SO}_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{SO}_2\text{-C}_{1-4}$  alkyl,  $\text{NR}^2\text{SO}_2\text{R}^5$ ,  
 $\text{S}(\text{O})_p\text{R}^5$ ,  $(\text{CF}_2)_r\text{CF}_3$ ,  $(\text{CH}_2)_r\text{-CF}_3$ ,  $\text{NCH}_2\text{R}^{1c}$ ,  $\text{OCH}_2\text{R}^{1c}$ ,  $\text{SCH}_2\text{R}^{1c}$ ,  
 15  $\text{N}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  $\text{O}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  $\text{S}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ , 5-6  
 membered carbocycle substituted with 0-1  $\text{R}^5$ , and 5-6  
 membered heterocycle consisting of: carbon atoms and  
 1-4 heteroatoms selected from the group consisting of  
 N, O, and  $\text{S}(\text{O})_p$  substituted with 0-1  $\text{R}^5$ ;

$\text{R}^{4a}$ , at each occurrence, is selected from H, =O,  $(\text{CH}_2)_r\text{OR}^2$ ,  
 $(\text{CF}_2)_r\text{CF}_3$ ,  $(\text{CH}_2)_r\text{-CF}_3$ ,  $(\text{CH}_2)_r\text{-F}$ ,  $(\text{CH}_2)_r\text{-Br}$ ,  $(\text{CH}_2)_r\text{-Cl}$ ,  
 $\text{C}_{1-4}$  alkyl,  $(\text{CH}_2)_r\text{CN}$ ,  $(\text{CH}_2)_r\text{NO}_2$ ,  $(\text{CH}_2)_r\text{NR}^2\text{R}^{2a}$ ,  
 $(\text{CH}_2)_r\text{C}(\text{O})\text{R}^{2c}$ ,  $\text{NR}^2\text{C}(\text{O})\text{R}^{2b}$ ,  $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$ ,  $(\text{CH}_2)_r\text{N}=\text{CHOR}^3$ ,  
 20  $\text{C}(\text{O})\text{NH}(\text{CH}_2)_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$ ,  $\text{C}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  
 $\text{NHC}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  $\text{SO}_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{SO}_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{SO}_2\text{-C}_{1-4}$   
 alkyl,  $\text{NR}^2\text{SO}_2\text{R}^5$ ,  $\text{C}(\text{O})\text{NHSO}_2\text{-C}_{1-4}$  alkyl,  $\text{S}(\text{O})_p\text{R}^5$ , 5-6  
 membered carbocycle substituted with 0-1  $\text{R}^5$ , and 5-6  
 membered heterocycle consisting of: carbon atoms and  
 25 1-4 heteroatoms selected from the group consisting of  
 N, O, and  $\text{S}(\text{O})_p$  substituted with 0-1  $\text{R}^5$ ;

30



- $R^{4b}$ , at each occurrence, is selected from H, =O,  $(CH_2)_rOR^3$ ,  
 $(CH_2)_r-F$ ,  $(CH_2)_r-Cl$ ,  $(CH_2)_r-Br$ ,  $(CH_2)_r-I$ ,  $C_{1-4}$  alkyl,  
 $(CH_2)_r-CN$ ,  $(CH_2)_r-NO_2$ ,  $(CH_2)_rNR^3R^{3a}$ ,  $(CH_2)_rC(O)R^3$ ,  
 $(CH_2)_rC(O)OR^{3c}$ ,  $NR^3C(O)R^{3a}$ ,  $C(O)NR^3R^{3a}$ ,  $NR^3C(O)NR^3R^{3a}$ ,  
5  $C(=NR^3)NR^3R^{3a}$ ,  $NR^3C(=NR^3)NR^3R^{3a}$ ,  $SO_2NR^3R^{3a}$ ,  $NR^3SO_2NR^3R^{3a}$ ,  
 $NR^3SO_2-C_{1-4}$  alkyl,  $NR^3SO_2CF_3$ ,  $NR^3SO_2$ -phenyl,  $S(O)_pCF_3$ ,  
 $S(O)_p-C_{1-4}$  alkyl,  $S(O)_p$ -phenyl,  $(CH_2)_rCF_3$ , and  $(CF_2)_rCF_3$ ;
- $R^5$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, =O,  
10  $(CH_2)_rOR^3$ , F, Cl, Br, I, -CN,  $NO_2$ ,  $(CH_2)_rNR^3R^{3a}$ ,  
 $(CH_2)_rC(O)R^3$ ,  $(CH_2)_rC(O)OR^{3c}$ ,  $NR^3C(O)R^{3a}$ ,  $C(O)NR^3R^{3a}$ ,  
 $NR^3C(O)NR^3R^{3a}$ ,  $CH(=NOR^{3d})$ ,  $C(=NR^3)NR^3R^{3a}$ ,  
 $NR^3C(=NR^3)NR^3R^{3a}$ ,  $SO_2NR^3R^{3a}$ ,  $NR^3SO_2NR^3R^{3a}$ ,  $NR^3SO_2-C_{1-4}$   
alkyl,  $NR^3SO_2CF_3$ ,  $NR^3SO_2$ -phenyl,  $S(O)_pCF_3$ ,  $S(O)_p-C_{1-4}$   
15 alkyl,  $S(O)_p$ -phenyl,  $(CF_2)_rCF_3$ , phenyl substituted with  
0-2  $R^6$ , naphthyl substituted with 0-2  $R^6$ , and benzyl  
substituted with 0-2  $R^6$ ;
- $R^6$ , at each occurrence, is selected from H, OH,  $(CH_2)_rOR^2$ ,  
20 halo,  $C_{1-4}$  alkyl, CN,  $NO_2$ ,  $(CH_2)_rNR^2R^{2a}$ ,  $(CH_2)_rC(O)R^{2b}$ ,  
 $NR^2C(O)R^{2b}$ ,  $NR^2C(O)NR^2R^{2a}$ ,  $C(=NH)NH_2$ ,  $NHC(=NH)NH_2$ ,  
 $SO_2NR^2R^{2a}$ ,  $NR^2SO_2NR^2R^{2a}$ , and  $NR^2SO_2C_{1-4}$  alkyl;
- $R^7$ , at each occurrence, is selected from H, OH,  $C_{1-4}$   
25 alkoxycarbonyl,  $C_{6-10}$  aryloxy,  $C_{6-10}$  aryloxycarbonyl,  
 $C_{6-10}$  arylmethylcarbonyl,  $C_{1-4}$  alkylcarbonyloxy  $C_{1-4}$   
alkoxycarbonyl,  $C_{6-10}$  arylcarbonyloxy  $C_{1-4}$   
alkoxycarbonyl,  $C_{1-6}$  alkylaminocarbonyl,  
phenylaminocarbonyl, and phenyl  $C_{1-4}$  alkoxycarbonyl;  
30
- $R^8$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, and  
 $(CH_2)_n$ -phenyl;

alternatively,  $R^7$  and  $R^8$ , when attached to the same nitrogen, combine to form a 5-6 membered heterocyclic ring consisting of carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, O, and  $S(O)_p$ ;

$R^9$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, and  $(CH_2)_n$ -phenyl;

$n$ , at each occurrence, is selected from 0, 1, 2, and 3;

$m$ , at each occurrence, is selected from 0, 1, and 2;


$p$ , at each occurrence, is selected from 0, 1, and 2;

$r$ , at each occurrence, is selected from 0, 1, 2, and 3;

$s$ , at each occurrence, is selected from 0, 1, and 2; and,

$t$ , at each occurrence, is selected from 0, 1, 2, and 3.

[2] In a preferred embodiment, the present invention provides a novel compound, wherein the compound is of formula Ia<sub>1</sub>-Ic<sub>1</sub>, wherein:



ring D<sub>2</sub> is a 5-membered heteroaromatic ring system comprising E, carbon atoms, and 0-2 N atoms, wherein E

is selected from O, S, and N-R<sup>c</sup> and ring D<sub>2</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

ring D<sub>3</sub> is a 5-membered heteroaromatic ring system  
 5 comprising carbon atoms and from 0-3 additional N atoms  
 and ring D<sub>3</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

R is selected from H, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>,  
 NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub>  
 10 alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub>  
 alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


R<sup>a</sup> is selected from H, OH, SH, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> thioalkoxy,  
 NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub>  
 15 alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub>  
 alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


R<sup>b</sup> is selected from H, C<sub>1-4</sub> alkyl, Cl, F, Br, I, OH, C<sub>1-3</sub>  
 alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>,  
 20 CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


R<sup>c</sup> is selected from H, C<sub>1-4</sub> alkyl, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub>  
 alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl),  
 25 CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and  
 CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


G<sub>1</sub> is absent or is selected from CH<sub>2</sub>, C(O), O, NR<sup>3</sup>, S(O)<sub>p</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>, CH<sub>2</sub>C(O), OCH<sub>2</sub>, CH<sub>2</sub>O, NR<sup>3</sup>CH<sub>2</sub>, CH<sub>2</sub>NR<sup>3</sup>,  
 30 S(O)<sub>p</sub>CH<sub>2</sub>, CH<sub>2</sub>S(O)<sub>p</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>C(O)CH<sub>2</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>C(O), OCH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>OCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>O, NR<sup>3</sup>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>NR<sup>3</sup>CH<sub>2</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>NR<sup>3</sup>, S(O)<sub>p</sub>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>S(O)<sub>p</sub>CH<sub>2</sub>, and CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>p</sub>, and  
 provided that G<sub>1</sub>-Q form other than a N-N, O-N, or S-N  
 bond;

ring M is substituted with 0-2  $R^{1a}$  and is selected from the group:










$Z^2$  is selected from H,  $C_{1-4}$  alkyl, phenyl, benzyl,  $C(O)R^3$ ,  
and  $S(O)_pR^{3c}$ ;

5

ring P, including  $P_1$ ,  $P_2$ ,  $P_3$ , and  $P_4$  is selected from group:



- 10  $G_1$  is absent or is selected from  $(CR^3R^{3a})_{1-3}$ ,  
 $(CR^3R^{3a})_u C(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_u O(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_u NR^3(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_u C(O)NR^3(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_u NR^3C(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_u S(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_u S(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_u S(O)_2(CR^3R^{3a})_w$ ,  
15  $(CR^3R^{3a})_u S(O)NR^3(CR^3R^{3a})_w$ , and  $(CR^3R^{3a})_u S(O)_2NR^3(CR^3R^{3a})_w$ ,  
wherein  $u + w$  total 0, 1, or 2, provided that  $G_1$  does

not form a N-N, N-O, N-S, NCH<sub>2</sub>N, NCH<sub>2</sub>O, or NCH<sub>2</sub>S bond with either group to which it is attached;

A is selected from one of the following carbocyclic and  
 5 heterocyclic systems which are substituted with 0-2 R<sup>4</sup>;  
     phenyl, piperidinyl, piperazinyl, pyridyl,  
     pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl,  
     pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl,  
     isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl,  
 10 thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl,  
     1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,  
     1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl,  
     1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,  
     1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,  
 15 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl,  
     benzothiofuranyl, indolyl, benzimidazolyl,  
     benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl,  
     benzisothiazolyl, and isoindazolyl;


20 X is selected from -(CR<sup>2</sup>R<sup>2a</sup>)<sub>1-4</sub>-, -C(O)-, -C(=NR<sup>1c</sup>)-,  
     -CR<sup>2</sup>(NR<sup>1c</sup>R<sup>2</sup>)-, -C(O)CR<sup>2</sup>R<sup>2a</sup>-, -CR<sup>2</sup>R<sup>2a</sup>C(O)-, -C(O)NR<sup>2</sup>-,  
     -NR<sup>2</sup>C(O)-, -C(O)NR<sup>2</sup>CR<sup>2</sup>R<sup>2a</sup>-, -NR<sup>2</sup>C(O)CR<sup>2</sup>R<sup>2a</sup>-,  
     -CR<sup>2</sup>R<sup>2a</sup>C(O)NR<sup>2</sup>-, -CR<sup>2</sup>R<sup>2a</sup>NR<sup>2</sup>C(O)-, -NR<sup>2</sup>C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-,  
     -NR<sup>2</sup>CR<sup>2</sup>R<sup>2a</sup>-, -CR<sup>2</sup>R<sup>2a</sup>NR<sup>2</sup>-, O, -CR<sup>2</sup>R<sup>2a</sup>O-, and -OCR<sup>2</sup>R<sup>2a</sup>-;

25 Y is selected from one of the following carbocyclic and  
     heterocyclic systems that are substituted with 0-2 R<sup>4a</sup>;  
     cyclopropyl, cyclopentyl, cyclohexyl, phenyl,  
     piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl,  
 30 morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl,  
     oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl,  
     isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl,  
     thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl,  
     1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,  
 35 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl,



1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,  
 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,  
 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl,  
 benzothiofuranyl, indolyl, benzimidazolyl,  
 5 benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl,  
 benzisothiazolyl, and isoindazolyl;

alternatively, Y is selected from the following bicyclic  
 heteroaryl ring systems:



K is selected from O, S, NH, and N;

15 Z is selected from a bond, CH<sub>2</sub>O, OCH<sub>2</sub>, NH, CH<sub>2</sub>NH, NHCH<sub>2</sub>,  
 CH<sub>2</sub>C(O), C(O)CH<sub>2</sub>, C(O)NH, NHC(O), CH<sub>2</sub>S(O)<sub>2</sub>, S(O)<sub>2</sub>(CH<sub>2</sub>),  
 SO<sub>2</sub>NH, and NHSO<sub>2</sub>, provided that Z does not form a N-N,  
 N-O, N-S, NCH<sub>2</sub>N, NCH<sub>2</sub>O, or NCH<sub>2</sub>S bond with either group  
 to which it is attached;

20 R<sup>4</sup>, at each occurrence, is selected from H, =O, (CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, F,  
 Cl, Br, I, C<sub>1-4</sub> alkyl, CN, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>2</sup>R<sup>2a</sup>, C(O)R<sup>2c</sup>,  
 NR<sup>2</sup>C(O)R<sup>2b</sup>, C(O)NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>C(O)NR<sup>2</sup>R<sup>2a</sup>, C(=NR<sup>2</sup>)NR<sup>2</sup>R<sup>2a</sup>,  
 SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, NR<sup>2</sup>SO<sub>2</sub>R<sup>5</sup>,  
 S(O)<sub>p</sub>R<sup>5</sup>, CF<sub>3</sub>, NCH<sub>2</sub>R<sup>1c</sup>, OCH<sub>2</sub>R<sup>1c</sup>, SCH<sub>2</sub>R<sup>1c</sup>, N(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>,  
 25 O(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>, S(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>, 5-6 membered  
 carbocycle substituted with 0-1 R<sup>5</sup>, and 5-6 membered  
 heterocycle consisting of: carbon atoms and 1-4  
 heteroatoms selected from the group consisting of N, O,  
 and S(O)<sub>p</sub> substituted with 0-1 R<sup>5</sup>; and,

$R^{4a}$ , at each occurrence, is selected from H, =O,  $(CH_2)_rOR^2$ ,  
 $CF_3$ , F, Br, Cl,  $C_{1-4}$  alkyl, CN,  $NO_2$ ,  $(CH_2)_rNR^2R^{2a}$ ,  
 $(CH_2)_rC(O)R^{2c}$ ,  $NR^2C(O)R^{2b}$ ,  $C(O)NR^2R^{2a}$ ,  $NR^2C(O)NR^2R^{2a}$ ,  
5  $C(=NR^2)NR^2R^{2a}$ ,  $NHC(=NR^2)NR^2R^{2a}$ ,  $SO_2NR^2R^{2a}$ ,  $NR^2SO_2NR^2R^{2a}$ ,  
 $NR^2SO_2-C_{1-4}$  alkyl,  $NR^2SO_2R^5$ ,  $C(O)NHSO_2-C_{1-4}$  alkyl,  
 $S(O)_pR^5$ , 5-6 membered carbocycle substituted with 0-1  
 $R^5$ , and 5-6 membered heterocycle consisting of: carbon  
atoms and 1-4 heteroatoms selected from the group  
10 consisting of N, O, and  $S(O)_p$  substituted with 0-1  $R^5$ .

[3] In another preferred embodiment, the present invention  
provides a novel compound, wherein the compound is of  
15 formula Ib<sub>1</sub> or Ic<sub>1</sub>, wherein;

ring D<sub>2</sub> is a 5-membered heteroaromatic ring system  
comprising E, carbon atoms, and 0-2 N atoms, wherein E  
is selected from O, S, and  $N-R^c$  and ring D<sub>2</sub> is  
20 substituted with 1  $R^a$  and 0-1  $R^b$ ;


R is selected from H, Cl, F, Br, I, OH,  $C_{1-3}$  alkoxy,  $NH_2$ ,  
 $NH(C_{1-3}$  alkyl),  $N(C_{1-3}$  alkyl)<sub>2</sub>,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3}$   
alkyl), and  $CH_2N(C_{1-3}$  alkyl)<sub>2</sub>;


25  $R^a$  is selected from H, OH, SH,  $NH_2$ ,  $NH(C_{1-3}$  alkyl),  $N(C_{1-3}$   
alkyl)<sub>2</sub>,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3}$  alkyl), and  $CH_2N(C_{1-3}$   
alkyl)<sub>2</sub>;

30  $R^b$  is selected from H,  $C_{1-4}$  alkyl, Cl, F, Br, I, OH,  $C_{1-3}$   
alkoxy,  $NH_2$ ,  $NH(C_{1-3}$  alkyl),  $N(C_{1-3}$  alkyl)<sub>2</sub>,  $CH_2NH_2$ ,  
 $CH_2NH(C_{1-3}$  alkyl), and  $CH_2N(C_{1-3}$  alkyl)<sub>2</sub>;

$R^c$  is selected from H,  $C_{1-4}$  alkyl,  $C_{1-3}$  alkoxy,  $NH_2$ ,  $NH(C_{1-3}$  alkyl),  $N(C_{1-3}$  alkyl) $_2$ ,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3}$  alkyl), and  $CH_2N(C_{1-3}$  alkyl) $_2$ ;


5 ring M is substituted with 0-2  $R^{1a}$  and is selected from the group:





5

ring P, including P<sub>1</sub>, P<sub>2</sub>, P<sub>3</sub>, and P<sub>4</sub> is selected from group:



Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R<sup>4a</sup>;

- 5 phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazole, thiadiazole, triazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, benzofuran, benzothiofuran, indole, benzimidazole, benzimidazolone, benzoxazole, benzthiazole, indazole, benzisoxazole, benzisothiazole, and isoindazole;
- 10  
15

Z is selected from a bond, CH<sub>2</sub>O, OCH<sub>2</sub>, NH, CH<sub>2</sub>NH, NHCH<sub>2</sub>, CH<sub>2</sub>C(O), C(O)CH<sub>2</sub>, C(O)NH, NHC(O), CH<sub>2</sub>S(O)<sub>2</sub>, S(O)<sub>2</sub>(CH<sub>2</sub>), SO<sub>2</sub>NH, and NHSO<sub>2</sub>, provided that Z does not form a N-N, N-O, N-S, NCH<sub>2</sub>N, NCH<sub>2</sub>O, or NCH<sub>2</sub>S bond with either group to which it is attached;

20


R<sup>4</sup>, at each occurrence, is selected from H, =O, (CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, F, Cl, Br, I, C<sub>1-4</sub> alkyl, CN, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>2</sup>R<sup>2a</sup>, C(O)R<sup>2c</sup>,

25

NR<sup>2</sup>C(O)R<sup>2b</sup>, C(O)NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>C(O)NR<sup>2</sup>R<sup>2a</sup>, C(=NR<sup>2</sup>)NR<sup>2</sup>R<sup>2a</sup>,  
 SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, NR<sup>2</sup>SO<sub>2</sub>R<sup>5</sup>,  
 S(O)<sub>p</sub>R<sup>5</sup>, CF<sub>3</sub>, 5-6 membered carbocycle substituted with  
 0-1 R<sup>5</sup>, and 5-6 membered heterocycle consisting of:  
 5 carbon atoms and 1-4 heteroatoms selected from the  
 group consisting of N, O, and S(O)<sub>p</sub> substituted with 0-1  
 R<sup>5</sup>; and,

R<sup>4a</sup>, at each occurrence, is selected from H, =O, (CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>,  
 10 CF<sub>3</sub>, F, Br, Cl, C<sub>1-4</sub> alkyl, CN, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>2</sup>R<sup>2a</sup>,  
 (CH<sub>2</sub>)<sub>r</sub>C(O)R<sup>2c</sup>, NR<sup>2</sup>C(O)R<sup>2b</sup>, C(O)NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>C(O)NR<sup>2</sup>R<sup>2a</sup>,  
 C(=NR<sup>2</sup>)NR<sup>2</sup>R<sup>2a</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, C(O)NHSO<sub>2</sub>-C<sub>1-4</sub> alkyl, S(O)<sub>p</sub>R<sup>5</sup>,  
 5-6 membered carbocycle substituted with 0-1 R<sup>5</sup>, and 5-6  
 membered heterocycle consisting of: carbon atoms and  
 15 1-4 heteroatoms selected from the group consisting of  
 N, O, and S(O)<sub>p</sub> substituted with 0-1 R<sup>5</sup>.

[4] In another preferred embodiment, the present invention  
 20 provides a novel compound, wherein the compound is of  
 formula Ib<sub>2</sub>:

Ib<sub>2</sub>

or a stereoisomer or pharmaceutically acceptable salt  
 25 thereof, wherein;


ring D<sub>2</sub> is a 5-membered heteroaromatic ring system  
 comprising E, carbon atoms, and 0-2 N atoms, wherein E  
 is selected from O, S, and N- R<sup>c</sup> and ring D<sub>2</sub> is  
 30 substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;


R is selected from H, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;

5 R<sup>a</sup> is selected from H, OH, SH, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), and N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


R<sup>b</sup> is selected from H, C<sub>1-4</sub> alkyl, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>,  
 10 CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;

ring M is substituted with 0-1 R<sup>1a</sup> and is selected from the group:










G<sub>1</sub> is absent or is selected from CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>O, OCH<sub>2</sub>, NH, CH<sub>2</sub>NH, NHCH<sub>2</sub>, CH<sub>2</sub>C(O), C(O)CH<sub>2</sub>, C(O)NH, NHC(O),

5 CH<sub>2</sub>S(O)<sub>2</sub>, S(O)<sub>2</sub>(CH<sub>2</sub>), SO<sub>2</sub>NH, and NHSO<sub>2</sub>, provided that G<sub>1</sub> does not form a N-N, N-O, N-S, NCH<sub>2</sub>N, NCH<sub>2</sub>O, or NCH<sub>2</sub>S bond with either group to which it is attached.

10 [5] In another preferred embodiment, the present invention provides a novel compound, wherein the compound is selected for one of the formulas:



- 5 or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

G<sub>1</sub> is absent;

- 10 A is selected from phenyl, piperidinyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R<sup>4</sup>; and,
- B is selected from phenyl, pyrrolidino, N-pyrrolidino-carbonyl, morpholino, N-morpholino-carbonyl, 1,2,3-triazolyl, imidazolyl, and benzimidazolyl, and is
- 15 substituted with 0-1 R<sup>4a</sup>;

R<sup>2</sup>, at each occurrence, is selected from H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, cyclopropylmethyl, cyclobutyl, and cyclopentyl;

R<sup>2a</sup>, at each occurrence, is selected from H, CH<sub>3</sub>, and CH<sub>2</sub>CH<sub>3</sub>;

alternatively, R<sup>2</sup> and R<sup>2a</sup>, together with the atom to which they are attached, combine to form pyrrolidine

5 substituted with 0-2 R<sup>4b</sup> or piperidine substituted with 0-2 R<sup>4b</sup>;

R<sup>4</sup>, at each occurrence, is selected from OH, OR<sup>2</sup>, (CH<sub>2</sub>)OR<sup>2</sup>, (CH<sub>2</sub>)<sub>2</sub>OR<sup>2</sup>, F, Br, Cl, I, C<sub>1-4</sub> alkyl, NR<sup>2</sup>R<sup>2a</sup>, (CH<sub>2</sub>)NR<sup>2</sup>R<sup>2a</sup>,  
10 (CH<sub>2</sub>)<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, CF<sub>3</sub>, and (CF<sub>2</sub>)CF<sub>3</sub>;

R<sup>4a</sup> is selected from C<sub>1-4</sub> alkyl, CF<sub>3</sub>, OR<sup>2</sup>, (CH<sub>2</sub>)OR<sup>2</sup>, (CH<sub>2</sub>)<sub>2</sub>OR<sup>2</sup>, NR<sup>2</sup>R<sup>2a</sup>, (CH<sub>2</sub>)NR<sup>2</sup>R<sup>2a</sup>, (CH<sub>2</sub>)<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, SR<sup>5</sup>, S(O)R<sup>5</sup>, S(O)<sub>2</sub>R<sup>5</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, and 1-CF<sub>3</sub>-tetrazol-2-yl;

15

R<sup>4b</sup>, at each occurrence, is selected from H, CH<sub>3</sub>, and OH;

R<sup>5</sup>, at each occurrence, is selected from CF<sub>3</sub>, C<sub>1-6</sub> alkyl, phenyl, and benzyl; and,

20

r, at each occurrence, is selected from 0, 1, and 2.

[6] In another preferred embodiment, the present invention  
25 provides a novel compound, wherein;

A is selected from the group: phenyl, piperidinyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and,  
30

B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-

dimethylaminomethyl)phenyl, 2-(N-methylaminomethyl)phenyl, 2-(N-ethyl-N-methylaminomethyl)phenyl, 2-(N-pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-imidazolyl, 2-(methylaminomethyl)-1-imidazolyl, 2-(N-(cyclopropylmethyl)aminomethyl)phenyl, 2-(N-(cyclobutyl)aminomethyl)phenyl, 2-(N-(cyclopentyl)aminomethyl)phenyl, 2-(N-(4-hydroxypiperidinyl)methyl)phenyl, and 2-(N-(3-hydroxypyrrolidinyl)methyl)phenyl.

[7] In another preferred embodiment, the present invention provides a novel compound selected from the group:

1-[3-(2'-Amino-3',4'-thiadiazol-5'-yl)phenyl]-3-methyl-6-[2'-aminosulfonyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt;

1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
5
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
10
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
15
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
20
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
25
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
30
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
35
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
40
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
45
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
50
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-  
[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
pyrimidine-5,7-dione;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-  
trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
pyrimidine-5,7-dione;
- 10 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
pyrimidine-5,7-dione;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-  
[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
pyrimidine-5,7-dione;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-



- pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-

- fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
5
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
10
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
15
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
20
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
25
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
30
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
35
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
40
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
45
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
50

- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione; and,
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

or a pharmaceutically acceptable salt thereof.

35

[8] In another preferred embodiment, the present invention provides a novel compound selected from the group:

- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-

- biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-

- biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;



- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-  
[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-  
trifluoromethyl-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-  
[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-  
hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 30 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-  
hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-  
hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 50 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-  
hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; and,
- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- or a pharmaceutically acceptable salt thereof.

[9] In another preferred embodiment, the present invention provides a novel compound selected from the group:

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-

- biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;



- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50

- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one; and,
- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

or a pharmaceutically acceptable salt thereof.

[10] In another preferred embodiment, the present invention  
5 provides a novel compound selected from the group:

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-  
N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
10 pyridin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
15 [3,4-c]-pyridin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
20 [3,4-c]-pyridin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-  
N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
25 pyridin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-  
N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
30 pyridin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-  
trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
35 [3,4-c]-pyridin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
40 [3,4-c]-pyridin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-  
[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
45 pyridin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-  
[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
50 pyridin-7-one;



- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-

- fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-

- fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-  
dimethylamino)methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-  
dimethylamino)methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-  
dimethylamino)methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-  
dimethylamino)methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-  
methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-  
1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-  
(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-  
(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-  
trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;



- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one; and,
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 or a pharmaceutically acceptable salt thereof.

[11] In another preferred embodiment, the present invention provides a novel compound selected from the group:

- 15 1-[3-(5-oxo-4,5-Dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
- 20 6-(2'-{[(3S)-3-Hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-4-yl)-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
- 25 6-(2'-[(Dimethylamino)methyl]-1,1'-biphenyl-4-yl)-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
- 30 6-[2'-(Methylsulfonyl)-1,1'-biphenyl-4-yl]-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;
- 35 1-[3-(5-Amino-1,3,4-oxadiazol-2-yl)phenyl]-6-[2'-[(dimethylamino)methyl]-1,1'-biphenyl-4-yl]-3-

(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-{2'-  
5 [(dimethylamino)methyl]-1,1'-biphenyl-4-yl}-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-[2'-(1-  
10 pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-(4-{2-  
15 [(dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-{4-[2-(1-  
20 pyrrolidinylmethyl)-1H-imidazol-1-yl]phenyl}-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

6-(4-{2-[(Dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-1-  
25 [3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

3-Methyl-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-  
30 yl)phenyl]-6-{4-[2-(1-pyrrolidinylmethyl)-1H-imidazol-  
1-yl]phenyl}-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

7-Oxo-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-  
35 6-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-


4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridine-3-carboxamide;

1-[3-(5-Oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)phenyl]-7-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[3,4-*c*]azepin-8(1*H*)-one; and,

1-[2-(5-Oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)phenyl]-6-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7*H*-pyrazolo[3,4-*c*]pyridin-7-one;

or a pharmaceutically acceptable salt thereof.

In another embodiment, the present invention provides a novel compound, wherein the compound is of formula Ia<sub>1</sub>-Ic<sub>1</sub>, wherein:



ring D<sub>2</sub> is a 5-membered heteroaromatic ring system comprising E, carbon atoms, and 0-2 N atoms, wherein E is selected from O, S, and N-R<sup>c</sup> and ring D<sub>2</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

ring D<sub>3</sub> is a 5-membered heteroaromatic ring system comprising carbon atoms and from 0-3 additional N atoms and ring D<sub>3</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

R is selected from H, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;

5

R<sup>a</sup> is selected from H, OH, SH, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> thioalkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;

10

R<sup>b</sup> is selected from H, C<sub>1-4</sub> alkyl, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;

15

R<sup>c</sup> is selected from H, C<sub>1-4</sub> alkyl, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>; and,

20

G<sub>1</sub> is absent or is selected from CH<sub>2</sub>, C(O), O, NR<sup>3</sup>, S(O)<sub>p</sub>, CH<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>, CH<sub>2</sub>C(O), OCH<sub>2</sub>, CH<sub>2</sub>O, NR<sup>3</sup>CH<sub>2</sub>, CH<sub>2</sub>NR<sup>3</sup>, S(O)<sub>p</sub>CH<sub>2</sub>, CH<sub>2</sub>S(O)<sub>p</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>C(O)CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>C(O), OCH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>OCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>O, NR<sup>3</sup>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>NR<sup>3</sup>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NR<sup>3</sup>, S(O)<sub>p</sub>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>S(O)<sub>p</sub>CH<sub>2</sub>, and CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>p</sub>, and provided that G<sub>1</sub>-M form other than a N-N, O-N, or S-N bond.

25

30

In another embodiment, the present invention provides a novel compound, wherein the compound is of formula Ib<sub>1</sub> or Ic<sub>1</sub>, wherein;

ring D<sub>2</sub> is a 5-membered heteroaromatic ring system comprising E, carbon atoms, and 0-2 N atoms, wherein E is selected from O, S, and N-R<sup>c</sup> and ring D<sub>2</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

5

R is selected from H, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


10 R<sup>a</sup> is selected from H, OH, SH, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;

15 R<sup>b</sup> is selected from H, C<sub>1-4</sub> alkyl, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>; and,

R<sup>c</sup> is selected from H, C<sub>1-4</sub> alkyl, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and  
20 CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>.

In another embodiment, the present invention provides a novel compound, wherein the compound is of formula Ib<sub>2</sub>:

25

Ib<sub>2</sub>

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

30 ring D<sub>2</sub> is a 5-membered heteroaromatic ring system comprising E, carbon atoms, and 0-2 N atoms, wherein E


is selected from O, S, and N-R<sup>C</sup> and ring D<sub>2</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;


R is selected from H, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>,  
 5 NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


R<sup>a</sup> is selected from H, OH, SH, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), and N(C<sub>1-3</sub> alkyl)<sub>2</sub>; and,  
 10 R<sup>b</sup> is selected from H, C<sub>1-4</sub> alkyl, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>.

15


In another embodiment, the present invention provides a novel compound selected from one of the formulas:













or a stereoisomer or pharmaceutically acceptable salt thereof.

5

In another embodiment, the present invention provides a novel compound selected from one of the formulas:




10



5

or a stereoisomer or pharmaceutically acceptable salt thereof.

In another embodiment, the present invention provides a novel compound selected from one of the formulas:





or a stereoisomer or pharmaceutically acceptable salt thereof.


In another embodiment, the present invention provides a novel compound wherein:


15

ring M is substituted with 0-2  $R^{1a}$  and is selected from the group:










$Z^2$  is selected from H,  $C_{1-4}$  alkyl, phenyl, benzyl,  $C(O)R^3$ ,  
and  $S(O)_pR^{3c}$ ;

5

ring P, including  $P_1$ ,  $P_2$ ,  $P_3$ , and  $P_4$  is selected from group:




10


In another embodiment, the present invention provides a novel compound wherein:

ring M is substituted with 0-2  $R^{1a}$  and is selected from the  
group:


15









5 ring P, including P<sub>1</sub>, P<sub>2</sub>, P<sub>3</sub>, and P<sub>4</sub> is selected from group:




In another embodiment, the present invention provides a  
 5 novel compound wherein:

ring M is substituted with 0-1  $R^{1a}$  and is selected from the  
 group:







In another embodiment, the present invention provides a  
 5 novel compound wherein A is selected from one of the  
 following carbocyclic and heterocyclic systems that are  
 substituted with 0-2 R<sup>4</sup>;

phenyl, piperidinyl, piperazinyl, pyridyl,  
 pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl,  
 10 pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl,  
 isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl,  
 thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl,  
 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,  
 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl,  
 15 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,  
 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,  
 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl,  
 benzothiofuranyl, indolyl, benzimidazolyl,  
 benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl,  
 20 benzisothiazolyl, and isoindazolyl;

In another embodiment, the present invention provides a novel compound wherein A is selected from phenyl, piperidinyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R<sup>4</sup>.

5

In another embodiment, the present invention provides a novel compound wherein A is selected from the group: phenyl, piperidinyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl,  
 10 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl.

In another embodiment, the present invention provides a  
 15 novel compound wherein:

B is selected from: H, Y, and X-Y, provided that Z and B are attached to different atoms on A;


20 X is selected from  $-(CR^2R^{2a})_{1-4}-$ ,  $-C(O)-$ ,  $-C(=NR^{1c})-$ ,  $-CR^2(NR^{1c}R^2)-$ ,  $-C(O)CR^2R^{2a}-$ ,  $-CR^2R^{2a}C(O)-$ ,  $-C(O)NR^2-$ ,  $-NR^2C(O)-$ ,  $-C(O)NR^2CR^2R^{2a}-$ ,  $-NR^2C(O)CR^2R^{2a}-$ ,  $-CR^2R^{2a}C(O)NR^2-$ ,  $-CR^2R^{2a}NR^2C(O)-$ ,  $-NR^2C(O)NR^2-$ ,  $-NR^2-$ ,  $-NR^2CR^2R^{2a}-$ ,  $-CR^2R^{2a}NR^2-$ , O,  $-CR^2R^{2a}O-$ , and  $-OCR^2R^{2a}-$ ;

25

Y is selected from one of the following carbocyclic and heterocyclic systems that are substituted with 0-2 R<sup>4a</sup>;  
 cyclopropyl, cyclopentyl, cyclohexyl, phenyl,  
 piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl,  
 30 morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl,  
 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,  
 35 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl,

1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,  
 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,  
 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl,  
 benzothiofuranyl, indolyl, benzimidazolyl,  
 5 benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl,  
 benzisothiazolyl, and isoindazolyl;

alternatively, Y is selected from the following bicyclic  
 heteroaryl ring systems:



K is selected from O, S, NH, and N.

15 In another embodiment, the present invention provides a  
 novel compound wherein:

Y is selected from one of the following carbocyclic and  
 heterocyclic systems which are substituted with 0-2 R<sup>4a</sup>;  
 20 phenyl, piperidinyl, piperazinyl, pyridyl,  
 pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl,  
 pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl,  
 isothiazolyl, pyrazolyl, imidazolyl, oxadiazole,  
 thiadiazole, triazole, 1,2,3-oxadiazole, 1,2,4-  
 25 oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-  
 thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole,  
 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole,  
 1,2,5-triazole, 1,3,4-triazole, benzofuran,  
 benzothiofuran, indole, benzimidazole, benzimidazolone,

benzoxazole, benzthiazole, indazole, benzisoxazole, benzisothiazole, and isoindazole.

5 In another embodiment, the present invention provides a novel compound wherein B is selected from phenyl, pyrrolidino, N-pyrrolidino-carbonyl, morpholino, N-morpholino-carbonyl, 1,2,3-triazolyl, imidazolyl, and benzimidazolyl, and is substituted with 0-1 R<sup>4a</sup>.

10

In another embodiment, the present invention provides a novel compound wherein B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-dimethylaminomethyl)phenyl, 2-(N-methylaminomethyl)phenyl, 2-(N-ethyl-N-methylaminomethyl)phenyl, 2-(N-pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-imidazolyl, 2-(methylaminomethyl)-1-imidazolyl, 2-(N-(cyclopropylmethyl)aminomethyl)phenyl, 2-(N-(cyclobutyl)aminomethyl)phenyl, 2-(N-(cyclopentyl)aminomethyl)phenyl, 2-(N-(4-hydroxypiperidinyl)methyl)phenyl, and 2-(N-(3-hydroxypyrrolidinyl)methyl)phenyl.

15  
20  
25

In another embodiment, the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula Ia, Ib, or Ic or a pharmaceutically acceptable salt form thereof.

30

In another embodiment, the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of formula Ia, Ib, or Ic or a pharmaceutically acceptable salt form thereof.

In another embodiment, the present invention provides a compound of formula Ia, Ib, or Ic as described above for use in therapy.

In another embodiment, the present invention provides the use of a compound formula Ia, Ib, or Ic as described above for the manufacture of a medicament for the treatment of a thromboembolic disorder.

#### DEFINITIONS

The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes



used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. All tautomers of shown or described compounds are also considered to be part of the present  
5 invention.

The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that  
10 the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties.

The present invention is intended to include all  
15 isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

20 When any variable (e.g.,  $R^6$ ) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2  $R^6$ , then said group may optionally  
25 be substituted with up to two  $R^6$  groups and  $R^6$  at each occurrence is selected independently from the definition of  $R^6$ . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

30 When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then  
35 such substituent may be bonded via any atom in such

substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein, "alkyl" is intended to include both  
5 branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. C<sub>1-6</sub> alkyl, is intended to include C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, and C<sub>6</sub> alkyl groups. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl,  
10 t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C<sub>v</sub>F<sub>w</sub> where v = 1 to 3 and w = 1 to (2v+1)). Examples of haloalkyl  
15 include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. C<sub>1-6</sub> alkoxy, is intended to include C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>,  
20 C<sub>5</sub>, and C<sub>6</sub> alkoxy groups. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. C<sub>3-7</sub>  
25 cycloalkyl is intended to include C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, and C<sub>7</sub> cycloalkyl groups. "Alkenyl" is intended to include hydrocarbon chains of either straight or branched configuration and one or more unsaturated carbon-carbon bonds that may occur in any stable point along the chain,  
30 such as ethenyl and propenyl. C<sub>2-6</sub> alkenyl is intended to include C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, and C<sub>6</sub> alkenyl groups. "Alkynyl" is intended to include hydrocarbon chains of either straight or branched configuration and one or more triple carbon-carbon bonds that may occur in any stable point along the chain,

such as ethynyl and propynyl. C<sub>2-6</sub> Alkynyl is intended to include C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, and C<sub>6</sub> alkynyl groups.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to  
5 represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.

As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or  
10 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane,  
15 [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl.

As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5, 6, or 7-membered  
20 monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including  
25 any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable  
30 structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1,  
35 then these heteroatoms are not adjacent to one another. It

is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" or "heteroaryl" is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S. It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1.

10        Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, 15 benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indoliziny, 20 indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 25 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, 30 piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, 35 quinoxaliny, quinuclidinyl, tetrahydrofuranyl,

- tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
- 10       The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive
- 15       toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the
- 20       parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the
- 25       like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such
- conventional non-toxic salts include those derived from
- 30       inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic,
- 35       phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-

acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that  
5 contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two;  
10 generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby  
15 incorporated by reference.

Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc...) the compounds of the present invention may be delivered in prodrug form. Thus,  
20 the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. "Prodrugs" are intended to include any covalently bonded carriers that release an active parent drug of the present invention *in vivo* when such prodrug is administered to a mammalian  
25 subject. Prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound. Prodrugs  
30 include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group,  
35 respectively. Examples of prodrugs include, but are not

limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.

"Stable compound" and "stable structure" are meant to  
5 indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

"Substituted" is intended to indicate that one or more  
10 hydrogens on the atom indicated in the expression using "substituted" is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto  
15 (i.e., =O) group, then 2 hydrogens on the atom are replaced.

"Therapeutically effective amount" is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit factor Xa. The combination of compounds is  
20 preferably a synergistic combination. Synergy, as described, for example, by Chou and Talalay, *Adv. Enzyme Regul.* **1984**, 22:27-55, occurs when the effect (in this case, inhibition of factor Xa) of the compounds when administered in combination is greater than the additive effect of the  
25 compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination  
30 compared with the individual components.

#### SYNTHESIS

The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of  
35 organic synthesis. The compounds of the present invention

can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (*Protective Groups In Organic Synthesis*, Wiley and Sons, 1991). All references cited herein are hereby incorporated in their entirety herein by reference.

The compounds of the present invention represented by Formulas Ia, Ib, and Ic consist of a group "Ring D-G-G<sup>2</sup>-G<sup>1</sup>" (i.e., P<sub>4</sub> or M<sub>3</sub>) and a group "Z-A-B" (i.e., the remaining of P<sub>4</sub> or M<sub>3</sub>) attached to a [5,6]- or [5,7]-heterobicyclic core structure of varying composition. The five-membered ring can be pyrazole, triazole, isoxazole or isothiazole and this ring can be fused to a variety of six- or seven membered rings including but not limited to piperidinone, pyridinone, pyrimidinone, pyrimidinedione, pyranone, diazepinone, diazepinedione. The following discussion and schemes will describe methods for the syntheses of the heterobicyclic



cores and attachment of the groups "Ring D-G-G<sup>2</sup>-G<sup>12</sup>" and "Z-A-B".

The 4-aminopyrazole-5-carboxylate **V** is a useful intermediate for the preparation of many of the pyrazole fused compounds of Formulas Ia, Ib, and Ic wherein the P<sub>4</sub> residue is attached to a nitrogen atom of the pyrazole (Scheme I). This intermediate can be prepared in a variety of ways from aromatic hydrazines **I**. Hydrazines **I** are readily available starting materials. Specifically, they are conveniently prepared from the corresponding aniline by diazotization with NaNO<sub>2</sub> in acidic media followed by reduction of the resulting diazonium ion with a suitable reducing agent, with SnCl<sub>2</sub> being a preferred reagent. Non-aromatic hydrazines represented by **I** are readily prepared by a variety of methods, such as by displacement of a suitable halogen compound with hydrazine or with a protected hydrazine followed by deprotection.

Condensation of hydrazines **I** with a suitable hemiacetal or aldehyde followed by halogenation with NBS or NCS leads to hydrazidoyl halides **II**. Alternatively, the hydrazines **I** can be acylated with an acid chloride and converted to hydrazidoyl halides **II** by carbon tetrahalide/triphenylphosphine. The hydrazidoyl halides **II** are versatile intermediates for pyrazole synthesis (Shawali, A. S.; et. al. *J. Het. Chem.* **1980**, *17*, 833). The halide can be displaced with cyanide ion to afford cyanide **III**. Cyano compounds of this type can also be prepared more directly by diazotization of aniline **IV** followed by direct reaction with a cyano-containing active methylene compound, where R<sup>1a</sup> can include a variety of groups such as ester, ketone, cyano, trifluoromethyl, sulfone, aryl, etc. (Butler, R. N.; et. al. *J. Chem. Soc. Chem. Commun.* **1992**, *20*, 1481).

Treatment of **III** with a bromoacetate in the presence of a suitable base such as carbonate or trialkylamine results

in N-alkylation followed by ring closure to give the 4-aminopyrazole-5-carboxylate **V**. Alternatively, treatment of **II** with a nitropyruvate in the presence of a base such as alkoxide provides a 4-nitropyrazole by displacement of the halide followed by ring closure of the nitrogen onto the carbonyl group. Reduction of the nitro group can be accomplished by a variety of reducing agents, a preferred one of which is  $\text{SnCl}_2$ , to give the 4-aminopyrazole-5-carboxylate **V**.

10       The hyrazidoyl halide **II** can also be reacted with a ketoester where  $\text{R}'$  represents a masked ester, preferably a 2-furyl residue, to give a pyrazole-4-carboxylate **VI**. Ester hydrolysis, conversion to an acyl azide, either via the acid chloride or anhydride, heating to generate an isocyanate via  
15       Curtius rearrangement, and finally treatment with water affords the 4-aminopyrazole **VII**. Alternatively, the amino can be masked as an appropriate carbamate by using an alcohol instead of water in the Curtius rearrangement. When  $\text{R}' = 2\text{-furyl}$ , the furan can be oxidatively cleaved under a  
20       variety of conditions, such as sodium periodate with catalytic ruthenium trichloride, or  $\text{KMnO}_4$ , to afford a carboxylic acid which can be esterified to afford the 4-aminopyrazole-5-carboxylate **V**.


Another route to the 4-aminopyrazole **V** involves  
25       condensation of the hydrazine **I** with an appropriate diketone or monoprotected diketone to form a 3,5-disubstituted pyrazole in which the 5-substituent is a carboxylic ester. Usually, this pyrazole can be selectively nitrated at the 4-position with nitrating agents such as nitric acid or  
30       ammonium nitrate/trifluoroacetic anhydride. Reduction of the nitro group under a variety of conditions, such as with tin (II) chloride or catalytic hydrogenation, affords the 4-aminopyrazole **V**. This route can also be carried out using a diketone with a 2-furyl group as a latent carboxylate,

giving initially a 3,5-disubstituted pyrazole in which the 5-substituent is the 2-furyl group. Oxidative cleavage of the furyl group to a carboxylate, nitration of the pyrazole 4-position, esterification and nitro reduction then affords

5 4-aminopyrazole **V**. It will be recognized by those skilled in the art that the synthetic route chosen to **V** will depend on additional functionality present in the molecule of interest and the route may require additional protection/deprotection sequences as well as modifications in the order

10 of synthetic steps.

Scheme I



In Scheme II is shown how the 4-aminopyrazole-5-carboxylate **V** can be utilized to prepare a variety of structures described by Formulas Ia, Ib, and Ic where the A-

15

B residue is connected to a nitrogen atom of the bicyclic core. The 4-amino group can be protected as a suitable carbamate (see Greene and Wuts, *Protective Groups in Organic Synthesis*, Wiley and Sons, 1991) or as an azide group (NaNO<sub>2</sub>, acid, NaN<sub>3</sub>). In some cases it may not be necessary to protect the amino functionality, as will be recognized by those skilled in the art. Unmasking of the ester residue involves either basic hydrolysis (R = Me, Et), hydrogenolysis (R = Bn) or trifluoroacetic acid (R = t-Bu). Coupling of the resulting acid with the appropriate amine H<sub>2</sub>N-A-B can be accomplished by a wide variety of methods known to those skilled in the art, including dicyclohexylcarbodiimide and N,N-dimethylaminopyridine, the mixed anhydride method, and the BOP reagent. Alternatively, the amide bond can be formed directly from the ester (R = Me, Et) by reacting the ester with an aluminum reagent prepared from the amine H<sub>2</sub>N-A-B and trimethylaluminum. Deprotection of the amino group, if required, provides compounds **VIII**. Treating this amino amide with carbonyl diimidazole or other phosgene equivalent, such as triphosgene, provides pyrazolopyrimidinediones **IX**. Alternatively, aminocarboxylate **V** can be converted to pyrazolopyrimidinediones **IX** in a single step by heating with an appropriate isocyanate OCN-A-B in the presence of a base such as sodium hydride.

Treating **VIII** with a substituted bromoacetyl chloride or bromide in the presence of a base such as triethylamine affords the pyrazolodiazepinediones **X**. Refluxing **VIII** in the presence of formic acid provides the pyrazolopyrimidinones **XI** (R<sup>3</sup> = H). Substituted derivatives **XI** can be obtained by refluxing **VIII** in the presence of triethylorthoacetate (R<sup>3</sup> = Me) or other orthoesters. Reduction of **XI** with catalytic hydrogenation, sodium


borohydride in acidic medium or other reducing agent can provide compounds of type **XII**.

Additionally, **V** can be treated with a bromoacetate in the presence of a base such as carbonate or sodium hydride to provide **XIII**. Selective hydrolysis of either ester of **XIII** followed by standard coupling with  $H_2N-A-B$  and subsequent heating affords compounds **XIV**, which are regioisomeric with **X**.

Oxygen analogs of **XIV** are prepared by converting the amino group of **V** to a hydroxy group via a diazonium ion. Coupling with the amine  $H_2N-A-B$  by any of a wide variety of procedures yields **XV**. O-alkylation of **XV** with a bromoacetate in the presence of a base such as sodium hydride leads to **XVI**, the oxygen analogs of **XIV**.

In the cases of compounds **IX**, **X**, **XII** and **XIV** the nitrogen atom can be further functionalized to provide additional analogs, such as by treating with methyl iodide in the presence of a base to afford the N-methyl derivatives.

Scheme II




The 4-aminopyrazole-5-carboxylate can be used to prepare pyrazolopyranone and pyrazolopyridinone derivatives, in which the A-B residue is attached to a carbon atom of the bicyclic core, as shown in Scheme III. N-protection of **V** as described previously can be followed by straightforward conversion of the ester residue to an acid chloride. Treatment of this acid chloride with a zinc cuprate reagent

derived from Br-CH<sub>2</sub>-M<sub>3</sub> (the connecting portion of M<sub>3</sub> being aryl) will afford the ketone **XVII** after N-deprotection. Heating **XVII** with dimethylformamide dimethylacetal or with an orthoester can provide the pyrazolopyridinone compounds **XVIII**. Conversion of the 4-amino residue of **XVII** to a hydroxyl group via the diazonium ion will lead to **XIX**, which will provide the pyrazolopyranone derivatives **XX** under similar cyclization conditions.

Alternatively, treatment of the acid chloride **XXI**, obtained as described above where N-PG can represent a carbamate protected nitrogen or can represent conversion of the amino group to an azide group as described previously, with a suitable enamine in the presence of a base such as triethylamine can afford the ketone **XXII**. N-deprotection followed by heating will afford the pyrazolopyridinones **XXIII** (**XVIII** where R<sup>3</sup> = H).

Also, the ketone **XVII** can be prepared from the cyano compound **III** by treatment with a suitable bromoketone in the presence of a base such as carbonate or triethylamine. The required bromoketone is readily available by treating an appropriate acid chloride with diazomethane followed by HBr. It will be recognized by those skilled in the art that the syntheses of the compounds described in Scheme III may require additional protection/deprotection steps or modifications in the order of carrying out the steps, depending on additional functionality present in the compounds of interest.

Scheme III




Additional oxygen-containing bicyclic systems can be prepared as shown in Scheme IV. The 4-amino-5-carboxylate V can be converted to its 4-hydroxy derivative via the diazonium ion to give XXIV. Ester deprotection and amide bond formation with an appropriate H<sub>2</sub>N-M<sub>3</sub> as described in Scheme II will afford the amide XXV. Alternatively, the amide bond can be formed directly from the ester by addition of the aluminum reagent derived from H<sub>2</sub>N-M<sub>3</sub> and



trimethylaluminum. The 4-hydroxy substituent can be easily protected if required by any of a number of protecting groups, such as with *t*-butyldimethylsilyl ether (TBS), and then deprotected following amide bond formation. Treating the hydroxy amide **XXV** with carbonyl diimidazole or other phosgene equivalent, such as triphosgene, can provide the bicyclic core **XXVI**. Heating **XXV** in the presence of paraformaldehyde in the presence of a suitable acid such as *p*-toluenesulfonic acid will provide **XXVII** ( $R^3 = H$ ). Alternatively, **XXV** can be treated with dibromomethane in the presence of a suitable base such as carbonate to afford **XXVII** ( $R^3 = H$ ). Other aldehydes and substituted dibromomethanes can provide substituted derivatives of **XXVII** where  $R^3$  is not hydrogen.

Scheme IV



Additional bicyclic systems in which the  $\text{M}_3$  residue is substituted on a carbon atom can be prepared as shown in Scheme V. N-protection of 4-aminopyrazole-5-carboxylate **V**

can be followed by manipulation of the ester to afford an acid chloride or an N-methoxy-N-methyl amide. Addition of an enolate derived from  $\text{RO}_2\text{CCH}_2\text{-M}_3$  and a base such as lithium diisopropylamide or lithium hexamethyldisilazide provides

5 **XXVIII**. The N-methoxy-N-methyl amide is the preferred reaction partner for this addition, as this functionality prevents the formation of overaddition products. Alternatively, the enolate addition reaction could be done on the ester as well. N-Deprotection of the 4-amino

10 substituent allows it to close onto the ester residue and provides the pyrazolopiperidinedione **XXIX**.

Manipulation of the ester residue of **XXVIII** can lead to **XXX** where X represents a suitable leaving group such as a bromide or mesylate residue. A variety of methods can be

15 utilized for the transformation of **XXVIII** to **XXX**, such as ketone protection, reduction of the ester to a primary alcohol, ketone deprotection and conversion of the primary alcohol to a bromide using  $\text{CBr}_4/\text{PPh}_3$  or to a mesylate using methanesulfonyl chloride and a base such as triethylamine.

20 Alternatively, the ester can be hydrolyzed to the acid that can be reduced to the primary alcohol with borane and converted to a leaving group as just described. N-deprotection liberates the 4-amino group, which provides compounds of structure **XXXI** upon heating or treatment with


25 base.

The corresponding oxygen derivative is also available from **XXVIII**. N-deprotection, diazotization with  $\text{NaNO}_2$  in acidic medium and treatment with sulfuric acid produces the 4-hydroxy derivative **XXXII**. Protection of the alcohol

30 functionality, for example as the TBS ether, followed by ester manipulation as described above and subsequent alcohol deprotection, produces **XXXIII**. Treatment of **XXXIII** with a suitable base such as carbonate leads to ring closure to afford compounds **XXXIV**. Alternatively, compounds **XXXIII**

where X = OH can be closed to **XXXIV** via a Mitsunobu reaction by treatment with diethylazodicarboxylate and triphenylphosphine.

Scheme V




In scheme VI it is shown how to make additional bicyclic systems in which the M<sub>3</sub> residue is substituted on a carbon atom and the ring is substituted with an R<sup>3</sup> group.

10 Ester **XXVIII** can be converted under standard conditions to the N-methoxy-N-methyl amide **XXXV**. Addition of an appropriate Grignard reagent R<sup>3</sup>MgBr produces a ketone, which upon N-deprotection and heating in acidic conditions leads

to the substituted pyridones **XXXVI**. Hydride reduction, with REDAL for example, will produce the piperidone **XXXVII**.

Alternatively, diisobutylaluminum hydride reduction of the N-methoxy-N-methyl amide gives an aldehyde which will  
 5 add a suitable Grignard reagent  $R^3MgBr$  to afford **XXXVIII**. Conversion of the alcohol to a leaving group, for example by making the mesylate with methanesulfonyl chloride and a trialkylamine base, followed by N-deprotection leads to ring closure to piperidones **XXXVII**. The alcohol **XXXVIII** can also  
 10 be prepared from enamine **XXII** from Scheme III by hydrolysis to the corresponding aldehyde followed by addition of the appropriate Grignard reagent  $R^3MgBr$ .

Scheme VI




15

Preparation of a bicyclic system containing a seven-membered ring in which the  $M_3$  residue is attached to a carbon atom is described in Scheme VII. N-protection of aminoketone **XVII**, where N-PG represents preferably an N-protected nitrogen wherein both N-H groups are masked, such  
 20

as by conversion to an azide group, is followed by formation of a ketone enolate, with a base such as lithium diisopropylamide, and reaction with a bromoacetate to afford **XXXIX**. N-deprotection followed by heating of the resulting amino ester affords **XL**.

Alternatively, the ester can be converted by straightforward means to a more reactive species prior to ring closure, such as a mixed anhydride or acid chloride. Treatment of **XVII** with bromoacetyl bromide and a base such as triethylamine gives the acylamine **XLI** that can be cyclized by formation of the ketone enolate with a base such as lithium diisopropylamide.

Scheme VII




Additional seven-membered ring-containing bicyclic systems can be prepared as shown in Scheme VIII. The hydrazidoyl halide **II**, prepared as shown in Scheme I, can be cyclized with a cyanopyruvate in the presence of a base such as alkoxide to afford 4-cyanopyrazole **XLII**. Ester deprotection and coupling with  $H_2N-M_3$  as described in previous schemes yields cyanoamide **XLIII**. Reduction of the nitrile can be accomplished by various methods, such as by

catalytic hydrogenation or by reduction with sodium borohydride in the presence of cobalt chloride. Cyclization of the resulting aminoamide using carbonyl diimidazole or other phosgene equivalent as described previously affords  
5 compounds **XLIV**.

For the corresponding compound wherein the  $M_3$  residue is attached to carbon, the ester **XLII** can be converted to the N-methoxy-N-methyl amide as described previously. Treatment of this amide with the enolate derived from  $RO_2CH_2-$   
10  $M_3$  yields the ketone **XLV**. Catalytic hydrogenation of the nitrile affords an amine that upon heating undergoes cyclization to afford **XLVI**.

The oxygen containing analog corresponding to **XLIV** is obtained from ester **VI**, prepared as described in Scheme I.  
15 The group  $R'$  represents preferably a 2-furyl residue as a masked carboxylic acid. Reduction of the ester group of **VI** with a hydride reducing agent such as diisobutylaluminum hydride is followed by protection of the resulting primary alcohol, such as by a TBS ether. When  $R'$  is 2-furyl, the  
20 carboxylic acid can be unmasked by oxidation by a variety of reagents, including ozone, potassium permanganate, and sodium periodate in the presence of ruthenium trichloride. Coupling with a suitable with  $H_2N-M_3$  as described in previous schemes yields the amide **XLVII**. Deprotection of the alcohol  
25 affords a hydroxy amide, which can be cyclized using carbonyl diimidazole as described previously to afford compounds **XLVIII**.

Scheme VIII



Bicyclic compounds of Formulas Ia, Ib, and Ic containing a carbon atom at the pyrazole 4-position can be prepared by a [3+2] cycloaddition strategy as shown in Scheme IX (for a review of [3+2] cycloadditions, see 1,3-Dipolar Cycloaddition Chemistry (Padwa, ed.), Wiley, New York, 1984).

Treatment of unsaturated lactone **XLIX**, which is readily available by standard procedures known to those skilled in

the art, with an aluminum reagent prepared from an appropriate amine  $H_2N-M_3$  and trimethylaluminum affords the ring-opened amide **L**. Conversion of the primary alcohol under standard conditions to a suitable leaving group, such as a bromide or mesylate, and subjection to basic conditions affords the required unsaturated lactam **LI**. Treatment of hydrazidoyl halide **II**, prepared as shown in Scheme I where  $X = Cl$  or  $Br$ , with triethylamine generates a 1,3-dipolar intermediate **LII**, which can undergo a [3+2] cycloaddition with the olefin **LI** to produce the bicyclic pyrazolidine **LIII** as the predominant regioisomer. Mild oxidation with reagents such as chloranil or nickel peroxide will produce the pyrazolopiperidones **LIV**. Further oxidation, such as with DDQ, can produce the unsaturated derivatives **LV**. These steps can be reversed such that initial complete oxidation to **LV** can be followed by reduction, such as by catalytic hydrogenation, to produce **LIV**. The ketone derivatives can be prepared by condensation of an appropriate amine  $H_2N-M_3$  with the cyclic anhydride **LVI** to give **LVII**. Alternatively, a saturated derivative of **LVI** can be condensed with an appropriate amine  $H_2N-M_3$  followed by oxidation to the unsaturated derivative **LVII**, such as by treatment with LDA/PhSeSePh and subsequent oxidative selenoxide elimination. The olefin **LVII** undergoes similar [3+2] cycloaddition to give a pyrazolidine intermediate that is readily oxidized to the pyrazolopiperidinedione derivatives **LVIII** by a variety of oxidizing agents.


An alternative preparation of compound **LIV** is also described. A standard alkylation/acylation sequence on the amine  $H_2N-M_3$  affords amide ester **LIX**, which contains a protected ketone functionality. A variety of reaction conditions can be employed for these transformations, which are known to those skilled in the art. Deprotection of the ketone followed by Dieckmann condensation under basic



conditions affords the cyclic diketoamides **LX**. Condensation of **LX** with an appropriate hydrazine is readily accomplished by heating in a solvent such as acetic acid or ethanol to afford the previously described **LIV**.

- 5        Pyrazolopiperidone compounds **LXVI** (where  $n=1$ ) wherein the pyrazole 4-substituent  $R^{1a}$  is a trifluoromethyl group can be prepared via the method outlined in Scheme X. Coupling of the acid **LXI** with amines  $H_2N-M_3$  can be accomplished under a variety of conditions, such as via the acid chloride,
- 10    giving amide **LXII**. A straightforward sequence involving cleavage of the tetrahydrofuran ring and intramolecular cyclization on the amide nitrogen affords the ketolactam **LXIII**. This compound can also be prepared from the lactam **LXIV** by introduction of sulfur substituents and subsequent
- 15    oxidation to the ketolactam **LXIII**. Formation of the morpholine or related enamine followed by reaction with trifluoroacetic anhydride leads to the trifluoroacetylated intermediate **LXV**. Alternatively, dichlorination of lactam **LXIV** with  $PCl_5$  or analogous reagents, heating with excess
- 20    morpholine or related amine, and reacting the enamine derived in this way with trifluoroacetic anhydride also yields the trifluoroacetylated intermediate **LXV**. This compound can be readily condensed with an appropriate hydrazine to afford the pyrazolopiperidone compounds **LXVI**.
- 25    Analogous chemistry can be utilized to afford [5,7]-fused ring systems (where  $n=2$ ).

Scheme IX




Unsaturated analogs of the above compounds can be prepared as shown in the bottom of Scheme X. Bromination of **LXVII**, prepared as described in Scheme IX and the top of

Scheme X, affords bromo analog **LXVIII**. Elimination of HBr by treatment with any of a variety of bases, such as DBU, will afford the unsaturated bicyclic analogs **LXIX**. Additional analogs can be prepared by displacement of the

5 bromide **LXVIII** by any of a wide variety of nitrogen-, oxygen- and sulfur-based nucleophiles.

Scheme X




10 Additional [5,7]-fused bicyclic systems which contain an additional heteroatom in the seven-membered ring can be prepared as shown in Scheme XI. Compounds **LXXI** where X is O or S can be prepared from commercially available tetrahydro-4H-pyran-4-one and tetrahydrothiopyran-4-one. Photoinduced

15 Schmidt rearrangement of (triisopropylsilyl)azidohydrin (Evans, P. A. and Modi, D. P. *J. Org. Chem.* **1995**, *60*, 6662-6663), which is formed from tetrahydro-4H-pyran-4-one and tetrahydrothiopyran-4-one, provides tetrahydro-1,4-oxazepin-

5(2H)-one and tetrahydro-1,4-thiazepin-5(2H)-one. Compounds **LXXI** where X is NH or NR can be prepared by Schmidt rearrangement of 4-piperidone monohydrate hydrochloride or protected 4-piperidone (Groves, J. T. and Chambers, R. R. Jr. *J. Am. Chem. Soc.* **1984**, *106*, 630-638). Ullmann coupling of the lactam with I(Br)-M<sub>3</sub> provides the lactam **LXXII** with an M<sub>3</sub> residue. Dichlorination with phosphorus pentachloride or related reagent affords a dichlorinated intermediate which can react with morpholine to give the enamine **LXXIII**. Reaction of **LXXIII** with DMAP and an appropriate acid chloride or acid anhydride provides the acylenamine intermediate **LXXIV** which can be condensed with an appropriate hydrazine in acetic acid to afford the [5,7]-fused bicyclic compounds **LXXV**.


Scheme XI



Bicyclic compounds of Formulas Ia, Ib, and Ic which contain a carbon atom at the pyrazole 4-position and wherein the M<sub>3</sub> residue is attached to a carbon atom are also prepared by a [3+2] cycloaddition strategy as shown in Scheme XII. Unsaturated cyclic ketones **LXXVI** are readily available by standard synthetic methods known to those skilled in the art. The [3+2] cycloaddition with the 1,3-

dipole generated from **II** as described previously gives a pyrazolidine intermediate that can be readily oxidized to the pyrazolocyclohexanone **LXXVII**. Introduction of a double bond, such as by treating with LDA and PhSeSePh followed by oxidative selenoxide elimination, gives the unsaturated derivative **LXXVIII**. Incorporation of a residue such as a protected alcohol into the unsaturated ketone, represented by **LXXIX**, leads to pyrazolocyclohexanone **LXXX** following [3+2] cycloaddition and subsequent oxidation. Deprotection of the alcohol and oxidation by a variety of reagents affords the pyrazolocyclohexanedione **LXXXI**.

Scheme XII



Additional bicyclic compounds of Formulas Ia, Ib, and Ic containing a carbon atom at the pyrazole 4-position are

described in Scheme XIII. Condensation of hydrazidoyl halide **II** with a diketoester in the presence of a base such as alkoxide affords pyrazoles **LXXXII**. Heating this ketoester in the presence of readily available hydrazines

5  $M_3-NHNH_2$  affords the pyrazolopyridazinones **LXXXIII**.


For preparation of pyrazolopyridazinones where  $R^3$  is hydrogen, the hydrazidoyl halide **II** can be cyclized with a furyl ketoester in the presence of alkoxide base to afford **LXXXIV**. Standard functional group manipulations, involving

10 ester reduction and protection, furyl oxidation and esterification leads to **LXXXV**, although not necessarily in that order. Those skilled in the art will be able to determine a proper order and appropriate reagents for achieving these transformations. Alcohol deprotection and

15 oxidation, such as by manganese dioxide, affords an aldehyde ester which readily produces **LXXXVI** upon heating in the presence of a hydrazine  $M_3-NHNH_2$ . Appropriate functional group manipulation of **LXXXIV**, of which many methods are available, can also afford ester acids **LXXXVII**. Activation

20 of the carboxylic acid, such as by formation of the acid chloride with oxalyl chloride, followed by heating in the presence of a hydrazine  $M_3-NHNH_2$  affords the pyrazolopyridazinedione **LXXXVIII**.

Scheme XIII



The preparation of the compounds of Formulas Ia, Ib,  
 and Ic where the five-membered ring is triazole is  
 5 accomplished using azide intermediates. Azides readily  
 undergo [3+2] cycloaddition reactions with a variety of  
 olefins and alkynes, and the application of this reaction to  
 the synthesis of the triazole-fused bicyclic compounds of  
 Formulas Ia, Ib, and Ic is shown in Scheme XIV. As  
 10 described for the pyrazole-fused compounds previously, the  
 4-amino-1,2,3-triazole-5-carboxylate **XCII** is a particularly  
 useful intermediate for the preparation of many of the  
 triazole-fused bicyclic systems. The required azides **LXXXIX**

are readily available. Aliphatic azides are easily prepared from the corresponding bromide by displacement with sodium azide in solvents such as dimethylformamide and dimethyl sulfoxide.  $P_4$  represents an aryl azide. These types of  
5 azides are readily available from the corresponding aniline by diazotization with  $\text{NaNO}_2$  in acidic medium followed by displacement of the diazonium ion with sodium azide. The [3+2] cycloaddition of azides **LXXXIX** with nitroolefins **XC** ( $R' = \text{Me}, 2\text{-furyl}$ ) affords the triazoles **XCI** as the major  
10 product, in which initial cyclization to a triazoline intermediate is followed by autooxidation to the triazole products (Cailleux, P.; et. al. *Bull. Soc. Chim. Belg.* **1996**, *105*, 45). These reactions can be performed in refluxing benzene or similar solvents at similar temperatures.  
15 Conversion of **XCI** to the 4-amino-1,2,3-triazole-5-carboxylate **XCII** is straightforward. When  $R'$  is methyl, oxidation of the methyl group with an oxidant such as  $\text{KMnO}_4$  gives the carboxylic acid which can be esterified to an appropriate ester. Reduction of the nitro group by any of a  
20 variety of reducing agents, preferably  $\text{SnCl}_2$  or catalytic hydrogenation, gives **XCII**. When  $R'$  is 2-furyl, the carboxylic acid can be unmasked by a variety of oxidizing agents, including ozone,  $\text{KMnO}_4$  and sodium periodate/ruthenium trichloride, to give the carboxylic acid  
25 which can be esterified and reduced as described above to afford **XCII**. The 4-hydroxy-1,2,3-triazole-5-carboxylates can be obtained via the diazonium ion of **XCII** as described for the pyrazole series to afford **XCIV**.


The reaction of azides **LXXXIX** with active methylene  
30 compounds is also illustrated in Scheme XIV. Treating **LXXXIX** with cyano- or nitropyruvates in the presence of a base such as alkoxide affords triazoles **XCIII**. The triazole-4-carboxylate derivatives can be prepared by treating **LXXXIX** with a furyl ketoester in the presence of



alkoxide base to afford **XCV**. These reactions are analogous to those described in Scheme I for the pyrazole derivatives. The triazole-containing bicyclic systems having a carbon atom at the 4-position of the triazole can be prepared by  
5 [3+2] cycloaddition of an appropriate azide **LXXXIX** with an unsaturated lactam **LI** or an unsaturated cyclic ketone **LXXVI**. These cycloadditions are performed by heating in an appropriate solvent, such as benzene or toluene. The resulting triazoline intermediates are readily oxidized to  
10 the fused triazoles using chloroanil, nickel peroxide or other mild oxidant to give **XCVI** and **XCVII**, respectively.

The triazole intermediates **XCI**, **XCII**, **XCIII**, **XCIV**, **XCV**, **XCVI** and **XCVII** can be transformed into the final triazole-containing bicyclic compounds described by Formulas Ia, Ib,  
15 and Ic following the procedures described for the corresponding pyrazole derivatives in Schemes II-XI. The nitro group present in **XCI** and **XCIII** can correspond to the "N-PG" residue described in Schemes II-VIII, or alternatively, the nitro group can be reduced at an  
20 appropriate time and further protected as a suitable carbamate derivative or as an azido group.

Scheme XIV



The preparation of the compounds of Formulas Ia, Ib, and Ic where the five-membered ring is isoxazole is accomplished as shown in Scheme XV. The hydroximinoyl chloride **XCIX** is a useful intermediate for the preparation of isoxazole-fused compounds. This intermediate is readily available from appropriate aldehydes **XCVIII** by oxime formation with hydroxylamine followed by chlorination with N-chlorosuccinimide. Treatment of **XCIX** with a cyanoacetate


in the presence of a base such as carbonate results in cyclization to give a 5-aminoisoxazole-4-carboxylate **C**. The amino residue of **C** can be readily converted into the corresponding hydroxy or cyano derivatives **CI** and **CII**,  
5 respectively, via the diazonium ion, as described earlier for the pyrazole and triazole compounds.

The isoxazole-5-carboxylates are available from cyclization of **XCIX** with a furan ketoester to give **CIII**. Oxidation of the furan to a carboxylic acid residue is  
10 accomplished by a variety of oxidizing agents as described earlier.

The hydroxyiminoyl chloride **XCIX** can also be treated with a base such as triethylamine to generate a nitrile oxide intermediate, which can undergo [3+2] cycloaddition  
15 reactions with appropriate olefins or alkynes. This is a convenient method by which to prepare bicyclic compounds containing a carbon atom at the 5-position of the isoxazole ring. For example, cycloaddition with the unsaturated lactam **LI** leads to formation of a fused isoxazoline  
20 intermediate which is readily oxidized with reagents such as nickel peroxide, chloranil or DDQ to afford **CIV**.

Cycloaddition with unsaturated cyclic ketone and oxidation under the same conditions affords the ketone analog **CV**. The isoxazole-fused intermediates **C**, **CI**, **CII**, **CIII**, **CIV** and **CV**  
25 can be transformed into the final isoxazole-containing bicyclic compounds described by Formulas Ia, Ib, and Ic following the procedures described for the corresponding pyrazole derivatives in Schemes II-XI.

Scheme XV




The preparation of the compounds of Formulas Ia, Ib,  
 and Ic where the five-membered ring is isothiazole is  
 5 accomplished as shown in Scheme XVI. One method for  
 preparing the 5-aminoisothiazole-4-carboxylate intermediate  
**CVIII** proceeds from readily available acid chloride **CVI**.  
 Condensation of **CVI** with a cyanoacetate in the presence of a  
 base such as a magnesium alkoxide followed by treatment with

ammonia in an alcoholic solvent gives an aminonitrile **CVII**. Treatment with hydrogen sulfide in the presence of a base such as triethylamine affords a thioamide that can undergo an oxidative cyclization to **CVIII** upon treatment with  
5 hydrogen peroxide or bromine. As described in previous schemes, the amino residue can easily be converted into the corresponding hydroxyl or cyano derivatives **CIX** or **CX**, respectively.

Another useful intermediate for the preparation of  
10 isothiazole compounds of the present invention is the nitrile sulfide **CXIII**. This intermediate can be generated conveniently from heterocycle **CXII**, which itself can be prepared from amides **CXI** either by treating with chlorocarbonylsulphenyl chloride or by treating with  
15 trichloromethanesulphenyl chloride followed by aqueous sodium hydroxide. Thermolysis of heterocycle **CXII** affords the nitrile sulfide **CXIII**, which can undergo many of the same reactions as the corresponding nitrile oxide intermediates. For example, [3+2] cycloaddition of **CXIII** with olefins **LI**  
20 and **LXXVI** can afford, after subsequent mild oxidation as described previously, the isothiazole-fused compounds **CXIV** and **CXV**, respectively. Isothiazole intermediates **CVIII**, **CIX**, **CX**, **CXIV** and **CXV** can be transformed into the final isothiazole-containing bicyclic compounds described by  
25 Formulas Ia, Ib, and Ic following the procedures described for the corresponding pyrazole derivatives in Schemes II-XI.

Scheme XVI



Formulas Ia, Ib, and Ic also describes pyrazole-fused bicyclic compounds in which the  $\text{P}_4$  group resides on a carbon atom of the pyrazole ring. These compounds can be prepared as shown in Scheme XVII. Condensation of acid chlorides **CVI** with cyanoacetates in the presence of a base such as magnesium methoxide affords an enol derivative that is


converted to the enol ether **CXVI** (X = OMe) with diazomethane or to the chloro derivative **CXVI** (X = Cl) with POCl<sub>3</sub>.

Heating with hydrazine (R' = H) or a substituted hydrazine affords 5-amino-4-carboxylate **CXVII**. The amino residue of **CXVII** can be converted to the hydroxyl or cyano derivative **CXVIII** or **CXIX**, respectively via the diazonium ion as described previously.

The 5-carboxylate derivatives can be prepared by condensing a substituted hydrazine with a hemiacetal or related derivative represented by **CXX**. Chlorination or bromination with NCS or NBS, respectively, affords the hydrazidoyl halides **CXXI**. Reaction of **CXXI** with the anion of a furyl ketoester affords the 5-carboxylate **CXXII**, the furan residue of which can be oxidized to a carboxylic acid residue by methods described previously.

The hydrazidoyl halides **CXXI** can also participate in [3+2] cycloadditions as described previously to afford, after oxidation of the intermediate pyrazolines, the pyrazole-fused compounds **CXXIII** and **CXXIV**. The intermediates **CXVII**, **CXVIII**, **CXIX**, **CXXII**, **CXXIII** and **CXXIV** can be transformed into the final C-linked pyrazole-containing bicyclic compounds described by Formulas Ia, Ib, and Ic following the procedures described for the corresponding N-linked pyrazole derivatives in Schemes II-XI.

Scheme XVII




Bicyclic compounds of the present invention in which the five membered ring is pyrrole and the P<sub>4</sub> group is attached to a carbon atom can be prepared as shown in Scheme XVIII. For 5 compounds of this type wherein a nitrogen atom is required at the pyrrolo 2-position, the 2-aminopyrrole **CXXVI** is a useful intermediate. This compound can be prepared by condensation of



readily obtained aminocarbonyl compounds **CXXV** with an appropriate cyanoacetate. This condensation can be carried out under basic conditions or by heating with azeotropic removal of water. The 2-aminopyrroles **CXXVI** can be diazotized and  
5 subsequently converted into the 2-cyano- and 2-hydroxypyrroles **CXXVII**, which are suitable intermediates for a variety of the bicyclic compounds of this invention.

Pyrrole 2,3-dicarboxylates can also be prepared from aminocarbonyl compounds **CXXV**. Michael addition under basic  
10 conditions with acetylenedicarboxylate esters is followed by in situ ring closure to afford the pyrrole 2,3-dicarboxylate diester. Selective hydrolysis of one of the esters, typically the 2-ester, affords the pyrrole 2-carboxylic acid **CXXVIII**. Curtius rearrangement of **CXXVIII** affords another route to the  
15 2-aminopyrrole **CXXVI**. Also, the carboxylic acid can be reduced to the alcohol **CXXIX** using borane or by sodium borohydride reduction of the derived mixed anhydride. Following procedures described in Schemes II-VIII and Scheme XIII, the intermediates **CXXVI**, **CXXVII**, **CXXVIII** and **CXXIX** can be converted to the final  
20 pyrrolo-fused bicyclic compounds of Formulas Ia, Ib, and Ic. Other procedures not described here are also known to those skilled in the art and can be used to prepare the pyrrolo-fused bicyclic compounds of Formulas Ia, Ib, and Ic.

Scheme XVIII




Bicyclic compounds of the present invention in which the five membered ring is furan and the  $P_4$  is attached to a carbon atom can be prepared as shown in Scheme XIX. For compounds of this type wherein a nitrogen atom is required at the furyl 2-position, the 2-aminofuran **CXXXI** is a useful intermediate. These compounds can be prepared analogously to the pyrrole analogs described in Scheme XVIII. Thus, condensation of readily obtained hydroxycarbonyl compounds **CXXX** with an appropriate cyanoacetate affords the 2-aminofurans **CXXXI**. This condensation can be carried out under basic conditions or by heating with azeotropic removal of water. The 2-aminofurans **CXXXI** can be diazotized and subsequently converted into the 2-cyano- and 2-hydroxyfurans **CXXXII**, which are suitable intermediates for a variety of the bicyclic compounds of this invention.

Furan 2,3-dicarboxylates can also be prepared from hydroxycarbonyl compounds **CXXX**, analogously to the pyrrole analogs described in Scheme XVIII. Michael addition of **CXXX** under basic conditions with acetylenedicarboxylate esters is

followed by in situ ring closure to afford the furan 2,3-dicarboxylate diester. Selective hydrolysis of one of the esters, typically the 2-ester, affords the furan 2-carboxylic acid **CXXXIII**. Curtius rearrangement of **CXXXIII** affords another route to the 2-aminofurans **CXXXI**. Also, the carboxylic acid can be reduced to the alcohol **CXXXIV** using borane or by sodium borohydride reduction of the derived mixed anhydride. Following procedures described in Schemes II-VIII and Scheme XIII, the intermediates **CXXXI**, **CXXXII**, **CXXXIII** and **CXXXIV** can be converted to the final furan-fused bicyclic compounds of Formulas Ia, Ib, and Ic. Other procedures not described here are also known to those skilled in the art and can be used to prepare the furan-fused bicyclic compounds of Formulas Ia, Ib, and Ic.

Scheme XIX




Bicyclic compounds of the present invention in which the five membered ring is thiophene and the  $\text{P}_4$  is attached to a carbon atom can be prepared as shown in Scheme XX. For compounds of this type wherein a nitrogen atom is required at

the thiophene 2-position, the 2-aminothiophene **CXXXVI** is a useful intermediate. These compounds can be prepared analogously to the pyrrole analogs described in Scheme XVIII. Thus, condensation of readily obtained mercaptocarbonyl compounds **CXXXV** with an appropriate cyanoacetate affords the 2-aminothiophenes **CXXXVI**. This condensation can be carried out under basic conditions or by heating with azeotropic removal of water. Alternatively, condensation of the cyanoacetate with ketone **CXXXVIII** affords olefin **CXXXIX**. In a subsequent step, **CXXXIX** can be converted into 2-aminothiophenes **CXXXVI** by treatment with S<sub>8</sub> and a base such as triethylamine. The 2-aminothiophenes **CXXXVI** can be diazotized and subsequently converted into the 2-cyano- and 2-hydroxythiophenes **CXXXVII**, which are suitable intermediates for a variety of the bicyclic compounds of this invention.


Thiophene 2,3-dicarboxylates can be prepared from alkali-metal acetylenethiolates **CXL**. These compounds react with acetylenedicarboxylate esters in a [3+2] cycloaddition to afford thiophene 2,3-dicarboxylate diesters. Selective hydrolysis of one of the esters, typically the 2-ester, affords the thiophene 2-carboxylic acid **CXLI**. Curtius rearrangement of **CXLI** affords another route to the 2-aminothiophenes **CXXXVI**. Also, the carboxylic acid can be reduced to the alcohols **CXLII** using borane or by sodium borohydride reduction of the derived mixed anhydride. Following procedures described in Schemes II-VIII and Scheme XIII, the intermediates **CXXXVI**, **CXXXVII**, **CXLI** and **CXLII** can be converted to the final thiophene-fused bicyclic compounds of Formulas Ia, Ib, and Ic. Other procedures not described here are also known to those skilled in the art and can be used to prepare the thiophene-fused bicyclic compounds of Formulas Ia, Ib, and Ic.

Scheme XX





Bicyclic compounds of the present invention in which the five membered ring is imidazole and  $\text{P}_4$  is attached to a nitrogen atom can be prepared as shown in Scheme XXI. These compounds **CXLI** through **CLXIV**, where the R group may be alkyl, aryl or a protecting group PG, are available either from commercial sources or through known prior art and can be represented generically by **CLXV**. Suitable protection of the imidazole nitrogen affords compounds of the type **CLXVI**, which are further elaborated via a cupric mediated coupling of appropriate  $\text{M}_3$  containing boronic acid to yield **CLXVII**. Subsequent removal of the imidazole-protecting group PG affords compounds such as **CLXVIII**. The introduction of a  $\text{P}_4$  substituent is accomplished as before by the coupling of a  $\text{P}_4$  containing boronic acid in a manner such that the  $\text{P}_4$  group is transferred to the imidazole nitrogen as depicted by **CLXIX**.

Scheme XXI



Heterocyclic systems **CXLI** and **CXLII**, as shown in Scheme XXII (wherein D can be -CN or halo), can be easily prepared according to the Schemes I-XXI.


Scheme XXII

**CXLIII****CXLIV**

The compounds of the present invention have a group "A-B" and a group "G-D" attached to ring Q. Preparations of some of the "A-B" moieties can follow the same methods described in WO97/23212, WO97/30971, WO97/38984, WO98/01428, WO98/06694, WO98/28269, WO98/28282, WO98/57934, WO98/57937, and WO98/57951, the contents of which are incorporated herein by reference.

Compounds of this invention wherein G is absent and D is a cyano group **CXLV** can be easily manipulated to afford thiadiazoles **CXLVI**, oxadiazoles **CXLVII**, triazoles **CXLVIII**, pyrazoles **CXLIX-CL**, and triazolones **CLI-CLII** as outlined in Scheme XXIII.


Scheme XXIII



Other heterocycles contained in this invention can also be obtained via methods shown in Scheme XXIV




Scheme XXIV



The des-carbonyl compounds of this invention where M<sub>1</sub> is CH<sub>2</sub> can be prepared from the corresponding carbonyl intermediate A such as LIII (Scheme IX) by reduction as shown in Scheme XX.

Further manipulation of the R<sub>1</sub> and R<sub>2</sub> groups would lead to the final compounds of this invention.

Scheme XXV



10

## UTILITY

The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death,

transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin.

The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometrically by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant,  $K_i$ .

Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCl, and 0.5% PEG 8000. The Michaelis constant,  $K_m$ , for substrate hydrolysis was determined at 25°C using the method of Lineweaver and Burk. Values of  $K_i$  were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 mM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate  $K_i$  values:

$$(v_0 - v_s) / v_s = I / (K_i (1 + S / K_m))$$

where:

$v_0$  is the velocity of the control in the absence of inhibitor;

$v_s$  is the velocity in the presence of inhibitor;  
 $I$  is the concentration of inhibitor;  
 $K_i$  is the dissociation constant of the enzyme:inhibitor complex;  
5      $S$  is the concentration of substrate;  
       $K_m$  is the Michaelis constant.

Using the methodology described above, some compounds of the present invention were found to exhibit a  $K_i$  of  $\leq 10 \mu M$ , thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors.  
10

Compounds tested in the above assay are considered to be active if they exhibit a  $K_i$  of  $\leq 10 \mu M$ . Preferred compounds of the present invention have  $K_i$ 's of  $\leq 1 \mu M$ . More preferred compounds of the present invention have  $K_i$ 's of  $\leq 0.1 \mu M$ . Even more preferred compounds of the present invention have  $K_i$ 's of  $\leq 0.01 \mu M$ . Still more preferred compounds of the present invention have  $K_i$ 's of  $\leq 0.001 \mu M$ .  
15

The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae. The AV shunt device consists of a piece of 6-cm tygon tubing that contains a piece of silk thread. Blood will flow from the femoral artery via the AV-shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c., or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose  
20  
25  
30

which produces 50% inhibition of thrombus formation) are estimated by linear regression.

The compounds of the present invention may also be useful as inhibitors of serine proteases, notably human  
5 thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds  
10 have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes.

15 Some compounds of the present invention were shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. *In vitro* inhibition constants were determined by the method described  
20 by Kettner et al. in *J. Biol. Chem.* **1990**, *265*, 18289-18297, herein incorporated by reference. In these assays, thrombin-mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX) was monitored spectrophotometrically. Addition of an inhibitor to the  
25 assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% PEG 6000, was incubated with  
30 various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm that arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of  
35 the reaction velocity as a function of substrate

concentration using the standard method of Lineweaver and Burk. Using the methodology described above, some compounds of this invention were evaluated and found to exhibit a  $K_i$  of less than 10  $\mu\text{M}$ , thereby confirming the utility of the compounds of the present invention as effective thrombin inhibitors.

The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anti-coagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents.

The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" it is meant an amount of a compound of the present invention that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.

By "administered in combination" or "combination therapy" it is meant that the compound of the present invention and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention.

The term anti-platelet agents (or platelet inhibitory agents), as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA), and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include IIb/IIIa antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof.

The term thrombin inhibitors (or anti-thrombin agents), as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boro peptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boro peptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine,

arginine, homoarginine and corresponding isothiuronium  
analogs thereof. The term hirudin, as used herein, includes  
suitable derivatives or analogs of hirudin, referred to  
herein as hirulogs, such as disulfatohirudin. Boro-peptide  
5 thrombin inhibitors include compounds described in Kettner  
et al., U.S. Patent No. 5,187,157 and European Patent  
Application Publication Number 293 881 A2, the disclosures  
of which are hereby incorporated herein by reference. Other  
suitable boroarginine derivatives and boro-peptide thrombin  
10 inhibitors include those disclosed in PCT Application  
Publication Number 92/07869 and European Patent Application  
Publication Number 471,651 A2, the disclosures of which are  
hereby incorporated herein by reference.

The term thrombolytics (or fibrinolytic) agents (or  
15 thrombolytics or fibrinolytics), as used herein, denotes  
agents that lyse blood clots (thrombi). Such agents include  
tissue plasminogen activator, anistreplase, urokinase or  
streptokinase, including pharmaceutically acceptable salts  
or prodrugs thereof. The term anistreplase, as used herein,  
20 refers to anisoylated plasminogen streptokinase activator  
complex, as described, for example, in European Patent  
Application No. 028,489, the disclosure of which is hereby  
incorporated herein by reference herein. The term  
urokinase, as used herein, is intended to denote both dual  
25 and single chain urokinase, the latter also being referred  
to herein as prourokinase.

Administration of the compounds of the present  
invention in combination with such additional therapeutic  
agent, may afford an efficacy advantage over the compounds  
30 and agents alone, and may do so while permitting the use of  
lower doses of each. A lower dosage minimizes the potential  
of side effects, thereby providing an increased margin of  
safety.

The compounds of the present invention are also useful  
35 as standard or reference compounds, for example as a quality

standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness.

The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present.

#### Dosage and Formulation

The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical



carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage regimen for the compounds of the present invention will, of course, vary depending upon known  
5 factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment;  
10 the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.

15 By way of general guidance; the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20  
20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three,  
25 or four times daily.

Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal  
30 delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or  
35 carriers (collectively referred to herein as pharmaceutical

carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

5       For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl  
10       cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral  
administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically  
acceptable inert carrier such as ethanol, glycerol, water,  
15       and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring  
agents can also be incorporated into the mixture.. Suitable  
binders include starch, gelatin, natural sugars such as  
glucose or beta-lactose, corn sweeteners, natural and  
20       synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol,  
waxes, and the like. Lubricants used in these dosage forms  
include sodium oleate, sodium stearate, magnesium stearate,  
sodium benzoate, sodium acetate, sodium chloride, and the  
like. Disintegrators include, without limitation, starch,  
25       methyl cellulose, agar, bentonite, xanthan gum, and the like.

      The compounds of the present invention can also be administered in the form of liposome delivery systems, such  
as small unilamellar vesicles, large unilamellar vesicles,  
30       and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine,  
or phosphatidylcholines.

      Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such  
35       polymers can include polyvinylpyrrolidone, pyran copolymer,

polyhydroxypropylmethacrylamide-phenol,  
polyhydroxyethylaspartamidephenol, or polyethyleneoxide-  
polylysine substituted with palmitoyl residues.

Furthermore, the compounds of the present invention may be  
5 coupled to a class of biodegradable polymers useful in  
achieving controlled release of a drug, for example,  
polylactic acid, polyglycolic acid, copolymers of polylactic  
and polyglycolic acid, polyepsilon caprolactone, polyhydroxy  
butyric acid, polyorthoesters, polyacetals,  
10 polydihydropyrans, polycyanoacylates, and crosslinked or  
amphipathic block copolymers of hydrogels.

Dosage forms (pharmaceutical compositions) suitable for  
administration may contain from about 1 milligram to about  
100 milligrams of active ingredient per dosage unit. In  
15 these pharmaceutical compositions the active ingredient will  
ordinarily be present in an amount of about 0.5-95% by  
weight based on the total weight of the composition.

Gelatin capsules may contain the active ingredient and  
powdered carriers, such as lactose, starch, cellulose  
20 derivatives, magnesium stearate, stearic acid, and the like.  
Similar diluents can be used to make compressed tablets.  
Both tablets and capsules can be manufactured as sustained  
release products to provide for continuous release of  
medication over a period of hours. Compressed tablets can  
25 be sugar coated or film coated to mask any unpleasant taste  
and protect the tablet from the atmosphere, or enteric  
coated for selective disintegration in the gastrointestinal  
tract.

Liquid dosage forms for oral administration can contain  
30 coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous  
dextrose (glucose), and related sugar solutions and glycols  
such as propylene glycol or polyethylene glycols are  
suitable carriers for parenteral solutions. Solutions for  
35 parenteral administration preferably contain a water soluble

salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.

5 Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in  
10 Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.

Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

15       Capsules

A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams  
20 magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement  
25 pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried.

Tablets

Tablets may be prepared by conventional procedures so  
30 that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase  
35 palatability or delay absorption.

### Injectable

A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and  
5 water. The solution should be made isotonic with sodium chloride and sterilized.

### Suspension

An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely  
10 divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.

Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may  
15 be about 0.1 to 100 milligrams of the compound of the present invention and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10  
20 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit.

Where the compounds of the present invention are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be  
25 about 0.01 to 25 milligrams of the compound of the present invention and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of the present invention and about 1 to 3  
30 milligrams of anti-platelet agents, per kilogram of patient body weight.

Where the compounds of the present invention are administered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of the present invention, per kilogram of  
35 patient body weight and, in the case of the thrombolytic

agents, the usual dosage of the thrombolytic agent when administered alone may be reduced by about 70-80% when administered with a compound of the present invention.

Where two or more of the foregoing second therapeutic  
5 agents are administered with the compound of the present invention, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the  
10 therapeutic agents when administered in combination.

Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of the present invention and a second therapeutic  
15 agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric  
20 coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is  
25 not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material that effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active  
30 ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a  
35 sustained and/or enteric release polymer, and the other

component is also coated with a polymer such as a low-viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.


These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments that are given for illustration of the invention and are not intended to be limiting thereof.

#### EXAMPLES

##### Example 1

1-[3-(2'-Amino-3',4'-thiadiazol-5'-yl)phenyl]-3-methyl-6-[2'-aminosulfonyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one trifluoroacetic acid salt



acid salt

Part A: 1-[4-bromophenyl]-4-acetyl-2,3-dioxopiperidine was prepared in four steps in 10% overall yield by the following sequence of reactions. Commercially available 4-bromoaniline was treated with commercially available 5-chloro-2-pentanone ethylene ketal in dimethylformamide in the presence of potassium carbonate for three days. The

crude alkylated aniline was treated with ethyloxalyl chloride in THF the presence of triethylamine. Hydrolysis of the ketal was accomplished by treating with aqueous HCl and the resulting material was subjected to Dieckmann  
5 cyclization conditions (NaOMe, methanol). The crude dioxopiperidine was purified by flash chromatography (elution with 4:1 hexanes/ethylacetate) to afford the title compound.  $^1\text{H}$  NMR (dmsO  $d_6$ ):  $\delta$  7.56 (d, 2H,  $J$  = 8Hz), 7.26 (d, 2H,  $J$  = 8Hz), 3.60 (t, 2H), 3.28 (t, 2H), 2.30 (s, 3H).  
10 LRMS (ES+): 281.0 (M+H) $^+$ .

Part B: 1-[3-Cyanophenyl]-3-methyl-6-[2'-aminosulfonyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one was prepared by addition of 3-cyanophenyl  
15 hydrazine to a solution of 1-[4-bromophenyl]-4-acetyl-2,3-dioxopiperidine in glacial acetic acid was added. The reaction mixture was stirred at reflux for 3 h and then was cooled to ambient temperature. The volatiles were removed and the residue was taken up in ethyl acetate. The organics  
20 were washed with saturated aq sodium bicarbonate and brine, dried ( $\text{MgSO}_4$ ) and concentrated.


The residue was dissolved in benzene and then there was added tetrabutylammonium bromide, aqueous  $\text{Na}_2\text{CO}_3$  and 2-(*tert*-butylaminosulfonyl)phenylboronic. This solution was  
25 degassed with a stream of nitrogen for 30 minutes. Following the purge, tetrakis(triphenylphosphine)palladium(0) was added and the solution was stirred overnight at reflux. The solution was diluted with EtOAc and washed twice with brine and the  
30 organics dried over  $\text{MgSO}_4$ , filtered and the volatiles removed under reduced pressure. The residue was purified by column chromatography (elution with 1:1 hexane/EtOAc) to afford an intermediate biphenyl compound.



Part C: 1-[3-Cyanophenyl]-3-methyl-6-[2'-aminosulfonyl-  
[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
pyridin-7-one was (0.12 g, 0.22 mmol) was treated with  
thiosemicarbazide (0.02 g, 0.22 mmol) in 10 mL refluxing TFA  
5 for 4H. The reaction mixture was concentrated under reduced  
pressure and purified by HPLC to give the aminothiadiazo-  
le.  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300MHz) δ: 8.04 (d, 2H, J=7Hz), 7.72-7.51  
(m, 7H), 7.33 (d, 1H, J=7Hz), 7.26 (s, 2H), 4.15-4.13 (m,  
2H), 2.96 (bt, 2H, J=6Hz), 2.31 (s, 3H) ppm; LRMS: m/z 558  
10 (M+H); HRMS: calc'd for C<sub>27</sub> H<sub>24</sub> S<sub>2</sub> O<sub>3</sub> N<sub>7</sub>=558.4216.

### Example 2

1-[3-(5-oxo-4,5-Dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[2'-  
(1-pyrrolidinymethyl)-1,1'-biphenyl-4-yl]-3-  
15 (trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-  
c]pyridin-7-one, trifluoroacetic acid salt



Part A: Preparation of 1-(4-iodophenyl)-4-(2,2,2-  
20 trifluoropropanoyl)-2,3-piperidinedione

4-Iodoaniline (45.82 g, 209.2 m mol) and triethylamine  
(65.61 mL, 470.7 m mol) were dissolved into THF (800 mL) and  
cooled to 0°C. 5-Bromovaleryl chloride (50.0 g, 251.1 m mol)  
25 dissolved in THF (200 mL) was added dropwise to the  
reaction. The reaction was warmed to room temperature and  
stirred overnight. Reaction was cooled to 0°C and potassium

tert-butoxide (70.43 g, 627.6 m mol) was slowly added. The reaction was warmed to room temperature and stirred overnight. The reaction was concentrated and then redissolved in ethyl acetate (500 mL) and 3N HCl (500 mL),  
5 extracted with ethyl acetate (2x250 mL), washed with 1N HCl (3x250 mL), washed with brine (1x250 mL), and dried (Na<sub>2</sub>SO<sub>4</sub>). Purification by silica gel chromatography using 0%-100% ethyl acetate/hexane gradient as eluent to afford 51.03g (81%): <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.70(d, J=8.4Hz, 2H), 7.03(d, J=8.8Hz, 2H),  
10 3.62(t, J=5.9Hz, 2H), 2.56(t, J=5.7Hz, 2H), 2.50-1.88(m, 4H) ppm.

The product from the above reaction (85.17 g, 282.8 m mol) and phosphorus pentachloride (205.91 g, 990.0 m mol) was  
15 dissolved into CHCl<sub>3</sub> (750 mL) and refluxed for 3½ hours. The reaction was poured over ice and then quenched further with water, extracted with CHCl<sub>3</sub> (3x400 mL), washed with brine (1x400 mL), dried (MgSO<sub>4</sub>), and concentrated. This residue was dissolved in morpholine (400 mL) and refluxed overnight.  
20 The reaction was concentrated and purified by silica gel chromatography using 0%-100% ethyl acetate/hexane gradient as eluent to afford 68 g (63%) of desired morpholine adduct: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.68(d, J=8.8Hz, 2H), 7.11(d, J=8.8Hz, 2H), 5.66(t, J=4.8Hz, 1H), 3.82(t, J=4.8Hz, 4H), 3.77(t, J=6.8Hz, 2H), 2.89(t, J=4.8Hz, 4H), 2.53-2.47(m, 2H) ppm.  
25

4-Dimethylaminopyridine (3.92 g, 32.01 m mol) was dissolved into CH<sub>2</sub>Cl<sub>2</sub> (130 mL) and cooled to 0°C. Trifluoroacetic anhydride (4.54 g, 32.01 m mol) was added and the mixture  
30 was stirred at 0°C for 30 min. The above morpholine-enamine (10.25 g, 26.68 m mol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (370 mL) was added slowly and the reaction was warmed to room temperature and stirred overnight. Reaction was concentrated and purified by silica gel chromatography using 0%-50%  
35 ethylacetate/hexane gradient to isolate the intermediate.

The intermediate was dissolved in 20% HCl (50 mL) and diethyl ether (200 mL) and stirred at room temperature overnight. Reaction was quenched with water, extracted with ether (3x100 mL), washed with brine (1x100 mL), and dried (Na<sub>2</sub>SO<sub>4</sub>). The residue was redissolved in petroleum ether and the solids were filtered away. Concentrated filtrate afforded 9.99 g (78%) of the desired compound: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.77 (d, J=8.8Hz, 2H), 7.11 (d, J=8.8Hz, 2H), 3.93 (t, J=6.8Hz, 2H), 2.92 (t, J=6.8Hz, 2H) ppm.

10

**Part B: Preparation of 1-(3-cyanophenyl)-3-(trifluoromethyl)-6-(4-iodophenyl)-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one**

1-(4-iodophenyl)-4-(2,2,2-trifluoroacetyl)-2,3-piperidinedione prepared by the same methods described in WO 00/39131 (5.02 g, 12.2 mmol) and 3-cyanophenylhydrazine chloride (3.44 g, 20.4 mmol) were added together with 75 mL of Acetic acid. The mixture was refluxed for 4 hours. The mixture was cooled and the solvent was removed. The residue was partitioned between EtOAc and H<sub>2</sub>O. The EtOAc layer was washed with H<sub>2</sub>O, brine, dried over MgSO<sub>4</sub>, concentrated, and chromatographed with 1:5 EtOAc:hexane to afford 3.8 g of 1-(3-cyanophenyl)-3-(trifluoromethyl)-6-(4-iodophenyl)-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one as a yellow solid (61.3%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.91-7.90 (m, 1H), 7.87-7.83 (m, 1H), 7.75-7.69 (m, 3H), 7.56 (t, 1H), 7.09-7.04 (m, 2H), 4.15 (t, 2H), 3.19 (t, 2H).

**Part C: Preparation of 1-[3-(5-oxo-4,5-Dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[(4-iodophenyl)]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one**

1-(3-Cyanophenyl)-3-(trifluoromethyl)-6-(4-iodophenyl)-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (3.75 g, 7.38 mmol) was suspended in 100 mL of anhydrous MeOH and 50

mL of chloroform and cooled in a 0°C ice-bath. HCl gas was then bubbled in the mixture for 30 minutes resulting in a clear solution. The reaction vessel was sealed and stored at 0°C for 18 hours. The mixture was concentrated in vacuo and dried. The resulting yellow was suspended in 75 mL of anhydrous 1,4-dioxane. Semicarbazide hydrochloride (1.41 g, 12.6 mmol) was then added, followed by N-methylmorpholine (5.83 mL, 53 mmol). The mixture was refluxed for 48 hours. The precipitate was filtered and washed with 1,4-dioxane, water, and ether. The solid was pumped dry to afford 1.7g of the title compound as a yellow solid (40.7%). MS (ES<sup>-</sup>): 565.2, (M-H)<sup>-</sup>.

**Part D: Preparation of 1-[3-(5-oxo-4,5-Dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[2'-formyl-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one**

1-[3-(5-Oxo-4,5-Dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[(4-iodophenyl)]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one (300 mg, 0.53 mmol), 2-Formylbenzeneboronic acid (159 mg, 1.06 mmol), K<sub>2</sub>CO<sub>3</sub> (293 mg, 2.12 mmol), were dissolved in 15 mL of 1:2 EtOH:Toluene. The system was evacuated and flushed with N<sub>2</sub> three times. Pd(PPh<sub>3</sub>)<sub>4</sub> (61 mg, 0.053 mmol) was then added and the system was evacuated and flushed with N<sub>2</sub> three times. The mixture was refluxed for seven hours. The mixture was concentrated in vacuo and the residue partitioned between ethyl acetate and H<sub>2</sub>O. The aqueous layer was extracted with more ethyl acetate (2 x 50 mL). The ethyl acetate layers were combined and washed with brine. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>. All organic layers were combined and dried over MgSO<sub>4</sub>, concentrated and chromatographed with 1% to 4% MeOH:CHCl<sub>3</sub> to afford 170 mg of the title compound as an off-white solid (58.9%). MS (ES<sup>+</sup>): 545.3, (M+H)<sup>+</sup>.


35

**Part E: Preparation of 1-[3-(5-oxo-4,5-Dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, trifluoroacetic acid salt**

5        1-[3-(5-Oxo-4,5-Dihydro-1H-1,2,4-triazol-3-yl)phenyl]-  
6-[2'-formyl-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-  
1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one (82 mg,  
0.15 mmol) and pyrrolidine (32 mg, 0.45 mmol) were dissolved  
10    in 10 mL of methanol and stirred at room temperature for 18  
hours. Sodium cyanoborohydride (19 mg, 0.3 mmol) was then  
added and the mixture was stirred at room temperature for 3  
hours. The mixture was concentrated in vacuo and purified  
by reverse phase HPLC (C18 reverse phase column, eluted with  
a H<sub>2</sub>O/CH<sub>3</sub>CN gradient with 0.05% TFA) to give 40 mg of the  
15    title compound as a white solid (37.4% yield). LRMS (ES<sup>+</sup>),  
600.4 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz) δ 12.11(s, 1H),  
11.77 (s, 1H), 7.99 (s, 1H), 7.85 (d, 1H), 7.69-7.66 (m,  
2H), 7.61-7.55 (m, 1H), 7.48-7.46 (m, 4H), 7.37 (d, 2H),  
7.32-7.29 (m, 1H), 4.35 (s, 1H), 4.17 (t, 2H), 3.35-3.25 (m,  
20    2H), 3.14 (t, 2H), 2.85-2.75 (m, 2H), 1.8-1.7 (m, 4H).

**Example 3**


6-(2'-{[(3*S*)-3-Hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-  
4-yl)-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-  
25    3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-  
c]pyridin-7-one, trifluoroacetic acid salt



This compound was prepared by the methods described in Example 2. LRMS (ES<sup>+</sup>), 616.5 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz) δ 12.1(s, 1H), 11.75 (s, 1H), 7.99 (s, 1H), 7.85-7.83 (m, 1H), 7.75-7.67 (m, 2H), 7.58-7.42 (m, 5H), 7.37-7.25 (m, 3H), 4.45-4.2 (m, 3H), 4.2-4.15 (m, 2H), 3.2-3.1 (m, 2H), 2.9-2.75 (m, 4H), 1.87-1.65 (m, 2H).

#### Example 4


6-(2'-[(Dimethylamino)methyl]-1,1'-biphenyl-4-yl)-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, bistrifluoroacetic acid salt



This compound was prepared by the methods described in Example 2. LRMS (ES<sup>+</sup>), 574.4(M+H)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz) δ 12.11(s, 1H), 11.77 (s, 1H), 7.99 (s, 1H), 7.85 (d, 1H), 7.70-7.65 (m, 2H), 7.61-7.56 (m, 1H), 7.51-7.45 (m, 4H), 7.37-7.29 (m, 3H), 4.27(bs, 2H), 4.18 (t, 2H), 3.14 (t, 2H), 2.45 (s, 6H).

#### Example 5


6-[2'-(Methylsulfonyl)-1,1'-biphenyl-4-yl]-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one



This compound was prepared by the methods described in Example 2. LRMS (ES<sup>+</sup>), 617.5 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz) δ 12.1 (s, 1H), 11.76 (s, 1H), 8.07-8.05 (m, 1H), 7.99 (s, 1H), 7.85 (d, 1H), 7.75-7.58 (m, 4H), 7.41-7.35 (m, 5H), 4.18 (t, 2H), 3.14 (t, 2H), 2.81 (s, 3H).

#### Example 6

1- [3- (5-Amino-1,3,4-oxadiazol-2-yl)phenyl]-6-{2'-  
[(dimethylamino)methyl]-1,1'-biphenyl-4-yl}-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-  
c]pyridin-7-one, bistrifluoroacetic acid salt




This compound was prepared by the methods described in Example 2. LRMS (ES<sup>+</sup>), 574.4 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 8.12 (s, 1H), 7.97 (d, 1H), 7.78-7.75 (m, 1H), 7.66-7.39 (m, 6H), 7.42-7.36 (m, 3H), 4.34 (s, 2H), 4.24 (t, 2H), 3.30-3.21 (m, 2H), 2.60 (s, 6H).

#### Example 7

1- [3- (5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-{2'-  
[(dimethylamino)methyl]-1,1'-biphenyl-4-yl}-3-

**(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, bistrifluoroacetic acid salt**




This compound was prepared by the methods described in  
 5 Example 2. LRMS (ES<sup>+</sup>), 590.5 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz)  
 δ 8.09 (s, 1H), 7.9-7.85 (m, 1H), 7.75-7.7 (m, 1H), 7.65-7.5  
 (m, 6H), 7.4-7.35 (m, 3H), 4.36 (s, 2H), 4.26 (t, 2H), 3.25  
 (t, 2H), 2.62 (s, 6H).

10

**Example 8**

**1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-[2'-(1-  
 pyrrolidinymethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-  
 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one,  
 bistrifluoroacetic acid salt**




15

This compound was prepared by the methods described in  
 Example 2. LRMS (ES<sup>+</sup>), 616.5 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300  
 MHz) δ 8.01 (t, 1H), 7.81-7.78 (m, 1H), 7.69-7.63 (m, 2H),  
 7.59-7.45 (m, 5H), 7.38-7.29 (m, 3H), 4.35-4.33 (m, 2H),  
 20 4.18 (t, 2H), 3.35-3.22 (m, 2H), 3.14 (t, 2H), 2.81-2.72 (m,  
 2H), 1.8 -1.68 (m, 4H).



## Example 9


1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-(4-{2-  
 [(dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-3-  
 (trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-  
 c]pyridin-7-one, bistrifluoroacetic acid salt



This compound was prepared by the methods described in  
 Example 2. LRMS (ES<sup>+</sup>), 580.4 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300  
 MHz) δ 8.02-8.01 (m, 1H), 7.79-7.76 (m, 1H), 7.66-7.64 (m,  
 1H), 7.58-7.48 (m, 6H), 7.21-7.20 (m, 1H), 4.39 (s, 2H),  
 4.16 (t, 2H), 3.14 (t, 2H), 2.75 (s, 6H).

## Example 10

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-{4-[2-(1-  
 pyrrolidinylmethyl)-1H-imidazol-1-yl]phenyl}-3-  
 (trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-  
 c]pyridin-7-one, bistrifluoroacetic acid salt




This compound was prepared by the methods described in  
 Example 2. LRMS (ES<sup>+</sup>), 606.6 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz)  
 δ 8.06 (s, 1H), 7.88-7.82 (m, 1H), 7.7-7.65 (m, 1H), 7.61-  
 7.58 (m, 3H), 7.49 (d, 2H), 7.40 (d, 1H), 7.22 (s, 1H), 4.46

(s, 2H), 4.23 (t, 2H), 3.4 -3.3 (m, 4H), 3.22 (t, 2H), 2.03-1.98 (m, 4H).

### Example 11

5 6-(4-{2-[(Dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, bistrifluoroacetic acid salt




10 This compound was prepared by the methods described in Example 2. LRMS (ES<sup>+</sup>), 546.5 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 300 MHz) δ 8.0 (s, 1H), 7.85-7.81 (m, 1H), 7.7-7.65 (m, 1H), 7.6-7.5 (m, 6H), 7.2 (s, 1H), 4.4 (s, 2H), 4.19-4.15 (m, 2H), 3.18-3.13 (m, 2H), 2.76 (s, 6H).

15

### Example 12

20 3-Methyl-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-{4-[2-(1-pyrrolidinylmethyl)-1H-imidazol-1-yl]phenyl}-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, trifluoroacetic acid salt



This compound was prepared by the methods described in Example 2. LRMS (ES<sup>+</sup>), 546.5 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz)


$\delta$  7.98 (t, 1H), 7.81 (d, 1H), 7.68-7.64 (m, 2H), 7.56-7.49 (m, 5H), 7.41-7.38 (m, 3H), 4.42 (s, 2H), 4.21 (t, 2H), 3.4-3.3 (m, 2H), 3.05 (t, 2H), 2.88-2.78 (m, 2H), 2.37 (s, 3H), 1.93-1.84 (m, 4H).

5

**Example 13**

**7-Oxo-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide, trifluoroacetic acid salt**

10



This compound was prepared by the methods described in Example 2. LRMS ( $ES^+$ ), 575.6 ( $M+H$ ) $^+$ .  $^1H$  NMR ( $CD_3OD$ , 300 MHz)


$\delta$  8.06-8.05 (m, 1H), 7.88-7.84 (m, 1H), 7.78-7.74 (m, 1H), 7.61-7.45 (m, 6H), 7.4-7.35 (m, 3H), 4.41 (s, 2H), 4.21 (t, 2H), 3.4-3.3 (m, 4H), 2.82-2.78 (m, 2H), 1.9-1.82 (m, 4H).

15

**Example 14**

**1-[3-(5-Oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-7-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[3,4-c]azepin-8(1H)-one, trifluoroacetic acid salt**


20



This compound was prepared by the methods described in Example 2. LRMS (ES<sup>+</sup>), 632.6 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 7.96-7.95 (m, 1H), 7.88-7.84 (m, 1H), 7.65-7.53 (m, 6H), 7.41-7.38 (m, 1H), 7.31-7.23 (m, 2H), 4.4 (s, 2H), 4.05-4.01 (m, 2H), 3.35-3.29 (m, 2H), 3.13 (t, 2H), 2.84-2.81 (m, 2H), 2.33-2.30 (m, 2H), 1.93-1.85 (m, 4H).

#### Example 15


10 1-[2-(5-Oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, trifluoroacetic acid salt




15 This compound was prepared by the methods described in Example 2. LRMS (ES<sup>+</sup>), 574.5 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 7.71-7.53 (m, 6H), 7.43-7.35 (m, 6H), 4.34 (s, 2H), 4.16 (t, 2H), 3.21 (t, 2H), 2.61 (s, 6H).

20 The following tables contain representative examples of the present invention. Each entry in each table is intended to be paired with each formulas at the start of the table. For example, in Table 1, Example 1 is intended to be paired with each of the formulas.


The following nomenclature is intended for group A in the following tables.




phenyl




2-pyridyl




3-pyridyl




2-pyrimidyl




2-Cl-phenyl



2-F-phenyl





2,6-diF-phenyl



5-pyrimidyl

Table 1





$R^{1a}$  is  $CH_3$ ;

5	Ex#	A	B
	1.	phenyl	2-( $NH_2SO_2$ )phenyl
	2.	phenyl	2-( $CH_3SO_2$ )phenyl
	3.	phenyl	3- $NH_2SO_2$ -4-pyridyl
	4.	phenyl	3- $CH_3SO_2$ -4-pyridyl
10	5.	phenyl	2-( $CH_3NH$ )phenyl
	6.	phenyl	3-(( $CH_3$ ) <sub>2</sub> $NCH_2$ )-4-pyridyl
	7.	phenyl	2-(N-(3-R-HO-pyrrolidinyl) $CH_2$ )phenyl
	8.	phenyl	2-(N-(4-HO-piperidinyl) $CH_2$ )phenyl
	9.	phenyl	2-(( $CH_3$ ) <sub>2</sub> $NCH_2$ )phenyl
15	10.	phenyl	2-(( $CH_3$ ) $NHCH_2$ )phenyl
	11.	phenyl	2-(( $CH_3CH_2$ ) $NHCH_2$ )phenyl
	12.	phenyl	2-(( $CH_3CH_2$ ) <sub>2</sub> $NCH_2$ )phenyl
	13.	phenyl	2-(( $CH_3CH_2$ ) $N(CH_3)CH_2$ )phenyl
	14.	phenyl	2-((( $CH_3$ ) <sub>2</sub> $CH$ ) $NHCH_2$ )phenyl
20	15.	phenyl	2-((( $CH_3$ ) <sub>2</sub> $CH$ ) <sub>2</sub> $NCH_2$ )phenyl
	16.	phenyl	2-((cyclopropyl) $NHCH_2$ )phenyl
	17.	phenyl	2-((cyclopropyl) <sub>2</sub> $NCH_2$ )phenyl

	18.	phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
	19.	phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	20.	phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	21.	phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
5	22.	phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	23.	phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	24.	phenyl	1-CH <sub>3</sub> -2-imidazolyl
	25.	phenyl	2-CH <sub>3</sub> -1-imidazolyl
	26.	phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
10	27.	phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	28.	phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	29.	phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	30.	phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	31.	phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
15	32.	phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	33.	phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	34.	phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	35.	phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	36.	phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
20	37.	phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	38.	phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	39.	phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
	40.	phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	41.	2-pyridyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
25	42.	2-pyridyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	43.	2-pyridyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	44.	2-pyridyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	45.	2-pyridyl	2-(CH <sub>3</sub> NH)phenyl
	46.	2-pyridyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
30	47.	2-pyridyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	48.	2-pyridyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	49.	2-pyridyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	50.	2-pyridyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	51.	2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
35	52.	2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	53.	2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	54.	2-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
	55.	2-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	56.	2-pyridyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
40	57.	2-pyridyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	58.	2-pyridyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
	59.	2-pyridyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	60.	2-pyridyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	61.	2-pyridyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
45	62.	2-pyridyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	63.	2-pyridyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	64.	2-pyridyl	1-CH <sub>3</sub> -2-imidazolyl
	65.	2-pyridyl	2-CH <sub>3</sub> -1-imidazolyl
	66.	2-pyridyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
50	67.	2-pyridyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	68.	2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	69.	2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	70.	2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl



	71.	2-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
	72.	2-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	73.	2-pyridyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	74.	2-pyridyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
5	75.	2-pyridyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	76.	2-pyridyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	77.	2-pyridyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	78.	2-pyridyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	79.	2-pyridyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
10	80.	2-pyridyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	81.	3-pyridyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
	82.	3-pyridyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	83.	3-pyridyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	84.	3-pyridyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
15	85.	3-pyridyl	2-(CH <sub>3</sub> NH)phenyl
	86.	3-pyridyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
	87.	3-pyridyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	88.	3-pyridyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	89.	3-pyridyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
20	90.	3-pyridyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	91.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
	92.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	93.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	94.	3-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
25	95.	3-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	96.	3-pyridyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
	97.	3-pyridyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	98.	3-pyridyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
	99.	3-pyridyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
30	100.	3-pyridyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	101.	3-pyridyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	102.	3-pyridyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	103.	3-pyridyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	104.	3-pyridyl	1-CH <sub>3</sub> -2-imidazolyl
35	105.	3-pyridyl	2-CH <sub>3</sub> -1-imidazolyl
	106.	3-pyridyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	107.	3-pyridyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	108.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	109.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
40	110.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	111.	3-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
	112.	3-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	113.	3-pyridyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	114.	3-pyridyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
45	115.	3-pyridyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	116.	3-pyridyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	117.	3-pyridyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	118.	3-pyridyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	119.	3-pyridyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
50	120.	3-pyridyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	121.	2-pyrimidyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
	122.	2-pyrimidyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	123.	2-pyrimidyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl

124. 2-pyrimidyl 3-CH<sub>3</sub>SO<sub>2</sub>-4-pyridyl  
125. 2-pyrimidyl 2-(CH<sub>3</sub>NH)phenyl  
126. 2-pyrimidyl 3-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-4-pyridyl  
127. 2-pyrimidyl 2-(N-(3-R-HO-pyrrolidinyl)CH<sub>2</sub>)phenyl  
5 128. 2-pyrimidyl 2-(N-(4-HO-piperidinyl)CH<sub>2</sub>)phenyl  
129. 2-pyrimidyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl  
130. 2-pyrimidyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)phenyl  
131. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)phenyl  
132. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl  
10 133. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)phenyl  
134. 2-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)phenyl  
135. 2-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)phenyl  
136. 2-pyrimidyl 2-((cyclopropyl)NHCH<sub>2</sub>)phenyl  
137. 2-pyrimidyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
15 138. 2-pyrimidyl 2-((cyclobutyl)NHCH<sub>2</sub>)phenyl  
139. 2-pyrimidyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
140. 2-pyrimidyl 2-((cyclopentyl)NHCH<sub>2</sub>)phenyl  
141. 2-pyrimidyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
142. 2-pyrimidyl 2-((cyclohexyl)NHCH<sub>2</sub>)phenyl  
20 143. 2-pyrimidyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
144. 2-pyrimidyl 1-CH<sub>3</sub>-2-imidazolyl  
145. 2-pyrimidyl 2-CH<sub>3</sub>-1-imidazolyl  
146. 2-pyrimidyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
147. 2-pyrimidyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
25 148. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
149. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
150. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)-1-imidazolyl  
151. 2-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)-1-imidazolyl  
152. 2-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
30 153. 2-pyrimidyl 2-((cyclopropyl)NHCH<sub>2</sub>)-1-imidazolyl  
154. 2-pyrimidyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
155. 2-pyrimidyl 2-((cyclobutyl)NHCH<sub>2</sub>)-1-imidazolyl  
156. 2-pyrimidyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
157. 2-pyrimidyl 2-((cyclopentyl)NHCH<sub>2</sub>)-1-imidazolyl  
35 158. 2-pyrimidyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
159. 2-pyrimidyl 2-((cyclohexyl)NHCH<sub>2</sub>)-1-imidazolyl  
160. 2-pyrimidyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
161. 5-pyrimidyl 2-(NH<sub>2</sub>SO<sub>2</sub>)phenyl  
162. 5-pyrimidyl 2-(CH<sub>3</sub>SO<sub>2</sub>)phenyl  
40 163. 5-pyrimidyl 3-NH<sub>2</sub>SO<sub>2</sub>-4-pyridyl  
164. 5-pyrimidyl 3-CH<sub>3</sub>SO<sub>2</sub>-4-pyridyl  
165. 5-pyrimidyl 2-(CH<sub>3</sub>NH)phenyl  
166. 5-pyrimidyl 3-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-4-pyridyl  
167. 5-pyrimidyl 2-(N-(3-R-HO-pyrrolidinyl)CH<sub>2</sub>)phenyl  
45 168. 5-pyrimidyl 2-(N-(4-HO-piperidinyl)CH<sub>2</sub>)phenyl  
169. 5-pyrimidyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl  
170. 5-pyrimidyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)phenyl  
171. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)phenyl  
172. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl  
50 173. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)phenyl  
174. 5-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)phenyl  
175. 5-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)phenyl  
176. 5-pyrimidyl 2-((cyclopropyl)NHCH<sub>2</sub>)phenyl

177. 5-pyrimidyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
178. 5-pyrimidyl 2-((cyclobutyl)NHCH<sub>2</sub>)phenyl  
179. 5-pyrimidyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
180. 5-pyrimidyl 2-((cyclopentyl)NHCH<sub>2</sub>)phenyl  
5 181. 5-pyrimidyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
182. 5-pyrimidyl 2-((cyclohexyl)NHCH<sub>2</sub>)phenyl  
183. 5-pyrimidyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
184. 5-pyrimidyl 1-CH<sub>3</sub>-2-imidazolyl  
185. 5-pyrimidyl 2-CH<sub>3</sub>-1-imidazolyl  
10 186. 5-pyrimidyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
187. 5-pyrimidyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
188. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
189. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
190. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)-1-imidazolyl  
15 191. 5-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)-1-imidazolyl  
192. 5-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
193. 5-pyrimidyl 2-((cyclopropyl)NHCH<sub>2</sub>)-1-imidazolyl  
194. 5-pyrimidyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
195. 5-pyrimidyl 2-((cyclobutyl)NHCH<sub>2</sub>)-1-imidazolyl  
20 196. 5-pyrimidyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
197. 5-pyrimidyl 2-((cyclopentyl)NHCH<sub>2</sub>)-1-imidazolyl  
198. 5-pyrimidyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
199. 5-pyrimidyl 2-((cyclohexyl)NHCH<sub>2</sub>)-1-imidazolyl  
200. 5-pyrimidyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
25 201. 2-Cl-phenyl 2-(NH<sub>2</sub>SO<sub>2</sub>)phenyl  
202. 2-Cl-phenyl 2-(CH<sub>3</sub>SO<sub>2</sub>)phenyl  
203. 2-Cl-phenyl 3-NH<sub>2</sub>SO<sub>2</sub>-4-pyridyl  
204. 2-Cl-phenyl 3-CH<sub>3</sub>SO<sub>2</sub>-4-pyridyl  
205. 2-Cl-phenyl 2-(CH<sub>3</sub>NH)phenyl  
30 206. 2-Cl-phenyl 3-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-4-pyridyl  
207. 2-Cl-phenyl 2-(N-(3-R-HO-pyrrolidinyl)CH<sub>2</sub>)phenyl  
208. 2-Cl-phenyl 2-(N-(4-HO-piperidinyl)CH<sub>2</sub>)phenyl  
209. 2-Cl-phenyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl  
210. 2-Cl-phenyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)phenyl  
35 211. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)phenyl  
212. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl  
213. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)phenyl  
214. 2-Cl-phenyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)phenyl  
215. 2-Cl-phenyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)phenyl  
40 216. 2-Cl-phenyl 2-((cyclopropyl)NHCH<sub>2</sub>)phenyl  
217. 2-Cl-phenyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
218. 2-Cl-phenyl 2-((cyclobutyl)NHCH<sub>2</sub>)phenyl  
219. 2-Cl-phenyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
220. 2-Cl-phenyl 2-((cyclopentyl)NHCH<sub>2</sub>)phenyl  
45 221. 2-Cl-phenyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
222. 2-Cl-phenyl 2-((cyclohexyl)NHCH<sub>2</sub>)phenyl  
223. 2-Cl-phenyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
224. 2-Cl-phenyl 1-CH<sub>3</sub>-2-imidazolyl  
225. 2-Cl-phenyl 2-CH<sub>3</sub>-1-imidazolyl  
50 226. 2-Cl-phenyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
227. 2-Cl-phenyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
228. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
229. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl

	230.	2-Cl-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	231.	2-Cl-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
	232.	2-Cl-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
5	233.	2-Cl-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	234.	2-Cl-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	235.	2-Cl-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	236.	2-Cl-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	237.	2-Cl-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	238.	2-Cl-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
10	239.	2-Cl-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
	240.	2-Cl-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	241.	2-F-phenyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
	242.	2-F-phenyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	243.	2-F-phenyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
15	244.	2-F-phenyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	245.	2-F-phenyl	2-(CH <sub>3</sub> NH)phenyl
	246.	2-F-phenyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
	247.	2-F-phenyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	248.	2-F-phenyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
20	249.	2-F-phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	250.	2-F-phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	251.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
	252.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	253.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
25	254.	2-F-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
	255.	2-F-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	256.	2-F-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
	257.	2-F-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	258.	2-F-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
30	259.	2-F-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	260.	2-F-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	261.	2-F-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	262.	2-F-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	263.	2-F-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
35	264.	2-F-phenyl	1-CH <sub>3</sub> -2-imidazolyl
	265.	2-F-phenyl	2-CH <sub>3</sub> -1-imidazolyl
	266.	2-F-phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	267.	2-F-phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	268.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
40	269.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	270.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	271.	2-F-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
	272.	2-F-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	273.	2-F-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
45	274.	2-F-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	275.	2-F-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	276.	2-F-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	277.	2-F-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	278.	2-F-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
50	279.	2-F-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
	280.	2-F-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	281.	2,6-diF-phenyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
	282.	2,6-diF-phenyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl

	283.	2,6-diF-phenyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	284.	2,6-diF-phenyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	285.	2,6-diF-phenyl	2-(CH <sub>3</sub> NH)phenyl
	286.	2,6-diF-phenyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
5	287.	2,6-diF-phenyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	288.	2,6-diF-phenyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	289.	2,6-diF-phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	290.	2,6-diF-phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	291.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
10	292.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	293.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	294.	2,6-diF-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
	295.	2,6-diF-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	296.	2,6-diF-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
15	297.	2,6-diF-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	298.	2,6-diF-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
	299.	2,6-diF-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	300.	2,6-diF-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	301.	2,6-diF-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
20	302.	2,6-diF-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	303.	2,6-diF-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	304.	2,6-diF-phenyl	1-CH <sub>3</sub> -2-imidazolyl
	305.	2,6-diF-phenyl	2-CH <sub>3</sub> -1-imidazolyl
	306.	2,6-diF-phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
25	307.	2,6-diF-phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	308.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	309.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	310.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	311.	2,6-diF-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
30	312.	2,6-diF-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	313.	2,6-diF-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	314.	2,6-diF-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	315.	2,6-diF-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	316.	2,6-diF-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
35	317.	2,6-diF-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	318.	2,6-diF-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	319.	2,6-diF-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
	320.	2,6-diF-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	321.	piperidinyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
40	322.	piperidinyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	323.	piperidinyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	324.	piperidinyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	325.	piperidinyl	2-(CH <sub>3</sub> NH)phenyl
	326.	piperidinyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
45	327.	piperidinyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	328.	piperidinyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	329.	piperidinyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	330.	piperidinyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	331.	piperidinyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
50	332.	piperidinyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	333.	piperidinyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	334.	piperidinyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
	335.	piperidinyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl

336. piperidinyl 2-((cyclopropyl)NHCH<sub>2</sub>)phenyl  
337. piperidinyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
338. piperidinyl 2-((cyclobutyl)NHCH<sub>2</sub>)phenyl  
339. piperidinyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
5 340. piperidinyl 2-((cyclopentyl)NHCH<sub>2</sub>)phenyl  
341. piperidinyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
342. piperidinyl 2-((cyclohexyl)NHCH<sub>2</sub>)phenyl  
343. piperidinyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
344. piperidinyl 1-CH<sub>3</sub>-2-imidazolyl  
10 345. piperidinyl 2-CH<sub>3</sub>-1-imidazolyl  
346. piperidinyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
347. piperidinyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
348. piperidinyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
349. piperidinyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
15 350. piperidinyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)-1-imidazolyl  
351. piperidinyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)-1-imidazolyl  
352. piperidinyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
353. piperidinyl 2-((cyclopropyl)NHCH<sub>2</sub>)-1-imidazolyl  
354. piperidinyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
20 355. piperidinyl 2-((cyclobutyl)NHCH<sub>2</sub>)-1-imidazolyl  
356. piperidinyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
357. piperidinyl 2-((cyclopentyl)NHCH<sub>2</sub>)-1-imidazolyl  
358. piperidinyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
359. piperidinyl 2-((cyclohexyl)NHCH<sub>2</sub>)-1-imidazolyl  
25 360. piperidinyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl

## Table 2

Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:

5         $R^{1a}$  is  $CH_2CH_3$ .

## Table 3

Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:

10        $R^{1a}$  is  $CF_3$ .

## Table 4

Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:

15        $R^{1a}$  is  $SCH_3$ .

## Table 5

Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:

20        $R^{1a}$  is  $SOCH_3$ .

## Table 6

Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:

25        $R^{1a}$  is  $SO_2CH_3$ .

## Table 7

Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:

30        $R^{1a}$  is  $Cl$ .

Table 8

Examples 1-360 use the structures from Table 1 and the  
corresponding A and B groups from Examples 1-360 of Table 1,  
5 and:

$R^{1a}$  is F.

Table 9

Examples 1-360 use the structures from Table 1 and the  
10 corresponding A and B groups from Examples 1-360 of Table 1,  
and:

$R^{1a}$  is  $\text{CO}_2\text{CH}_3$ .

Table 10

15 Examples 1-360 use the structures from Table 1 and the  
corresponding A and B groups from Examples 1-360 of Table 1,  
and:

$R^{1a}$  is  $\text{CH}_2\text{OCH}_3$ .

Table 11

20 Examples 1-360 use the structures from Table 1 and the  
corresponding A and B groups from Examples 1-360 of Table 1,  
and:

$R^{1a}$  is  $\text{CONH}_2$ .

Table 12

25 Examples 1-360 use the structures from Table 1 and the  
corresponding A and B groups from Examples 1-360 of Table 1,  
and:

30  $R^{1a}$  is CN.

Table 13

35 Examples 1-360 use the structures from Table 1 and the  
corresponding A and B groups from Examples 1-360 of Table 1,  
and:



R<sup>1a</sup> is CH<sub>2</sub>NH<sub>2</sub>.

Table 14

5 Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:

R<sup>1a</sup> is CH<sub>2</sub>NHSO<sub>2</sub>CH<sub>3</sub>.

Table 15

10 Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:

R<sup>1a</sup> is 1-imidazolyl-CH<sub>2</sub>.


Table 16


15 Examples 1-360 use the structures from Table 1 and the corresponding A and B groups from Examples 1-360 of Table 1, and:


R<sup>1a</sup> is 1-tetrazolyl-CH<sub>2</sub>-.


20


Table 17














Ex#	A	B
5	1. phenyl	2-(NH <sub>2</sub> SO <sub>2</sub> ) phenyl
	2. phenyl	2-(CH <sub>3</sub> SO <sub>2</sub> ) phenyl
	3. phenyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	4. phenyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	5. phenyl	2-(CH <sub>3</sub> NH) phenyl
	6. phenyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
10	7. phenyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> ) phenyl
	8. phenyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> ) phenyl
	9. phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> ) phenyl
15	10. phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> ) phenyl
	11. phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> ) phenyl
	12. phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> ) phenyl
	13. phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> ) phenyl
	14. phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> ) phenyl
	15. phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> ) phenyl
	16. phenyl	2-((cyclopropyl)NHCH <sub>2</sub> ) phenyl
	17. phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> ) phenyl
20	18. phenyl	2-((cyclobutyl)NHCH <sub>2</sub> ) phenyl
	19. phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> ) phenyl
	20. phenyl	2-((cyclopentyl)NHCH <sub>2</sub> ) phenyl

	21. phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	22. phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	23. phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	24. phenyl	1-CH <sub>3</sub> -2-imidazolyl
5	25. phenyl	2-CH <sub>3</sub> -1-imidazolyl
	26. phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	27. phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	28. phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	29. phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
10	30. phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	31. phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
	32. phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	33. phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	34. phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
15	35. phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	36. phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	37. phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	38. phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	39. phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
20	40. phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	41. 2-pyridyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
	42. 2-pyridyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	43. 2-pyridyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	44. 2-pyridyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
25	45. 2-pyridyl	2-(CH <sub>3</sub> NH)phenyl
	46. 2-pyridyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
	47. 2-pyridyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	48. 2-pyridyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	49. 2-pyridyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
30	50. 2-pyridyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	51. 2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
	52. 2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	53. 2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	54. 2-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
35	55. 2-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	56. 2-pyridyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
	57. 2-pyridyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	58. 2-pyridyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
	59. 2-pyridyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
40	60. 2-pyridyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	61. 2-pyridyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	62. 2-pyridyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	63. 2-pyridyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	64. 2-pyridyl	1-CH <sub>3</sub> -2-imidazolyl
45	65. 2-pyridyl	2-CH <sub>3</sub> -1-imidazolyl
	66. 2-pyridyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	67. 2-pyridyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	68. 2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	69. 2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
50	70. 2-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	71. 2-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
	72. 2-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	73. 2-pyridyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl



	74.	2-pyridyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	75.	2-pyridyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	76.	2-pyridyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	77.	2-pyridyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
5	78.	2-pyridyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	79.	2-pyridyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
	80.	2-pyridyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	81.	3-pyridyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
	82.	3-pyridyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
10	83.	3-pyridyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	84.	3-pyridyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	85.	3-pyridyl	2-(CH <sub>3</sub> NH)phenyl
	86.	3-pyridyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
	87.	3-pyridyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
15	88.	3-pyridyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	89.	3-pyridyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	90.	3-pyridyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	91.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
	92.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
20	93.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	94.	3-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
	95.	3-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	96.	3-pyridyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
	97.	3-pyridyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
25	98.	3-pyridyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
	99.	3-pyridyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	100.	3-pyridyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	101.	3-pyridyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	102.	3-pyridyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
30	103.	3-pyridyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	104.	3-pyridyl	1-CH <sub>3</sub> -2-imidazolyl
	105.	3-pyridyl	2-CH <sub>3</sub> -1-imidazolyl
	106.	3-pyridyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	107.	3-pyridyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
35	108.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	109.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	110.	3-pyridyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	111.	3-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
	112.	3-pyridyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
40	113.	3-pyridyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	114.	3-pyridyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	115.	3-pyridyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	116.	3-pyridyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	117.	3-pyridyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
45	118.	3-pyridyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	119.	3-pyridyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
	120.	3-pyridyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	121.	2-pyrimidyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
	122.	2-pyrimidyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
50	123.	2-pyrimidyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	124.	2-pyrimidyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	125.	2-pyrimidyl	2-(CH <sub>3</sub> NH)phenyl
	126.	2-pyrimidyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl

127. 2-pyrimidyl 2-(N-(3-R-HO-pyrrolidinyl)CH<sub>2</sub>)phenyl
128. 2-pyrimidyl 2-(N-(4-HO-piperidinyl)CH<sub>2</sub>)phenyl
129. 2-pyrimidyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl
130. 2-pyrimidyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)phenyl
- 5 131. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)phenyl
132. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl
133. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)phenyl
134. 2-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)phenyl
135. 2-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)phenyl
- 10 136. 2-pyrimidyl 2-((cyclopropyl)NHCH<sub>2</sub>)phenyl
137. 2-pyrimidyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)phenyl
138. 2-pyrimidyl 2-((cyclobutyl)NHCH<sub>2</sub>)phenyl
139. 2-pyrimidyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)phenyl
140. 2-pyrimidyl 2-((cyclopentyl)NHCH<sub>2</sub>)phenyl
- 15 141. 2-pyrimidyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)phenyl
142. 2-pyrimidyl 2-((cyclohexyl)NHCH<sub>2</sub>)phenyl
143. 2-pyrimidyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)phenyl
144. 2-pyrimidyl 1-CH<sub>3</sub>-2-imidazolyl
145. 2-pyrimidyl 2-CH<sub>3</sub>-1-imidazolyl
- 20 146. 2-pyrimidyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl
147. 2-pyrimidyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)-1-imidazolyl
148. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)-1-imidazolyl
149. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl
150. 2-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)-1-imidazolyl
- 25 151. 2-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)-1-imidazolyl
152. 2-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl
153. 2-pyrimidyl 2-((cyclopropyl)NHCH<sub>2</sub>)-1-imidazolyl
154. 2-pyrimidyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl
155. 2-pyrimidyl 2-((cyclobutyl)NHCH<sub>2</sub>)-1-imidazolyl
- 30 156. 2-pyrimidyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl
157. 2-pyrimidyl 2-((cyclopentyl)NHCH<sub>2</sub>)-1-imidazolyl
158. 2-pyrimidyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl
159. 2-pyrimidyl 2-((cyclohexyl)NHCH<sub>2</sub>)-1-imidazolyl
160. 2-pyrimidyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl
- 35 161. 5-pyrimidyl 2-(NH<sub>2</sub>SO<sub>2</sub>)phenyl
162. 5-pyrimidyl 2-(CH<sub>3</sub>SO<sub>2</sub>)phenyl
163. 5-pyrimidyl 3-NH<sub>2</sub>SO<sub>2</sub>-4-pyridyl
164. 5-pyrimidyl 3-CH<sub>3</sub>SO<sub>2</sub>-4-pyridyl
165. 5-pyrimidyl 2-(CH<sub>3</sub>NH)phenyl
- 40 166. 5-pyrimidyl 3-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-4-pyridyl
167. 5-pyrimidyl 2-(N-(3-R-HO-pyrrolidinyl)CH<sub>2</sub>)phenyl
168. 5-pyrimidyl 2-(N-(4-HO-piperidinyl)CH<sub>2</sub>)phenyl
169. 5-pyrimidyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl
170. 5-pyrimidyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)phenyl
- 45 171. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)phenyl
172. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl
173. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)phenyl
174. 5-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)phenyl
175. 5-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)phenyl
- 50 176. 5-pyrimidyl 2-((cyclopropyl)NHCH<sub>2</sub>)phenyl
177. 5-pyrimidyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)phenyl
178. 5-pyrimidyl 2-((cyclobutyl)NHCH<sub>2</sub>)phenyl
179. 5-pyrimidyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)phenyl

180. 5-pyrimidyl 2-((cyclopentyl)NHCH<sub>2</sub>)phenyl  
181. 5-pyrimidyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
182. 5-pyrimidyl 2-((cyclohexyl)NHCH<sub>2</sub>)phenyl  
183. 5-pyrimidyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
5 184. 5-pyrimidyl 1-CH<sub>3</sub>-2-imidazolyl  
185. 5-pyrimidyl 2-CH<sub>3</sub>-1-imidazolyl  
186. 5-pyrimidyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
187. 5-pyrimidyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
188. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
10 189. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
190. 5-pyrimidyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)-1-imidazolyl  
191. 5-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)-1-imidazolyl  
192. 5-pyrimidyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
193. 5-pyrimidyl 2-((cyclopropyl)NHCH<sub>2</sub>)-1-imidazolyl  
15 194. 5-pyrimidyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
195. 5-pyrimidyl 2-((cyclobutyl)NHCH<sub>2</sub>)-1-imidazolyl  
196. 5-pyrimidyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
197. 5-pyrimidyl 2-((cyclopentyl)NHCH<sub>2</sub>)-1-imidazolyl  
198. 5-pyrimidyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
20 199. 5-pyrimidyl 2-((cyclohexyl)NHCH<sub>2</sub>)-1-imidazolyl  
200. 5-pyrimidyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
201. 2-Cl-phenyl 2-(NH<sub>2</sub>SO<sub>2</sub>)phenyl  
202. 2-Cl-phenyl 2-(CH<sub>3</sub>SO<sub>2</sub>)phenyl  
203. 2-Cl-phenyl 3-NH<sub>2</sub>SO<sub>2</sub>-4-pyridyl  
25 204. 2-Cl-phenyl 3-CH<sub>3</sub>SO<sub>2</sub>-4-pyridyl  
205. 2-Cl-phenyl 2-(CH<sub>3</sub>NH)phenyl  
206. 2-Cl-phenyl 3-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-4-pyridyl  
207. 2-Cl-phenyl 2-(N-(3-R-HO-pyrrolidinyl)CH<sub>2</sub>)phenyl  
208. 2-Cl-phenyl 2-(N-(4-HO-piperidinyl)CH<sub>2</sub>)phenyl  
30 209. 2-Cl-phenyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl  
210. 2-Cl-phenyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)phenyl  
211. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)phenyl  
212. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)phenyl  
213. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)phenyl  
35 214. 2-Cl-phenyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)phenyl  
215. 2-Cl-phenyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)phenyl  
216. 2-Cl-phenyl 2-((cyclopropyl)NHCH<sub>2</sub>)phenyl  
217. 2-Cl-phenyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
218. 2-Cl-phenyl 2-((cyclobutyl)NHCH<sub>2</sub>)phenyl  
40 219. 2-Cl-phenyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
220. 2-Cl-phenyl 2-((cyclopentyl)NHCH<sub>2</sub>)phenyl  
221. 2-Cl-phenyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
222. 2-Cl-phenyl 2-((cyclohexyl)NHCH<sub>2</sub>)phenyl  
223. 2-Cl-phenyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
45 224. 2-Cl-phenyl 1-CH<sub>3</sub>-2-imidazolyl  
225. 2-Cl-phenyl 2-CH<sub>3</sub>-1-imidazolyl  
226. 2-Cl-phenyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
227. 2-Cl-phenyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
228. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
50 229. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
230. 2-Cl-phenyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)-1-imidazolyl  
231. 2-Cl-phenyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)-1-imidazolyl  
232. 2-Cl-phenyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl

	233.	2-Cl-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	234.	2-Cl-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	235.	2-Cl-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	236.	2-Cl-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
5	237.	2-Cl-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	238.	2-Cl-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	239.	2-Cl-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
	240.	2-Cl-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	241.	2-F-phenyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
10	242.	2-F-phenyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	243.	2-F-phenyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	244.	2-F-phenyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	245.	2-F-phenyl	2-(CH <sub>3</sub> NH)phenyl
	246.	2-F-phenyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
15	247.	2-F-phenyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	248.	2-F-phenyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	249.	2-F-phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	250.	2-F-phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	251.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
20	252.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	253.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	254.	2-F-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
	255.	2-F-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	256.	2-F-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
25	257.	2-F-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	258.	2-F-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
	259.	2-F-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	260.	2-F-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	261.	2-F-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
30	262.	2-F-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	263.	2-F-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	264.	2-F-phenyl	1-CH <sub>3</sub> -2-imidazolyl
	265.	2-F-phenyl	2-CH <sub>3</sub> -1-imidazolyl
	266.	2-F-phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
35	267.	2-F-phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	268.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	269.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	270.	2-F-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	271.	2-F-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
40	272.	2-F-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	273.	2-F-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	274.	2-F-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	275.	2-F-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	276.	2-F-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
45	277.	2-F-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	278.	2-F-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	279.	2-F-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
	280.	2-F-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	281.	2,6-diF-phenyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
50	282.	2,6-diF-phenyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	283.	2,6-diF-phenyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	284.	2,6-diF-phenyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
	285.	2,6-diF-phenyl	2-(CH <sub>3</sub> NH)phenyl


	286.	2,6-diF-phenyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
	287.	2,6-diF-phenyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	288.	2,6-diF-phenyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	289.	2,6-diF-phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
5	290.	2,6-diF-phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	291.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
	292.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	293.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	294.	2,6-diF-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
10	295.	2,6-diF-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	296.	2,6-diF-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
	297.	2,6-diF-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	298.	2,6-diF-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl
	299.	2,6-diF-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
15	300.	2,6-diF-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )phenyl
	301.	2,6-diF-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	302.	2,6-diF-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )phenyl
	303.	2,6-diF-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	304.	2,6-diF-phenyl	1-CH <sub>3</sub> -2-imidazolyl
20	305.	2,6-diF-phenyl	2-CH <sub>3</sub> -1-imidazolyl
	306.	2,6-diF-phenyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	307.	2,6-diF-phenyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	308.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )-1-imidazolyl
	309.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
25	310.	2,6-diF-phenyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )-1-imidazolyl
	311.	2,6-diF-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )-1-imidazolyl
	312.	2,6-diF-phenyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	313.	2,6-diF-phenyl	2-((cyclopropyl)NHCH <sub>2</sub> )-1-imidazolyl
	314.	2,6-diF-phenyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
30	315.	2,6-diF-phenyl	2-((cyclobutyl)NHCH <sub>2</sub> )-1-imidazolyl
	316.	2,6-diF-phenyl	2-((cyclobutyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	317.	2,6-diF-phenyl	2-((cyclopentyl)NHCH <sub>2</sub> )-1-imidazolyl
	318.	2,6-diF-phenyl	2-((cyclopentyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	319.	2,6-diF-phenyl	2-((cyclohexyl)NHCH <sub>2</sub> )-1-imidazolyl
35	320.	2,6-diF-phenyl	2-((cyclohexyl) <sub>2</sub> NCH <sub>2</sub> )-1-imidazolyl
	321.	piperidinyl	2-(NH <sub>2</sub> SO <sub>2</sub> )phenyl
	322.	piperidinyl	2-(CH <sub>3</sub> SO <sub>2</sub> )phenyl
	323.	piperidinyl	3-NH <sub>2</sub> SO <sub>2</sub> -4-pyridyl
	324.	piperidinyl	3-CH <sub>3</sub> SO <sub>2</sub> -4-pyridyl
40	325.	piperidinyl	2-(CH <sub>3</sub> NH)phenyl
	326.	piperidinyl	3-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )-4-pyridyl
	327.	piperidinyl	2-(N-(3-R-HO-pyrrolidinyl)CH <sub>2</sub> )phenyl
	328.	piperidinyl	2-(N-(4-HO-piperidinyl)CH <sub>2</sub> )phenyl
	329.	piperidinyl	2-((CH <sub>3</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
45	330.	piperidinyl	2-((CH <sub>3</sub> )NHCH <sub>2</sub> )phenyl
	331.	piperidinyl	2-((CH <sub>3</sub> CH <sub>2</sub> )NHCH <sub>2</sub> )phenyl
	332.	piperidinyl	2-((CH <sub>3</sub> CH <sub>2</sub> ) <sub>2</sub> NCH <sub>2</sub> )phenyl
	333.	piperidinyl	2-((CH <sub>3</sub> CH <sub>2</sub> )N(CH <sub>3</sub> )CH <sub>2</sub> )phenyl
	334.	piperidinyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH)NHCH <sub>2</sub> )phenyl
50	335.	piperidinyl	2-(((CH <sub>3</sub> ) <sub>2</sub> CH) <sub>2</sub> NCH <sub>2</sub> )phenyl
	336.	piperidinyl	2-((cyclopropyl)NHCH <sub>2</sub> )phenyl
	337.	piperidinyl	2-((cyclopropyl) <sub>2</sub> NCH <sub>2</sub> )phenyl
	338.	piperidinyl	2-((cyclobutyl)NHCH <sub>2</sub> )phenyl

339. piperidinyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
340. piperidinyl 2-((cyclopentyl)NHCH<sub>2</sub>)phenyl  
341. piperidinyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
342. piperidinyl 2-((cyclohexyl)NHCH<sub>2</sub>)phenyl  
5 343. piperidinyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)phenyl  
344. piperidinyl 1-CH<sub>3</sub>-2-imidazolyl  
345. piperidinyl 2-CH<sub>3</sub>-1-imidazolyl  
346. piperidinyl 2-((CH<sub>3</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
347. piperidinyl 2-((CH<sub>3</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
10 348. piperidinyl 2-((CH<sub>3</sub>CH<sub>2</sub>)NHCH<sub>2</sub>)-1-imidazolyl  
349. piperidinyl 2-((CH<sub>3</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
350. piperidinyl 2-((CH<sub>3</sub>CH<sub>2</sub>)N(CH<sub>3</sub>)CH<sub>2</sub>)-1-imidazolyl  
351. piperidinyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)NHCH<sub>2</sub>)-1-imidazolyl  
352. piperidinyl 2-(((CH<sub>3</sub>)<sub>2</sub>CH)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
15 353. piperidinyl 2-((cyclopropyl)NHCH<sub>2</sub>)-1-imidazolyl  
354. piperidinyl 2-((cyclopropyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
355. piperidinyl 2-((cyclobutyl)NHCH<sub>2</sub>)-1-imidazolyl  
356. piperidinyl 2-((cyclobutyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
357. piperidinyl 2-((cyclopentyl)NHCH<sub>2</sub>)-1-imidazolyl  
20 358. piperidinyl 2-((cyclopentyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
359. piperidinyl 2-((cyclohexyl)NHCH<sub>2</sub>)-1-imidazolyl  
360. piperidinyl 2-((cyclohexyl)<sub>2</sub>NCH<sub>2</sub>)-1-imidazolyl  
  
25

Numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the  
30 appended claims, the invention may be practiced otherwise that as specifically described herein.

## WHAT IS CLAIMED IS:

1. A compound of formula Ia, Ib, or Ic:



or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

- 10 ring D<sub>1</sub> is selected from pyridine, pyrazine, pyridazine, and pyrimidine and is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

- ring D<sub>2</sub> is a 5-membered heteroaromatic ring system comprising E, carbon atoms, and 0-3 N atoms, wherein E  
15 is selected from O, S, and N-R<sup>c</sup> and ring D<sub>2</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

- ring D<sub>3</sub> is a 5-membered heteroaromatic ring system comprising carbon atoms and from 0-3 additional N atoms  
20 and ring D<sub>3</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

- R is selected from H, C<sub>1-4</sub> alkyl, F, Cl, Br, I, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH(CH<sub>3</sub>)<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CN, C(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>,  
NHC(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>, NR<sup>8</sup>CH(=NR<sup>7</sup>), NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub>  
25 alkyl)<sub>2</sub>, C(=NH)NH<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>NR<sup>7</sup>R<sup>8</sup>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>C(O)NR<sup>7</sup>R<sup>8</sup>, and OCF<sub>3</sub>;

- R<sup>a</sup> is selected from H, C<sub>1-4</sub> alkyl, F, Cl, Br, I, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH(CH<sub>3</sub>)<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CN, C(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>,  
30 NHC(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>, NR<sup>8</sup>CH(=NR<sup>7</sup>), NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub>

alkyl)<sub>2</sub>, C(=NH)NH<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>NR<sup>7</sup>R<sup>8</sup>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>C(O)NR<sup>7</sup>R<sup>8</sup>, and OCF<sub>3</sub>;

- 5 R<sup>b</sup> is selected from H, C<sub>1-4</sub> alkyl, F, Cl, Br, I, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH(CH<sub>3</sub>)<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CN, C(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>, NHC(=NR<sup>8</sup>)NR<sup>7</sup>R<sup>9</sup>, NR<sup>8</sup>CH(=NR<sup>7</sup>), NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, C(=NH)NH<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>NR<sup>7</sup>R<sup>8</sup>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>C(O)NR<sup>7</sup>R<sup>8</sup>, and OCF<sub>3</sub>;

- R<sup>c</sup> is selected from H, C<sub>1-4</sub> alkyl, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH(CH<sub>3</sub>)<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, C(=NH)NH<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>NR<sup>7</sup>R<sup>8</sup>, (CR<sup>8</sup>R<sup>9</sup>)<sub>t</sub>C(O)NR<sup>7</sup>R<sup>8</sup>, and OCF<sub>3</sub>;

- G is absent or is selected from CH<sub>2</sub>, C(O), O, NR<sup>3</sup>, S(O)<sub>p</sub>, CH<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>, CH<sub>2</sub>C(O), OCH<sub>2</sub>, CH<sub>2</sub>O, NR<sup>3</sup>CH<sub>2</sub>, CH<sub>2</sub>NR<sup>3</sup>, S(O)<sub>p</sub>CH<sub>2</sub>, CH<sub>2</sub>S(O)<sub>p</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>C(O)CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>C(O), OCH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>OCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>O, NR<sup>3</sup>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>NR<sup>3</sup>CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NR<sup>3</sup>, S(O)<sub>p</sub>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>S(O)<sub>p</sub>CH<sub>2</sub>, and CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>p</sub>;


- G<sub>1</sub> is absent or is selected from (CR<sup>3</sup>R<sup>3a</sup>)<sub>1-5</sub>,  
 25 (CR<sup>3</sup>R<sup>3a</sup>)<sub>0-2</sub>CR<sup>3</sup>=CR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>0-2</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>0-2</sub>C≡C(CR<sup>3</sup>R<sup>3a</sup>)<sub>0-2</sub>,  
 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>C(O)(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>C(O)O(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,  
 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>OC(O)(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>O(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,  
 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>NR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>C(O)NR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,  
 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>NR<sup>3</sup>C(O)(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>OC(O)NR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,  
 30 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>NR<sup>3</sup>C(O)O(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>NR<sup>3</sup>C(O)NR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,  
 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>NR<sup>3</sup>C(S)NR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>S(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,  
 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>S(O)(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>S(O)<sub>2</sub>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,  
 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>S(O)NR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>NR<sup>3</sup>S(O)<sub>2</sub>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,  
 (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>S(O)<sub>2</sub>NR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>, and (CR<sup>3</sup>R<sup>3a</sup>)<sub>u</sub>NR<sup>3</sup>S(O)<sub>2</sub>NR<sup>3</sup>(CR<sup>3</sup>R<sup>3a</sup>)<sub>w</sub>,



wherein  $u + w$  total 0, 1, 2, 3, or 4, provided that  $G_1$  does not form a N-N, N-O, N-S,  $NCH_2N$ ,  $NCH_2O$ , or  $NCH_2S$  bond with either group to which it is attached;

- 5  $G^2$  is phenyl, naphthyl, or a 5-10 membered heteroaryl consisting of carbon atoms and from 1-3 heteroatoms selected from N, O, and S;

Q is a group of formula II:



II


10

one of  $P_4$  and  $M_3$  is -Z-A-B and the other is attached to  $G_1$ ;

- 15 ring M, including  $M_1$  and  $M_2$ , is a 6 or 7 membered carbocycle or 6 or 7 membered heterocycle, consisting of: carbon atoms and 1-3 heteroatoms selected from O,  $S(O)_p$ , N, and  $NZ^2$ ;

- 20 ring M is substituted with 0-2  $R^{1a}$  and 0-2 carbonyl groups, and, comprises: 0-2 additional double bonds;

ring P, including  $P_1$ ,  $P_2$ ,  $P_3$ , and  $P_4$  is selected from group:



"a" is absent or is a bond

5 provided that when Q is a dihydroimidazolo[4,5-c]-pyridin-4-one then:

- (i) G<sub>1</sub> is present and is other than alkylene;
- (ii) Z is present and is other than alkylene;
- (iii) Ring D<sub>1</sub>-G is present, D<sub>1</sub>-G is other than

10 benzyloxy;

- (iv) Ring D<sub>3</sub> is present; or

- (v) Ring D<sub>2</sub> is present and is other than 5-methyl-1,2,4-oxadiazole or 5-oxo-1,2,4-oxadiazole;

15 Z is selected from a bond,  $-(CR^2R^{2a})_{1-4}-$ ,  $(CR^2R^{2a})_qO(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qC(O)(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qC(O)O(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qOC(O)(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qC(O)NR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3C(O)(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qOC(O)O(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qOC(O)NR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3C(O)O(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3C(O)NR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qS(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qS(O)(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qS(O)_2(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qSO_2NR^3(CR^2R^{2a})_{q^1}$ ,  $(CR^2R^{2a})_qNR^3SO_2(CR^2R^{2a})_{q^1}$ , and  $(CR^2R^{2a})_qNR^3SO_2NR^3(CR^2R^{2a})_{q^1}$ ,  
 20 wherein  $q + q^1$  total 0, 1, or 2, provided that Z does

not form a N-N, N-O, N-S, NCH<sub>2</sub>N, NCH<sub>2</sub>O, or NCH<sub>2</sub>S bond with either group to which it is attached;

5        Z<sup>2</sup> is selected from H, C<sub>1-4</sub> alkyl, phenyl, benzyl, C(O)R<sup>3</sup>,  
and S(O)<sub>p</sub>R<sup>3c</sup>;

R<sup>1a</sup> is selected from H, -(CH<sub>2</sub>)<sub>r</sub>-R<sup>1b</sup>, -CH=CH-R<sup>1b</sup>, NCH<sub>2</sub>R<sup>1c</sup>,  
OCH<sub>2</sub>R<sup>1c</sup>, SCH<sub>2</sub>R<sup>1c</sup>, NH(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>, O(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>,  
S(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>, S(O)<sub>p</sub>(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, O(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, NR<sup>3</sup>(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>,  
10        OC(O)NR<sup>3</sup>(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, NR<sup>3</sup>C(O)NR<sup>3</sup>(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, NR<sup>3</sup>C(O)O(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>,  
and NR<sup>3</sup>C(O)(CH<sub>2</sub>)<sub>r</sub>R<sup>1d</sup>, provided that R<sup>1a</sup> forms other than  
an N-halo, N-N, N-S, N-O, or N-CN bond;

alternatively, when two R<sup>1a</sup>'s are attached to adjacent atoms,  
15        together with the atoms to which they are attached they  
form a 5-7 membered ring consisting of: carbon atoms  
and 0-2 heteroatoms selected from the group consisting  
of N, O, and S(O)<sub>p</sub>, this ring being substituted with 0-2  
R<sup>4b</sup> and comprising: 0-3 double bonds;

20        R<sup>1b</sup> is selected from H, C<sub>1-3</sub> alkyl, F, Cl, Br, I, -CN, -CHO,  
(CF<sub>2</sub>)<sub>r</sub>CF<sub>3</sub>, (CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, NR<sup>2</sup>R<sup>2a</sup>, C(O)R<sup>2c</sup>, OC(O)R<sup>2</sup>,  
(CF<sub>2</sub>)<sub>r</sub>CO<sub>2</sub>R<sup>2a</sup>, S(O)<sub>p</sub>R<sup>2b</sup>, NR<sup>2</sup>(CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, C(=NR<sup>2c</sup>)NR<sup>2</sup>R<sup>2a</sup>,  
NR<sup>2</sup>C(O)R<sup>2b</sup>, NR<sup>2</sup>C(O)NHR<sup>2b</sup>, NR<sup>2</sup>C(O)<sub>2</sub>R<sup>2a</sup>, OC(O)NR<sup>2a</sup>R<sup>2b</sup>,  
25        C(O)NR<sup>2</sup>R<sup>2a</sup>, C(O)NR<sup>2</sup>(CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>R<sup>2b</sup>, C<sub>3-6</sub>  
carbocycle substituted with 0-2 R<sup>4a</sup>, and 5-10 membered  
heterocycle consisting of carbon atoms and from 1-4  
heteroatoms selected from the group consisting of N, O,  
and S(O)<sub>p</sub> substituted with 0-2 R<sup>4a</sup>, provided that R<sup>1b</sup>  
30        forms other than an N-halo, N-N, N-S, N-O, or N-CN  
bond;

$R^{1c}$  is selected from H,  $CH(CH_2OR^2)_2$ ,  $C(O)R^{2c}$ ,  $C(O)NR^2R^{2a}$ ,  
 $S(O)R^{2b}$ ,  $S(O)_2R^{2b}$ , and  $SO_2NR^2R^{2a}$ ;

5  $R^{1d}$  is selected from  $C_{3-13}$  carbocycle substituted with 0-2  
 $R^{4a}$ , and 5-13 membered heterocycle consisting of carbon  
atoms and from 1-4 heteroatoms selected from the group  
consisting of N, O, and  $S(O)_p$  substituted with 0-2  $R^{4a}$ ,  
provided that  $R^{1d}$  forms other than an N-N, N-S, or N-O  
bond;

10

$R^2$ , at each occurrence, is selected from H,  $CF_3$ ,  $C_{1-6}$  alkyl,  
benzyl,  $C_{3-6}$  carbocyclic residue substituted with 0-2  
 $R^{4b}$ , and 5-6 membered heterocyclic system comprising  
carbon atoms and from 1-4 heteroatoms selected from the  
15 group consisting of N, O, and S substituted with 0-2  
 $R^{4b}$ ;

$R^{2a}$ , at each occurrence, is selected from H,  $CF_3$ ,  $C_{1-6}$  alkyl,  
benzyl, phenethyl,  $C_{3-6}$  carbocyclic residue substituted  
20 with 0-2  $R^{4b}$ , and 5-6 membered heterocyclic system  
comprising carbon atoms and from 1-4 heteroatoms  
selected from the group consisting of N, O, and S  
substituted with 0-2  $R^{4b}$ ;

25  $R^{2b}$ , at each occurrence, is selected from  $CF_3$ ,  $C_{1-4}$  alkoxy,  
 $C_{1-6}$  alkyl, benzyl,  $C_{3-6}$  carbocyclic residue substituted  
with 0-2  $R^{4b}$ , and 5-6 membered heterocyclic system  
comprising carbon atoms and from 1-4 heteroatoms  
selected from the group consisting of N, O, and S  
30 substituted with 0-2  $R^{4b}$ ;

$R^{2c}$ , at each occurrence, is selected from  $CF_3$ , OH,  $C_{1-4}$   
alkoxy,  $C_{1-6}$  alkyl, benzyl,  $C_{3-6}$  carbocyclic residue

substituted with 0-2 R<sup>4b</sup>, and 5-6 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R<sup>4b</sup>;

5

alternatively, R<sup>2</sup> and R<sup>2a</sup>, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R<sup>4b</sup> and comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

10

R<sup>3</sup>, at each occurrence, is selected from H, C<sub>1-4</sub> alkyl, and phenyl;

15

R<sup>3a</sup>, at each occurrence, is selected from H, C<sub>1-4</sub> alkyl, and phenyl;

R<sup>3b</sup>, at each occurrence, is selected from H, C<sub>1-4</sub> alkyl, and phenyl;

20

R<sup>3c</sup>, at each occurrence, is selected from C<sub>1-4</sub> alkyl, and phenyl;

R<sup>3d</sup>, at each occurrence, is selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl-phenyl, and C(=O)R<sup>3c</sup>;

25

A is selected from:

C<sub>3-10</sub> carbocyclic residue substituted with 0-2 R<sup>4</sup>, and 5-12 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R<sup>4</sup>;

30

B is selected from: H, Y, and X-Y, provided that Z and B are attached to different atoms on A;

X is selected from  $-(CR^2R^{2a})_{1-4}-$ ,  $-CR^2(CR^2R^{2b})(CH_2)_t-$ ,  $-C(O)-$ ,  
 5  $-C(=NR^{1c})-$ ,  $-CR^2(NR^{1c}R^2)-$ ,  $-CR^2(OR^2)-$ ,  $-CR^2(SR^2)-$ ,  
 $-C(O)CR^2R^{2a}-$ ,  $-CR^2R^{2a}C(O)-$ ,  $-S-$ ,  $-S(O)-$ ,  $-S(O)_2-$ ,  
 $-SCR^2R^{2a}-$ ,  $-S(O)CR^2R^{2a}-$ ,  $-S(O)_2CR^2R^{2a}-$ ,  $-CR^2R^{2a}S-$ ,  
 $-CR^2R^{2a}S(O)-$ ,  $-CR^2R^{2a}S(O)_2-$ ,  $-S(O)_2NR^2-$ ,  $-NR^2S(O)_2-$ ,  
 $-NR^2S(O)_2CR^2R^{2a}-$ ,  $-CR^2R^{2a}S(O)_2NR^2-$ ,  $-NR^2S(O)_2NR^2-$ ,  
 10  $-C(O)NR^2-$ ,  $-NR^2C(O)-$ ,  $-C(O)NR^2CR^2R^{2a}-$ ,  $-NR^2C(O)CR^2R^{2a}-$ ,  
 $-CR^2R^{2a}C(O)NR^2-$ ,  $-CR^2R^{2a}NR^2C(O)-$ ,  $-NR^2C(O)O-$ ,  $-OC(O)NR^2-$ ,  
 $-NR^2C(O)NR^2-$ ,  $-NR^2-$ ,  $-NR^2CR^2R^{2a}-$ ,  $-CR^2R^{2a}NR^2-$ , O,  
 $-CR^2R^{2a}O-$ , and  $-OCR^2R^{2a}-$ ;

15 Y is selected from:

C<sub>3-10</sub> carbocyclic residue substituted with 0-2 R<sup>4a</sup>, and  
 5-12 membered heterocyclic system comprising carbon  
 atoms and from 1-4 heteroatoms selected from the group  
 consisting of N, O, and S substituted with 0-2 R<sup>4a</sup>;

20

R<sup>4</sup>, at each occurrence, is selected from H, =O,  $(CH_2)_rOR^2$ ,  
 $(CH_2)_rF$ ,  $(CH_2)_rCl$ ,  $(CH_2)_rBr$ ,  $(CH_2)_rI$ , C<sub>1-4</sub> alkyl,  
 $(CH_2)_rCN$ ,  $(CH_2)_rNO_2$ ,  $(CH_2)_rNR^2R^{2a}$ ,  $(CH_2)_rN(\rightarrow O)R^2R^{2a}$ ,  
 $(CH_2)_rC(O)R^{2c}$ ,  $(CH_2)_rNR^2C(O)R^{2b}$ ,  $(CH_2)_rC(O)NR^2R^{2a}$ ,  
 25  $(CH_2)_rNR^2C(O)NR^2R^{2a}$ ,  $(CH_2)_rC(=NR^2)NR^2R^{2a}$ ,  
 $(CH_2)_rC(=NS(O)_2R^5)NR^2R^{2a}$ ,  $(CH_2)_rNHC(=NR^2)NR^2R^{2a}$ ,  
 $(CH_2)_rC(O)NHC(=NR^2)NR^2R^{2a}$ ,  $(CH_2)_rSO_2NR^2R^{2a}$ ,  
 $(CH_2)_rNR^2SO_2NR^2R^{2a}$ ,  $(CH_2)_rNR^2SO_2-C_{1-4}$  alkyl,  
 $(CH_2)_rNR^2SO_2R^5$ ,  $(CH_2)_r-NR^2SO_2R^{5a}$ ,  $(CH_2)_rS(O)_pR^5$ ,  $(CH_2)_r-$   
 30  $S(O)_pR^{5a}$ ,  $(CF_2)_rCF_3$ ,  $(CH_2)_r-CF_3$ ,  $(CR^{4c}R^{4d})(CR^{3e}R^{3e})_r-NR^{4e}R^{4f}$ ,  
 $(CR^{4c}R^{4d})(CR^{3e}R^{3e})_r-OR^{4e}$ ,  $(CR^{4c}R^{4d})(CR^{3e}R^{3e})_r-SR^{4e}$ ,  
 $(CR^{4c}R^{4d})(CR^{3e}R^{3e})_r-N(\rightarrow O)R^{4e}R^{4f}$ ,  $(CH_2)_rNCH_2R^{1c}$ ,

$(\text{CH}_2)_r\text{OCH}_2\text{R}^{1c}$ ,  $(\text{CH}_2)_r\text{SCH}_2\text{R}^{1c}$ ,  $(\text{CH}_2)_r\text{N}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  
 $(\text{CH}_2)_r\text{O}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  $(\text{CH}_2)_r\text{S}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  $(\text{CH}_2)_r$  5-6  
 membered carbocycle substituted with 0-1  $\text{R}^5$ , and  
 $(\text{CH}_2)_r$  5-6 membered heterocycle consisting of: carbon  
 5 atoms and 1-4 heteroatoms selected from the group  
 consisting of N, O, and  $\text{S}(\text{O})_p$  substituted with 0-1  $\text{R}^5$ ;  
  
 $\text{R}^4$ , at each occurrence, is selected from H, =O,  $(\text{CH}_2)_r\text{OR}^2$ ,  
 $(\text{CH}_2)_r\text{F}$ ,  $(\text{CH}_2)_r\text{Cl}$ ,  $(\text{CH}_2)_r\text{Br}$ ,  $(\text{CH}_2)_r\text{I}$ ,  $\text{C}_{1-4}$  alkyl,  
 10  $(\text{CH}_2)_r\text{CN}$ ,  $(\text{CH}_2)_r\text{NO}_2$ ,  $(\text{CH}_2)_r\text{NR}^2\text{R}^{2a}$ ,  $\text{C}(\text{O})\text{R}^{2c}$ ,  $\text{NR}^2\text{C}(\text{O})\text{R}^{2b}$ ,  
 $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$ ,  $\text{C}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  
 $\text{C}(=\text{NS}(\text{O})_2\text{R}^5)\text{NR}^2\text{R}^{2a}$ ,  $\text{NHC}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  $\text{C}(\text{O})\text{NHC}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  
 $\text{SO}_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{SO}_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{SO}_2\text{-C}_{1-4}$  alkyl,  $\text{NR}^2\text{SO}_2\text{R}^5$ ,  
 $\text{S}(\text{O})_p\text{R}^5$ ,  $(\text{CF}_2)_r\text{CF}_3$ ,  $(\text{CH}_2)_r\text{-CF}_3$ ,  $\text{NCH}_2\text{R}^{1c}$ ,  $\text{OCH}_2\text{R}^{1c}$ ,  $\text{SCH}_2\text{R}^{1c}$ ,  
 15  $\text{N}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  $\text{O}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ ,  $\text{S}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1b}$ , 5-6  
 membered carbocycle substituted with 0-1  $\text{R}^5$ , and 5-6  
 membered heterocycle consisting of: carbon atoms and  
 1-4 heteroatoms selected from the group consisting of  
 N, O, and  $\text{S}(\text{O})_p$  substituted with 0-1  $\text{R}^5$ ;  
  
 $\text{R}^{4a}$ , at each occurrence, is selected from H, =O,  $(\text{CH}_2)_r\text{OR}^2$ ,  
 $(\text{CF}_2)_r\text{CF}_3$ ,  $(\text{CH}_2)_r\text{-CF}_3$ ,  $(\text{CH}_2)_r\text{-F}$ ,  $(\text{CH}_2)_r\text{-Br}$ ,  $(\text{CH}_2)_r\text{-Cl}$ ,  
 $\text{C}_{1-4}$  alkyl,  $(\text{CH}_2)_r\text{CN}$ ,  $(\text{CH}_2)_r\text{NO}_2$ ,  $(\text{CH}_2)_r\text{NR}^2\text{R}^{2a}$ ,  
 $(\text{CH}_2)_r\text{C}(\text{O})\text{R}^{2c}$ ,  $\text{NR}^2\text{C}(\text{O})\text{R}^{2b}$ ,  $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$ ,  $(\text{CH}_2)_r\text{N=CHOR}^3$ ,  
 20  $\text{C}(\text{O})\text{NH}(\text{CH}_2)_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$ ,  $\text{C}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  
 $\text{NHC}(=\text{NR}^2)\text{NR}^2\text{R}^{2a}$ ,  $\text{SO}_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{SO}_2\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{SO}_2\text{-C}_{1-4}$   
 alkyl,  $\text{NR}^2\text{SO}_2\text{R}^5$ ,  $\text{C}(\text{O})\text{NHSO}_2\text{-C}_{1-4}$  alkyl,  $\text{S}(\text{O})_p\text{R}^5$ , 5-6  
 membered carbocycle substituted with 0-1  $\text{R}^5$ , and 5-6  
 membered heterocycle consisting of: carbon atoms and  
 30 1-4 heteroatoms selected from the group consisting of  
 N, O, and  $\text{S}(\text{O})_p$  substituted with 0-1  $\text{R}^5$ ;

$R^{4b}$ , at each occurrence, is selected from H, =O,  $(CH_2)_rOR^3$ ,  
 $(CH_2)_rF$ ,  $(CH_2)_rCl$ ,  $(CH_2)_rBr$ ,  $(CH_2)_rI$ ,  $C_{1-4}$  alkyl,  
 $(CH_2)_rCN$ ,  $(CH_2)_rNO_2$ ,  $(CH_2)_rNR^3R^{3a}$ ,  $(CH_2)_rC(O)R^3$ ,  
 $(CH_2)_rC(O)OR^{3c}$ ,  $NR^3C(O)R^{3a}$ ,  $C(O)NR^3R^{3a}$ ,  $NR^3C(O)NR^3R^{3a}$ ,  
5  $C(=NR^3)NR^3R^{3a}$ ,  $NR^3C(=NR^3)NR^3R^{3a}$ ,  $SO_2NR^3R^{3a}$ ,  $NR^3SO_2NR^3R^{3a}$ ,  
 $NR^3SO_2-C_{1-4}$  alkyl,  $NR^3SO_2CF_3$ ,  $NR^3SO_2$ -phenyl,  $S(O)_pCF_3$ ,  
 $S(O)_p-C_{1-4}$  alkyl,  $S(O)_p$ -phenyl,  $(CH_2)_rCF_3$ , and  $(CF_2)_rCF_3$ ;

$R^5$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, =O,  
10  $(CH_2)_rOR^3$ , F, Cl, Br, I, -CN,  $NO_2$ ,  $(CH_2)_rNR^3R^{3a}$ ,  
 $(CH_2)_rC(O)R^3$ ,  $(CH_2)_rC(O)OR^{3c}$ ,  $NR^3C(O)R^{3a}$ ,  $C(O)NR^3R^{3a}$ ,  
 $NR^3C(O)NR^3R^{3a}$ ,  $CH(=NOR^{3d})$ ,  $C(=NR^3)NR^3R^{3a}$ ,  
 $NR^3C(=NR^3)NR^3R^{3a}$ ,  $SO_2NR^3R^{3a}$ ,  $NR^3SO_2NR^3R^{3a}$ ,  $NR^3SO_2-C_{1-4}$   
alkyl,  $NR^3SO_2CF_3$ ,  $NR^3SO_2$ -phenyl,  $S(O)_pCF_3$ ,  $S(O)_p-C_{1-4}$   
15 alkyl,  $S(O)_p$ -phenyl,  $(CF_2)_rCF_3$ , phenyl substituted with  
0-2  $R^6$ , naphthyl substituted with 0-2  $R^6$ , and benzyl  
substituted with 0-2  $R^6$ ;

$R^6$ , at each occurrence, is selected from H, OH,  $(CH_2)_rOR^2$ ,  
20 halo,  $C_{1-4}$  alkyl, CN,  $NO_2$ ,  $(CH_2)_rNR^2R^{2a}$ ,  $(CH_2)_rC(O)R^{2b}$ ,  
 $NR^2C(O)R^{2b}$ ,  $NR^2C(O)NR^2R^{2a}$ ,  $C(=NH)NH_2$ ,  $NHC(=NH)NH_2$ ,  
 $SO_2NR^2R^{2a}$ ,  $NR^2SO_2NR^2R^{2a}$ , and  $NR^2SO_2C_{1-4}$  alkyl;

$R^7$ , at each occurrence, is selected from H, OH,  $C_{1-4}$   
25 alkoxycarbonyl,  $C_{6-10}$  aryloxy,  $C_{6-10}$  aryloxycarbonyl,  
 $C_{6-10}$  arylmethylcarbonyl,  $C_{1-4}$  alkylcarbonyloxy  $C_{1-4}$   
alkoxycarbonyl,  $C_{6-10}$  arylcarbonyloxy  $C_{1-4}$   
alkoxycarbonyl,  $C_{1-6}$  alkylaminocarbonyl,  
phenylaminocarbonyl, and phenyl  $C_{1-4}$  alkoxycarbonyl;

30  $R^8$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, and  
 $(CH_2)_n$ -phenyl;



alternatively,  $R^7$  and  $R^8$ , when attached to the same nitrogen,  
 combine to form a 5-6 membered heterocyclic ring  
 consisting of carbon atoms and 0-2 additional  
 5 heteroatoms selected from the group consisting of N, O,  
 and  $S(O)_p$ ;

$R^9$ , at each occurrence, is selected from H,  $C_{1-6}$  alkyl, and  
 $(CH_2)_n$ -phenyl;

10  $n$ , at each occurrence, is selected from 0, 1, 2, and 3;

$m$ , at each occurrence, is selected from 0, 1, and 2;




15  $p$ , at each occurrence, is selected from 0, 1, and 2;

$r$ , at each occurrence, is selected from 0, 1, 2, and 3;

$s$ , at each occurrence, is selected from 0, 1, and 2; and,  
 20

$t$ , at each occurrence, is selected from 0, 1, 2, and 3.

2. A compound according to Claim 1, wherein the  
 25 compound is of formula Ia<sub>1</sub>-Ic<sub>1</sub>, wherein:



30 ring  $D_2$  is a 5-membered heteroaromatic ring system  
 comprising E, carbon atoms, and 0-2 N atoms, wherein E

is selected from O, S, and N-R<sup>c</sup> and ring D<sub>2</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

ring D<sub>3</sub> is a 5-membered heteroaromatic ring system  
 5 comprising carbon atoms and from 0-3 additional N atoms  
 and ring D<sub>3</sub> is substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;

R is selected from H, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>,  
 NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub>  
 10 alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub>  
 alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


R<sup>a</sup> is selected from H, OH, SH, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> thioalkoxy,  
 NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub>  
 15 alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub>  
 alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


R<sup>b</sup> is selected from H, C<sub>1-4</sub> alkyl, Cl, F, Br, I, OH, C<sub>1-3</sub>  
 alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>,  
 20 CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


R<sup>c</sup> is selected from H, C<sub>1-4</sub> alkyl, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub>  
 alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl),  
 25 CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and  
 CH<sub>2</sub>CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


G<sub>1</sub> is absent or is selected from CH<sub>2</sub>, C(O), O, NR<sup>3</sup>, S(O)<sub>p</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>, CH<sub>2</sub>C(O), OCH<sub>2</sub>, CH<sub>2</sub>O, NR<sup>3</sup>CH<sub>2</sub>, CH<sub>2</sub>NR<sup>3</sup>,  
 30 S(O)<sub>p</sub>CH<sub>2</sub>, CH<sub>2</sub>S(O)<sub>p</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>C(O)CH<sub>2</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>C(O), OCH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>OCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>O, NR<sup>3</sup>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>NR<sup>3</sup>CH<sub>2</sub>,  
 CH<sub>2</sub>CH<sub>2</sub>NR<sup>3</sup>, S(O)<sub>p</sub>CH<sub>2</sub>CH<sub>2</sub>, CH<sub>2</sub>S(O)<sub>p</sub>CH<sub>2</sub>, and CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>p</sub>, and  
 provided that G<sub>1</sub>-Q form other than a N-N, O-N, or S-N  
 bond;

ring M is substituted with 0-2  $R^{1a}$  and is selected from the group:










$Z^2$  is selected from H,  $C_{1-4}$  alkyl, phenyl, benzyl,  $C(O)R^3$ ,  
and  $S(O)_pR^{3c}$ ;

5

ring P, including  $P_1$ ,  $P_2$ ,  $P_3$ , and  $P_4$  is selected from group:



- 10  $G_1$  is absent or is selected from  $(CR^3R^{3a})_{1-3}$ ,  
 $(CR^3R^{3a})_u C(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_u O(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_u NR^3(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_u C(O)NR^3(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_u NR^3C(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_u S(CR^3R^{3a})_w$ ,  
 $(CR^3R^{3a})_u S(O)(CR^3R^{3a})_w$ ,  $(CR^3R^{3a})_u S(O)_2(CR^3R^{3a})_w$ ,  
15  $(CR^3R^{3a})_u S(O)NR^3(CR^3R^{3a})_w$ , and  $(CR^3R^{3a})_u S(O)_2NR^3(CR^3R^{3a})_w$ ,  
wherein  $u + w$  total 0, 1, or 2, provided that  $G_1$  does

not form a N-N, N-O, N-S, NCH<sub>2</sub>N, NCH<sub>2</sub>O, or NCH<sub>2</sub>S bond with either group to which it is attached;


A is selected from one of the following carbocyclic and  
 5 heterocyclic systems which are substituted with 0-2 R<sup>4</sup>;  
     phenyl, piperidinyl, piperazinyl, pyridyl,  
     pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl,  
     pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl,  
     isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl,  
 10 thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl,  
     1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,  
     1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl,  
     1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,  
     1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,  
 15 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl,  
     benzothiofuranyl, indolyl, benzimidazolyl,  
     benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl,  
     benzisothiazolyl, and isoindazolyl;

20 X is selected from -(CR<sup>2</sup>R<sup>2a</sup>)<sub>1-4</sub>-, -C(O)-, -C(=NR<sup>1c</sup>)-,  
     -CR<sup>2</sup>(NR<sup>1c</sup>CR<sup>2</sup>)-, -C(O)CR<sup>2</sup>R<sup>2a</sup>-, -CR<sup>2</sup>R<sup>2a</sup>C(O)-, -C(O)NR<sup>2</sup>-,  
     -NR<sup>2</sup>C(O)-, -C(O)NR<sup>2</sup>CR<sup>2</sup>R<sup>2a</sup>-, -NR<sup>2</sup>C(O)CR<sup>2</sup>R<sup>2a</sup>-,  
     -CR<sup>2</sup>R<sup>2a</sup>C(O)NR<sup>2</sup>-, -CR<sup>2</sup>R<sup>2a</sup>NR<sup>2</sup>C(O)-, -NR<sup>2</sup>C(O)NR<sup>2</sup>-, -NR<sup>2</sup>-,  
     -NR<sup>2</sup>CR<sup>2</sup>R<sup>2a</sup>-, -CR<sup>2</sup>R<sup>2a</sup>NR<sup>2</sup>-, O, -CR<sup>2</sup>R<sup>2a</sup>O-, and -OCR<sup>2</sup>R<sup>2a</sup>-;

25 Y is selected from one of the following carbocyclic and  
     heterocyclic systems that are substituted with 0-2 R<sup>4a</sup>;  
     cyclopropyl, cyclopentyl, cyclohexyl, phenyl,  
     piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl,  
 30 morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl,  
     oxazolyl, isoxazolyl, isoxazoliny, thiazolyl,  
     isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl,  
     thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl,  
     1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,  
 35 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl,

1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,  
 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,  
 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl,  
 benzothiofuranyl, indolyl, benzimidazolyl,  
 5 benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl,  
 benzisothiazolyl, and isoindazolyl;

alternatively, Y is selected from the following bicyclic  
 heteroaryl ring systems:



K is selected from O, S, NH, and N;

Z is selected from a bond, CH<sub>2</sub>O, OCH<sub>2</sub>, NH, CH<sub>2</sub>NH, NHCH<sub>2</sub>,  
 15 CH<sub>2</sub>C(O), C(O)CH<sub>2</sub>, C(O)NH, NHC(O), CH<sub>2</sub>S(O)<sub>2</sub>, S(O)<sub>2</sub>(CH<sub>2</sub>),  
 SO<sub>2</sub>NH, and NHSO<sub>2</sub>, provided that Z does not form a N-N,  
 N-O, N-S, NCH<sub>2</sub>N, NCH<sub>2</sub>O, or NCH<sub>2</sub>S bond with either group  
 to which it is attached;

20 R<sup>4</sup>, at each occurrence, is selected from H, =O, (CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>, F,  
 Cl, Br, I, C<sub>1-4</sub> alkyl, CN, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>2</sup>R<sup>2a</sup>, C(O)R<sup>2c</sup>,  
 NR<sup>2</sup>C(O)R<sup>2b</sup>, C(O)NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>C(O)NR<sup>2</sup>R<sup>2a</sup>, C(=NR<sup>2</sup>)NR<sup>2</sup>R<sup>2a</sup>,  
 SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, NR<sup>2</sup>SO<sub>2</sub>R<sup>5</sup>,  
 S(O)<sub>p</sub>R<sup>5</sup>, CF<sub>3</sub>, NCH<sub>2</sub>R<sup>1c</sup>, OCH<sub>2</sub>R<sup>1c</sup>, SCH<sub>2</sub>R<sup>1c</sup>, N(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>,  
 25 O(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>, S(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>t</sub>R<sup>1b</sup>, 5-6 membered  
 carbocycle substituted with 0-1 R<sup>5</sup>, and 5-6 membered  
 heterocycle consisting of: carbon atoms and 1-4  
 heteroatoms selected from the group consisting of N, O,  
 and S(O)<sub>p</sub> substituted with 0-1 R<sup>5</sup>; and,



$R^{4a}$ , at each occurrence, is selected from H, =O,  $(CH_2)_xOR^2$ ,  
 $CF_3$ , F, Br, Cl,  $C_{1-4}$  alkyl, CN,  $NO_2$ ,  $(CH_2)_xNR^2R^{2a}$ ,  
 $(CH_2)_xC(O)R^{2c}$ ,  $NR^2C(O)R^{2b}$ ,  $C(O)NR^2R^{2a}$ ,  $NR^2C(O)NR^2R^{2a}$ ,  
5  $C(=NR^2)NR^2R^{2a}$ ,  $NHC(=NR^2)NR^2R^{2a}$ ,  $SO_2NR^2R^{2a}$ ,  $NR^2SO_2NR^2R^{2a}$ ,  
 $NR^2SO_2-C_{1-4}$  alkyl,  $NR^2SO_2R^5$ ,  $C(O)NHSO_2-C_{1-4}$  alkyl,  
 $S(O)_pR^5$ , 5-6 membered carbocycle substituted with 0-1  
 $R^5$ , and 5-6 membered heterocycle consisting of: carbon  
atoms and 1-4 heteroatoms selected from the group  
10 consisting of N, O, and  $S(O)_p$  substituted with 0-1  $R^5$ .

3. A compound according to Claim 2, wherein the  
compound is of formula Ib<sub>1</sub> or Ic<sub>1</sub>, wherein:

15 ring D<sub>2</sub> is a 5-membered heteroaromatic ring system  
comprising E, carbon atoms, and 0-2 N atoms, wherein E  
is selected from O, S, and N- $R^c$  and ring D<sub>2</sub> is  
substituted with 1  $R^a$  and 0-1  $R^b$ ;


20 R is selected from H, Cl, F, Br, I, OH,  $C_{1-3}$  alkoxy,  $NH_2$ ,  
 $NH(C_{1-3}$  alkyl),  $N(C_{1-3}$  alkyl)<sub>2</sub>,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3}$   
alkyl), and  $CH_2N(C_{1-3}$  alkyl)<sub>2</sub>;


25  $R^a$  is selected from H, OH, SH,  $NH_2$ ,  $NH(C_{1-3}$  alkyl),  $N(C_{1-3}$   
alkyl)<sub>2</sub>,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3}$  alkyl), and  $CH_2N(C_{1-3}$   
alkyl)<sub>2</sub>;

30  $R^b$  is selected from H,  $C_{1-4}$  alkyl, Cl, F, Br, I, OH,  $C_{1-3}$   
alkoxy,  $NH_2$ ,  $NH(C_{1-3}$  alkyl),  $N(C_{1-3}$  alkyl)<sub>2</sub>,  $CH_2NH_2$ ,  
 $CH_2NH(C_{1-3}$  alkyl), and  $CH_2N(C_{1-3}$  alkyl)<sub>2</sub>;

$R^c$  is selected from H,  $C_{1-4}$  alkyl,  $C_{1-3}$  alkoxy,  $NH_2$ ,  $NH(C_{1-3}$  alkyl),  $N(C_{1-3}$  alkyl) $_2$ ,  $CH_2NH_2$ ,  $CH_2NH(C_{1-3}$  alkyl), and  $CH_2N(C_{1-3}$  alkyl) $_2$ ;


5 ring M is substituted with 0-2  $R^{1a}$  and is selected from the group:





5

ring P, including P<sub>1</sub>, P<sub>2</sub>, P<sub>3</sub>, and P<sub>4</sub> is selected from group:



Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2  $R^{4a}$ ;

5           phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazole, thiadiazole, triazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, benzofuran, benzothiofuran, indole, benzimidazole, benzimidazolone, 15           benzoxazole, benzthiazole, indazole, benzisoxazole, benzisothiazole, and isoindazole;


Z is selected from a bond,  $CH_2O$ ,  $OCH_2$ ,  $NH$ ,  $CH_2NH$ ,  $NHCH_2$ ,  $CH_2C(O)$ ,  $C(O)CH_2$ ,  $C(O)NH$ ,  $NHC(O)$ ,  $CH_2S(O)_2$ ,  $S(O)_2(CH_2)$ , 20            $SO_2NH$ , and  $NHSO_2$ , provided that Z does not form a N-N, N-O, N-S,  $NCH_2N$ ,  $NCH_2O$ , or  $NCH_2S$  bond with either group to which it is attached;

$R^4$ , at each occurrence, is selected from H,  $=O$ ,  $(CH_2)_xOR^2$ , F, 25           Cl, Br, I,  $C_{1-4}$  alkyl, CN,  $NO_2$ ,  $(CH_2)_xNR^2R^{2a}$ ,  $C(O)R^{2c}$ ,

NR<sup>2</sup>C(O)R<sup>2b</sup>, C(O)NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>C(O)NR<sup>2</sup>R<sup>2a</sup>, C(=NR<sup>2</sup>)NR<sup>2</sup>R<sup>2a</sup>,  
 SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>SO<sub>2</sub>-C<sub>1-4</sub> alkyl, NR<sup>2</sup>SO<sub>2</sub>R<sup>5</sup>,  
 S(O)<sub>p</sub>R<sup>5</sup>, CF<sub>3</sub>, 5-6 membered carbocycle substituted with  
 0-1 R<sup>5</sup>, and 5-6 membered heterocycle consisting of:  
 5 carbon atoms and 1-4 heteroatoms selected from the  
 group consisting of N, O, and S(O)<sub>p</sub> substituted with 0-1  
 R<sup>5</sup>; and,

R<sup>4a</sup>, at each occurrence, is selected from H, =O, (CH<sub>2</sub>)<sub>r</sub>OR<sup>2</sup>,  
 10 CF<sub>3</sub>, F, Br, Cl, C<sub>1-4</sub> alkyl, CN, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>r</sub>NR<sup>2</sup>R<sup>2a</sup>,  
 (CH<sub>2</sub>)<sub>r</sub>C(O)R<sup>2c</sup>, NR<sup>2</sup>C(O)R<sup>2b</sup>, C(O)NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>C(O)NR<sup>2</sup>R<sup>2a</sup>,  
 C(=NR<sup>2</sup>)NR<sup>2</sup>R<sup>2a</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, C(O)NHSO<sub>2</sub>-C<sub>1-4</sub> alkyl, S(O)<sub>p</sub>R<sup>5</sup>,  
 5-6 membered carbocycle substituted with 0-1 R<sup>5</sup>, and 5-6  
 membered heterocycle consisting of: carbon atoms and  
 15 1-4 heteroatoms selected from the group consisting of  
 N, O, and S(O)<sub>p</sub> substituted with 0-1 R<sup>5</sup>.

4. A compound according to Claim 3, wherein the  
 20 compound is of wherein the compound is of formula Ib<sub>2</sub>:

Ib<sub>2</sub>

or a stereoisomer or pharmaceutically acceptable salt  
 thereof, wherein;

25 ring D<sub>2</sub> is a 5-membered heteroaromatic ring system  
 comprising E, carbon atoms, and 0-2 N atoms, wherein E  
 is selected from O, S, and N- R<sup>c</sup> and ring D<sub>2</sub> is  
 substituted with 1 R<sup>a</sup> and 0-1 R<sup>b</sup>;


30


R is selected from H, Cl, F, Br, I, OH, C<sub>1-3</sub> alkoxy, NH<sub>2</sub>,  
 - NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1-3</sub>  
 alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;


5 R<sup>a</sup> is selected from H, OH, SH, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), and N(C<sub>1-3</sub>  
 alkyl)<sub>2</sub>;

R<sup>b</sup> is selected from H, C<sub>1-4</sub> alkyl, Cl, F, Br, I, OH, C<sub>1-3</sub>  
 alkoxy, NH<sub>2</sub>, NH(C<sub>1-3</sub> alkyl), N(C<sub>1-3</sub> alkyl)<sub>2</sub>, CH<sub>2</sub>NH<sub>2</sub>,  
 10 CH<sub>2</sub>NH(C<sub>1-3</sub> alkyl), and CH<sub>2</sub>N(C<sub>1-3</sub> alkyl)<sub>2</sub>;

ring M is substituted with 0-1 R<sup>1a</sup> and is selected from the  
 group:








$G_1$  is absent or is selected from  $CH_2$ ,  $CH_2CH_2$ ,  $CH_2O$ ,  $OCH_2$ ,  $NH$ ,  $CH_2NH$ ,  $NHCH_2$ ,  $CH_2C(O)$ ,  $C(O)CH_2$ ,  $C(O)NH$ ,  $NHC(O)$ ,

5  $CH_2S(O)_2$ ,  $S(O)_2(CH_2)$ ,  $SO_2NH$ , and  $NHSO_2$ , provided that  $G_1$  does not form a N-N, N-O, N-S,  $NCH_2N$ ,  $NCH_2O$ , or  $NCH_2S$  bond with either group to which it is attached.

10 5. A compound according to Claim 4, wherein the compound is selected from one of the formulas:





5 or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

$G_1$  is absent;

10 A is selected from phenyl, piperidinyl, pyridyl, and pyrimidyl, and is substituted with 0-2  $R^4$ ; and,

B is selected from phenyl, pyrrolidino, N-pyrrolidino-carbonyl, morpholino, N-morpholino-carbonyl, 1,2,3-  
 15 triazolyl, imidazolyl, and benzimidazolyl, and is substituted with 0-1  $R^{4a}$ ;

$R^2$ , at each occurrence, is selected from H,  $CH_3$ ,  $CH_2CH_3$ , cyclopropylmethyl, cyclobutyl, and cyclopentyl;

20

R<sup>2a</sup>, at each occurrence, is selected from H, CH<sub>3</sub>, and CH<sub>2</sub>CH<sub>3</sub>;

alternatively, R<sup>2</sup> and R<sup>2a</sup>, together with the atom to which they are attached, combine to form pyrrolidine

5 substituted with 0-2 R<sup>4b</sup> or piperidine substituted with 0-2 R<sup>4b</sup>;

R<sup>4</sup>, at each occurrence, is selected from OH, OR<sup>2</sup>, (CH<sub>2</sub>)OR<sup>2</sup>, (CH<sub>2</sub>)<sub>2</sub>OR<sup>2</sup>, F, Br, Cl, I, C<sub>1-4</sub> alkyl, NR<sup>2</sup>R<sup>2a</sup>, (CH<sub>2</sub>)NR<sup>2</sup>R<sup>2a</sup>,  
10 (CH<sub>2</sub>)<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, CF<sub>3</sub>, and (CF<sub>2</sub>)CF<sub>3</sub>;

R<sup>4a</sup> is selected from C<sub>1-4</sub> alkyl, CF<sub>3</sub>, OR<sup>2</sup>, (CH<sub>2</sub>)OR<sup>2</sup>, (CH<sub>2</sub>)<sub>2</sub>OR<sup>2</sup>, NR<sup>2</sup>R<sup>2a</sup>, (CH<sub>2</sub>)NR<sup>2</sup>R<sup>2a</sup>, (CH<sub>2</sub>)<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, SR<sup>5</sup>, S(O)R<sup>5</sup>, S(O)<sub>2</sub>R<sup>5</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>2a</sup>, and 1-CF<sub>3</sub>-tetrazol-2-yl;

15

R<sup>4b</sup>, at each occurrence, is selected from H, CH<sub>3</sub>, and OH;

R<sup>5</sup>, at each occurrence, is selected from CF<sub>3</sub>, C<sub>1-6</sub> alkyl, phenyl, and benzyl; and,

20

r, at each occurrence, is selected from 0, 1, and 2.

6. A compound according to Claim 5, wherein:

25

A is selected from the group: phenyl, piperidinyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and,

30

B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-dimethylaminomethyl)phenyl, 2-(N-

methylaminomethyl)phenyl, 2-(N-ethyl-N-  
 methylaminomethyl)phenyl, 2-(N-  
 pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-  
 methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-  
 5 imidazolyl, 2-(methylaminomethyl)-1-imidazolyl, 2-(N-  
 (cyclopropylmethyl)aminomethyl)phenyl, 2-(N-  
 (cyclobutyl)aminomethyl)phenyl, 2-(N-  
 (cyclopentyl)aminomethyl)phenyl, 2-(N-(4-  
 hydroxypiperidinyl)methyl)phenyl, and 2-(N-(3-  
 10 hydroxypyrrolidinyl)methyl)phenyl.

7. A compound according to Claim 1, wherein the  
 compound is selected from the group:

15 1-[3-(2'-Amino-3',4'-thiadiazol-5'-yl)phenyl]-3-methyl-6-  
 [2'-aminosulfonyl-[1,1']-biphen-4-yl]-1,4,5,6-  
 tetrahydropyrazolo-[3,4-c]-pyridin-7-one  
 trifluoroacetic acid salt;

20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-  
 N,N-dimethylaminomethyl-[1,1']-biphen-4-  
 yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
 pyrimidine-5,7-dione;

25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
 trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
 biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
 pyrimidine-5,7-dione;

30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
 (ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
 biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
 pyrimidine-5,7-dione;

35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-  
 N,N-dimethylaminomethyl-[1,1']-biphen-4-  
 yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
 pyrimidine-5,7-dione;

40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-  
 N,N-dimethylaminomethyl-[1,1']-biphen-4-  
 yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
 pyrimidine-5,7-dione;

45

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-  
[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
pyrimidine-5,7-dione;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-  
trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
pyrimidine-5,7-dione;
- 10 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
pyrimidine-5,7-dione;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-  
[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-  
pyrimidine-5,7-dione;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N-  
pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-

- pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-



- fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 35 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
5
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
10
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
15
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
20
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
25
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
30
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
35
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
40
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
45
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;  
50

- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 25 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione; and,
- or a pharmaceutically acceptable salt thereof.

35

8. A compound according to Claim 1, wherein the compound is selected from the group:

- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-

- biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-

- biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;



- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-  
[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-  
trifluoromethyl-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-  
[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-  
hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 30 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-  
hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-  
pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-  
1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-  
hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;
- 50 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-  
hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-  
pyrimidin-7-one;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; and,
- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one;

or a pharmaceutically acceptable salt thereof.

9. A compound according to Claim 1, wherein the compound is selected from the group:

1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-

- biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-  
[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl) aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;



- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50

- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 15 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 20 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 35 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 40 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one; and,
- 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,6-dihydropyrazolo-[4,3-d]-pyridazin-7-one;

or a pharmaceutically acceptable salt thereof.

10. A compound according to Claim 1, wherein the  
5 compound is selected from the group:

- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-  
N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
10 pyridin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
15 [3,4-c]-pyridin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
20 [3,4-c]-pyridin-7-one;
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-  
N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
25 pyridin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-  
N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
30 pyridin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-  
trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
35 [3,4-c]-pyridin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-  
biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
40 [3,4-c]-pyridin-7-one;
- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-  
[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
45 pyridin-7-one;
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-  
[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-  
yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-  
50 pyridin-7-one;

- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10
- 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15
- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20
- 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25
- 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30
- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35
- 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45
- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50
- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;



- 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

- 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

- 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[(2'-(3"-hydroxy-N-pyrrolidinylmethyl)-[1,1']-biphen-4-yl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl)aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-

- fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 10 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 30 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 50 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-dimethylamino)methylimidazol-1'-yl)-2-

- fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 5 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-(N,N-  
dimethylamino)methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 10 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-(N,N-  
dimethylamino)methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 15 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-(N,N-  
dimethylamino)methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 20 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-(N,N-  
dimethylamino)methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 25 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-cyano-6-[4-(2'-  
methylimidazol-1'-yl)-2-fluorophenyl) aminocarbonyl]-  
1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 35 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-  
(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 40 1-[3-(1',3',4'-Triazol-2'-on-5'-yl)phenyl]-3-methyl-6-[4-  
(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 45 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-cyano-6-[4-  
(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;
- 50 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-  
trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-  
fluorophenyl) aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-  
[3,4-c]-pyridin-7-one;

- 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 5 1-[3-(2'-Amino-3',4'-oxadiazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 10 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 15 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 20 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 25 1-[3-(2'-Amino-1',3',4'-triazol-5'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 30 1-[3-(Pyrid-3'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 35 1-[3-(Pyrid-3'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 40 1-[3-(Pyrid-3'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 45 1-[3-(Pyrid-3'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 50 1-[3-(Pyrid-4'-yl)phenyl]-3-cyano-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;
- 1-[3-(Pyrid-4'-yl)phenyl]-3-trifluoromethyl-6-[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one;

- 1-[3-(Pyrid-4'-yl)phenyl]-3-(ethoxycarbonyl)-6-[4-(2'-  
methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]-  
1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one; and,  
5 1-[3-(Pyrid-4'-yl)phenyl]-3-methyl-6-[4-(2'-methylimidazol-  
1'-yl)-2-fluorophenyl]aminocarbonyl]-1,4,5,6-  
tetrahydropyrazolo-[3,4-c]-pyridin-7-one;  
10 or a pharmaceutically acceptable salt thereof.

11. A compound according to Claim 1, wherein the  
compound is selected from the group:

- 15 1-[3-(5-oxo-4,5-Dihydro-1H-1,2,4-triazol-3-yl)phenyl]-6-[2'-  
(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-  
c]pyridin-7-one;  
20 6-(2'-{[(3S)-3-Hydroxy-1-pyrrolidinyl]methyl}-1,1'-biphenyl-  
4-yl)-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-  
yl)phenyl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-  
pyrazolo[3,4-c]pyridin-7-one;  
25 6-{2'-[(Dimethylamino)methyl]-1,1'-biphenyl-4-yl}-1-[3-(5-  
oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-  
c]pyridin-7-one;  
30 6-[2'-(Methylsulfonyl)-1,1'-biphenyl-4-yl]-1-[3-(5-oxo-4,5-  
dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-  
c]pyridin-7-one;  
35 1-[3-(5-Amino-1,3,4-oxadiazol-2-yl)phenyl]-6-{2'-  
[(dimethylamino)methyl]-1,1'-biphenyl-4-yl}-3-



(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-{2'-  
5 [(dimethylamino)methyl]-1,1'-biphenyl-4-yl}-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-[2'-(1-  
10 pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-(4-{2-  
15 [(dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

1-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]-6-{4-[2-(1-  
20 pyrrolidinylmethyl)-1H-imidazol-1-yl]phenyl}-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

6-(4-{2-[(Dimethylamino)methyl]-1H-imidazol-1-yl}phenyl)-1-  
25 [3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-3-  
(trifluoromethyl)-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

3-Methyl-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-  
30 yl)phenyl]-6-{4-[2-(1-pyrrolidinylmethyl)-1H-imidazol-1-yl]phenyl}-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;

7-Oxo-1-[3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl]-  
35 6-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-

4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridine-3-carboxamide;

1-[3-(5-Oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)phenyl]-7-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[3,4-*c*]azepin-8(1*H*)-one; and,

1-[2-(5-Oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)phenyl]-6-[2'-(1-pyrrolidinylmethyl)-1,1'-biphenyl-4-yl]-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7*H*-pyrazolo[3,4-*c*]pyridin-7-one;

or a pharmaceutically acceptable salt thereof.

15

12. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or a pharmaceutically acceptable salt form thereof.

13. A method for treating or preventing a thromboembolic disorder, comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or a pharmaceutically acceptable salt form thereof.

30

14. A compound of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 for use in therapy.

15. Use of a compound of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 for the manufacture of a medicament for the treatment of a thromboembolic disorder.

## INTERNATIONAL SEARCH REPORT

 Int'l Application No  
 PCT/US 01/20113

## A. CLASSIFICATION OF SUBJECT MATTER

 IPC 7 C07D471/04 C07D487/04 A61K31/415 //(C07D471/04,231:00,  
 221:00),(C07D487/04,239:00,231:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 57937 A (DU PONT MERCK PHARMA) 23 December 1998 (1998-12-23) cited in the application page 191; claims	7-15
Y	WO 00 20416 A (BERNOTAT DANIELOWSKI SABINE ;MERCK PATENT GMBH (DE); DORSCH DIETER) 13 April 2000 (2000-04-13) cited in the application abstract; claims	7-15
Y	WO 97 23212 A (DU PONT MERCK PHARMA) 3 July 1997 (1997-07-03) cited in the application compounds IIIa, claim 1	7-15
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

4 October 2001

Date of mailing of the international search report

11/10/2001

Name and mailing address of the ISA

 European Patent Office, P.B. 5816 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/20113

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 50255 A (DU PONT PHARM CO) 7 October 1999 (1999-10-07) compounds (I), claim 1 ---	7-15
A,P	WO 00 40583 A (BERNOTAT DANIELOWSKI SABINE ;MERCK PATENT GMBH (DE); DORSCH DIETER) 13 July 2000 (2000-07-13) cited in the application abstract; claims ---	7-15
A,P	WO 00 39131 A (DU PONT PHARM CO) 6 July 2000 (2000-07-06) abstract; claims ---	7-15
T	FEVIG J M ET AL: "Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 5, 12 March 2001 (2001-03-12), pages 641-645, XP004230080 ISSN: 0960-894X the whole document -----	7-15

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-6,12-15(part)

Present claims 1-6,12-15 relate to an extremely large number of possible compounds. In fact, so many options, variables, possible permutations and combinations result in a claimed subject-matter that is so broad in scope that it is rendered virtually incomprehensible and therefore very difficult, if not impossible, to determine the matter for which a protection might legitimately be sought (Art. 6 PCT).

Note also that the claimed subject-matter lacks a significant structural element qualifying as the special technical feature that clearly defines a contribution over the art.

Support within the meaning of Art. 6 PCT and disclosure within the meaning of Art. 5 PCT is to be found, however, for only a selection of the compounds. The present application fails to comply with the clarity, conciseness, support and disclosure requirements of the PCT to such an extent that a meaningful search of the claims is impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear, concise and supported by the description, namely those parts relating to the compounds specified in the examples and the compounds claimed in claims 7 to 11, i.e., 1-(heteroaryl-3-phenyl)-pyrazolo(pyridin- or pyrimidin- or pyridazin)-7-one and/or 1-(heteroaryl-3-phenyl)-pyrazoloazepin-8-one derivatives.

Note that certain claimed condensations between rings P and M are not possible.

The reasons of some provisos are not clear.

Note additionally that claim 2 is not searchable since it claims two different definitions for the same group G1 (page 205 and 209).

In claim 4, according to the given formula Ib2, G1 should be absent and therefore cannot be given a definition like on page 219.

Claim 5 (and claim 6 depending thereon) lacks also consistency where the group M is not defined as a substituent whereas the same symbol M is used in preceeding claims for a condensed ring.

Even if M were meant for Q (= (P/M)), claim 5 remains unsearchable by referring implicitly to two different claims: to claim 4 for the definition of M and to claim 3 for P, this is a contravention of Rule 6.4 PCT, 2nd sentence.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/US 01/20113

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9857937	A	23-12-1998	AU 8150398 A	04-01-1999
			BR 9810151 A	08-08-2000
			EE 9900584 A	15-08-2000
			EP 0991625 A2	12-04-2000
			HR 980334 A1	30-04-1999
			HU 0003906 A2	28-05-2001
			LT 99146 A ,B	25-05-2000
			LV 12516 A	20-07-2000
			LV 12516 B	20-03-2001
			NO 996316 A	17-12-1999
			PL 337831 A1	11-09-2000
			SI 20208 A	31-10-2000
			SK 174699 A3	14-08-2000
			WO 9857937 A2	23-12-1998
			US 5998424 A	07-12-1999
WO 0020416	A	13-04-2000	DE 19845153 A1	06-04-2000
			AU 5861899 A	26-04-2000
			BR 9914213 A	26-06-2001
			WO 0020416 A1	13-04-2000
			EP 1117664 A1	25-07-2001
			NO 20011638 A	30-03-2001
WO 9723212	A	03-07-1997	AU 1335897 A	17-07-1997
			CA 2240946 A1	03-07-1997
			EP 0874629 A1	04-11-1998
			HR 960597 A1	30-04-1998
			JP 2001502655 T	27-02-2001
			WO 9723212 A1	03-07-1997
			US 5939418 A	17-08-1999
WO 9950255	A	07-10-1999	AU 3110999 A	18-10-1999
			EP 1064270 A2	03-01-2001
			WO 9950255 A2	07-10-1999
			US 6191159 B1	20-02-2001
			US 2001000179 A1	05-04-2001
WO 0040583	A	13-07-2000	DE 19900471 A1	13-07-2000
			AU 3041700 A	24-07-2000
			WO 0040583 A2	13-07-2000
			NO 20013384 A	06-07-2001
WO 0039131	A	06-07-2000	AU 2371700 A	31-07-2000
			HR 990396 A1	31-08-2000
			NO 20013072 A	20-06-2001
			WO 0039131 A1	06-07-2000

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**